Compounds > trichostatin a
Page last updated: 2024-09-27

trichostatin a

Description

trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID444732
CHEBI ID46024
CHEBI ID93196
SCHEMBL ID675951
SCHEMBL ID19886
MeSH IDM0059711

Synonyms (97)

Synonym
HY-15144
2,4-heptadienamide, 7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxo-, (2e,4e,6r)-
TSA ,
(2e,4e,6r)-7-(4-dimethylaminophenyl)-4,6-dimethyl-7-oxo-hepta-2,4-dienehydroxamic acid
trichlostatin a
SGCTO-002
tricostatin a
trichostatin a
58880-19-6
(2e,4e,6r)-7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
c17h22n2o3
2,4-heptadienamide, 7-(4-(dimethylamino)phenyl)-n-hydroxy-4,6-dimethyl-7-oxo-, (2e,4e,6r)-
3C10 ,
7-(4-(dimethylamino)phenyl)-n-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide
a-300-i
2,4-heptadienamide, 7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxo-, (2e,4e,6r)- (9ci)
trichostatin a from streptomyces sp.
antibiotic a-300
(r)-trichostatin a
2,4-heptadienamide, 7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxo-, [r-(e,e)]-
2,4-heptadienamide, 7-(4-(dimethylamino)phenyl)-n-hydroxy-4,6-dimethyl-7-oxo-
[r-(e,e)]-7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide
TSN ,
trichostatin a, >=98% (hplc), from streptomyces sp.
(2e,4e,6r)-7-(4-(dimethylamino)phenyl)-n-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide
CHEBI:46024 ,
NCGC_TSA
1C3R
DB04297
(2e,4e,6r)-7-(4-dimethylaminophenyl)-n-hydroxy-4,6-dimethyl-7-oxo-hepta-2,4-dienamide
NCGC00162453-01
NCGC00162453-02
NCGC00162453-03
dtxsid6037063 ,
trichostatin a (tsa) ,
LMPK01000055
trichostatin
HMS1990L09
BRD-K68202742-001-04-1
T2477
gnf-pf-1011 ,
trichostatin(s)
BRD-K68202742-001-05-8
HMS1362L09
HMS1792L09
A25618
NCGC00162453-05
NCGC00162453-04
TRICHOSTATIN-A - TSA
3x2s926l3z ,
unii-3x2s926l3z
nsc 311042
BCPP000035
trichostatin a,tsa
M02571
3F0R
CS-0499
S1045
AKOS015899840
gtpl7005
CCG-208681
CCG-208142
MLS006011095
smr004702883
SCHEMBL675951
SCHEMBL19886
2,4-heptadienamide, 7-(4-(dimethylamino)phenyl)-n-hydroxy-4,6-dimethyl-7-oxo-,(2e,4e,6r)-
vtr-297
trichostatin a [mi]
trichostatina
trichostatine a
Q-201864
bdbm50005711
7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6r-dimethyl-7-oxo-2e,4e-heptadienamide
(2e,4e,6r)-7-(4-(dimethylamino)phen yl)-n-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamid e
HB1402
(r,2e,4e)-7-(4-(dimethylamino)phenyl)-n-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
HMS3403L09
HMS3649O20
mfcd03848392
CHEBI:93196
AS-74315
trichostatin a??, vetec(tm) reagent grade, from streptomyces sp., >=98%
NCGC00162453-15
SW219664-1
'7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide'
trichostatin-a
BCP01776
trichostatin a, streptomyces sp. - cas 58880-19-6
58880-19-6 (r-isomer)
EX-A1665
sr-05000013796
SR-05000013796-3
Q425894
2,4-heptadienamide,7-[4-(dimethylamino)phenyl]-n-hydroxy-4,6-dimethyl-7-oxo-, (2e,4e,6r)-
PD119680
AC-35470

Research Excerpts

Overview

ExcerptReference
"Trichostatin A (TSA) is a novel histone deacetylase inhibitor (HDACI) that was recently reported to exert multiple pharmacological functions."( Hao, T; Jiang, H; Lv, X; Qiu, J; Tan, Y; Zhang, H, 2021)
"Trichostatin A (TSA) is a noncompetitive, reversible inhibitor of class I and II histone deacetylases (HDACs)."( Jung, J; Kim, M; Park, C; Yeo, SG, 2019)
"Trichostatin A (TsA) is a pan-inhibitor of HDAC."( Bujak, J; Kopytko, P; Pawlik, A; Piotrowska, K; Tarnowski, M; Tkacz, M, 2019)
"Trichostatin A (TSA) is a classic histone deacetylases inhibitor (HDACi) that specifically inhibits the biochemical functions of HDAC and is demonstrated to be an active anticancer drug."( He, G; Pang, X; Wang, Y; Zhang, B, 2014)
"Trichostatin A (TSA) is a selective inhibitor of mammalian histone deacetylase. "( Kanasaki, H; Mijiddorj, T; Miyazaki, K; Oride, A; Sukhbaatar, U, 2014)
"Trichostatin A (TSA) is a histone deacetylase (HDAC) inhibitor. "( Lina, X; Liu, XC; Lu, SM; Qin, MB; Wu, H; Wu, HY; Wu, YH; Yang, XL; Zhang, CD; Zhang, YN, 2014)
"Trichostatin A (TSA) is a histone deacetylase inhibitor with beneficial effects in spinal muscular atrophy mouse models that carry the human SMN2 transgene."( Beauvais, A; Kothary, R; Liu, H; Murray, LM; Yazdani, A, 2014)
"Trichostatin A (TSA) is a kind of classical histone deacetylase (HDAC) inhibitor. "( Cai, S; Du, J; Wang, H; Wang, X; Wu, L; Xu, J; Yuan, W, 2015)
"Trichostatin A (TSA) is a histone deacetylase inhibitor with anti-inflammatory effects. "( Chu, SJ; Hsu, HH; Huang, KL; Li, MH; Tang, SE; Wu, GC; Wu, SY, 2015)
"Trichostatin A (TSA) is an anti-inflammatory agent that has been shown to exert protective effects against cisplatin-induced ototoxicity."( Chen, J; Chen, X; Ge, J; Huang, J; Li, M; Wang, P, 2015)
"Trichostatin A (TSA) is a histone deacetylase inhibitor and a potential therapeutic for various malignancies. "( Allen, TD; Dong, F; Li, L; Li, Y; Liu, J; Lobe, CG; Masuda, T, 2015)
"Trichostatin A (TSA) is a selective inhibitor of mammalian histone deacetylase and is widely used to modify the ability of DNA transcription factors to bind DNA within chromatin by interfering with histone deacetylation. "( Ishihara, T; Kanasaki, H; Kyo, S; Mijiddorj, T; Oride, A; Sukhbaatar, U; Yamagami, I, 2015)
"Trichostatin A (TSA) is a potent cell-permeable HDAC inhibitor that blocks cell cycle progression."( Asari, Y; Daimon, M; Desaki, R; Ishigame, N; Iwasaki, Y; Kageyama, K; Murasawa, S; Nakada, Y; Niioka, K; Sugiyama, A; Takayasu, S, 2015)
"Trichostatin A (TSA) is a well-known histone deacetylases (HDACs) inhibitor that has been reported to show potent anti-tumor capabilities in some types of cancer cell lines. "( Li, C; Liu, B; Liu, H; Liu, J; Tao, Y; Wang, G, 2016)
"Trichostatin A (TSA) is an HDAC inhibitor specific in class I and II HDAC enzymes."( Chu, XG; Gong, ZJ; Li, X; Wang, LW; Yang, F; Zhang, H; Zhang, HY; Zhang, Q, 2016)
"Trichostatin A (TSA) is an inhibitor of histone deacetylase, potentially enhancing cloning efficiency."( Bolund, L; Bøgh, IB; Du, Y; Kragh, PM; Li, J; Lin, L; Maddox-Hyttel, P; Purup, S; Schmidt, M; Svarcova, O; Vajta, G; Villemoes, K; Xue, Q; Yang, H; Zhang, Y, 2008)
"Trichostatin A (TSA) is a histone deacetylase inhibitor that has antiproliferative and differentiation-inducing effects on cancer cells, and in cultures of primary hepatocytes has been shown to maintain xenobiotic metabolic capacity. "( Athersuch, TJ; Cavill, R; Chan, PH; Doktorova, T; Ellis, JK; Keun, HC; M D Ebbels, T; Nicholson, JK; Rogiers, V; Vanhaecke, T; Vinken, M, 2010)
"Trichostatin A (TSA) is a well-characterized histone deacetylase (HDAC) inhibitor. "( Kang, HJ; Kim, SH; Lee, MO; Na, H, 2010)
"Trichostatin A (TSA) is a histone deacetylase inhibitor (HDACi) known to modulate differentiation of many cells. "( Chen, TH; Chen, YT; Chiang, ER; Hung, SC; Lee, HH; Lee, YT; Liu, CL; Wang, JP; Wen, MH, 2011)
"Trichostatin A (TSA) is a histone deacetylase inhibitor that induces histone hyperacetylation and increases gene expression levels. "( de Lima, MR; de Souza, MM; Garcia, JM; Oliveira, CS; Saraiva, NZ; Tetzner, Tde A, 2013)
"Trichostatin A (TSA) is a most potent reversible inhibitor of mammalian histone deacetylases."( Qi, J; Yang, ZG; Zhang, FQ, 2011)
"Trichostatin A (TSA) is a potent histone deacetylase inhibitor and widely used as a promising anticancer agent. "( Chen, X; Lu, M; Wang, P; Yu, L, 2012)
"Trichostatin A (TSA) is a potent histone deacetylase (HDAC) inhibitor with a broad spectrum of epigenetic activities known to regulate diverse cellular mechanisms, including differentiation of mesenchymal stem cells. "( Choi, H; Choung, PH; Jin, H; Park, JY, 2013)
"Trichostatin A (TSA) is a histone deacetylase (HDAC) inhibitor with potential in cancer therapeutics. "( Ailenberg, M; Silverman, M, 2003)
"Trichostatin A is a potent and specific histone deacetylase inhibitor with promising antitumor activity in preclinical models. "( Aboagye, EO; Alao, JP; Coombes, RC; Latigo, JR; Sanderson, L; Taylor, GW; Vigushin, DM, 2004)
"Trichostatin A (TSA) is a histone deacetylase inhibitor that causes growth inhibition of malignant cells. "( Arnold, B; Pollack, IF; Premkumar, DR; Wetzel, M, 2005)
"Trichostatin A (TSA) is a potent histone deacetylase inhibitor and has demonstrated significant antitumor activity against a variety of cancer cell lines. "( Cutshaw, A; Davidoff, AM; Dickson, PV; Hamner, JB; McGee, M; Ng, CY; Rosati, S; Sims, TL, 2008)
"Trichostatin A (TSA) is a Streptomyces metabolite which specifically inhibits mammalian histone deacetylase at a nanomolar concentration and causes accumulation of highly acetylated histone molecules in mammalian cells. "( Beppu, T; Horinouchi, S; Hoshikawa, Y; Kwon, HJ; Yoshida, M, 1994)
"Trichostatin A is a specific inhibitor of histone deacetylase; therefore, we propose that hyperacetylation of histones after drug treatment changes the structure of chromatin on integrated viral sequences and relieves repression of transduced genes."( Bailey, EC; Chen, WY; Dong, JY; McCune, SL; Townes, TM, 1997)
"Trichostatin A (TSA) is a potent reversible inhibitor of histone deacetylase, and it has been reported to have variable effects on the expression of a number of genes. "( Fisher, CU; Nambiar, MP; Tsokos, GC; Warke, VG, 2002)
"(R)-Trichostatin A (TSA) is a Streptomyces product which causes the induction of Friend cell differentiation and specific inhibition of the cell cycle of normal rat fibroblasts in the G1 and G2 phases at the very low concentrations. "( Akita, M; Beppu, T; Kijima, M; Yoshida, M, 1990)

Effects

ExcerptReference
"Trichostatin A (TSA) has been revealed to show protective effect on central nervous systems in Alzheimer's disease (AD) and hypoxic-ischemic brain injury."( Hao, J; Jin, T; Kong, D; Li, F; Wei, W; Zhang, Q; Zhao, J; Zhao, S; Zhu, L, 2023)
"Trichostatin A (TSA) has been shown to mitigate whole body γ-radiation-induced morbidity and mortality. "( Agrawala, PK; Gupta, N; Kainthola, A; Tiwari, M, 2020)
"Trichostatin A (TSA) has previously been used in somatic cell nuclear transfer (SCNT) to improve the cloning efficiency in several species, which led our team to investigate the effects of TSA on the full-term development of bovine SCNT and gaur-bovine interspecies SCNT (gaur iSCNT; gaur somatic cells as donors and bovine oocytes as recipients) embryos. "( Chaimongkol, C; Imsoonthornruksa, S; Ketudat-Cairns, M; Laowtammathron, C; Parnpai, R; Sangmalee, A; Srirattana, K; Thongprapai, T; Tunwattana, W, 2012)
"Trichostatin A (TSA) has been shown to prevent fibrosis in vitro and in vivo. "( Chen, P; Danielson, P; Duan, H; Qu, M; Shi, W; Wang, Y; Yang, L; Zhou, Q, 2013)
"Trichostatin A (TSA) has potent antitumor activity, but its exact mechanism on EBV-infected cells is unclear."( Choi, KC; Jang, YS; Jeon, YM; Kim, J; Kim, JG; Kook, SH; Lee, HJ; Lee, JC; Lee, WK; Son, YO, 2006)

Actions

ExcerptReference
"Trichostatin A (TSA) promotes SCNT embryo development, but whether TSA modifies SCNT blastocyst numbers is unclear."( Fu, B; Guo, Z; Liu, D; Lv, L, 2018)
"Trichostatin A was used to inhibit histone deacetylases (HDACs)."( Alexander, JS; Gu, Y; Lewis, DF; Wang, Y, 2019)
"Trichostatin A did not inhibit degradation of IκBα, nuclear translocation and DNA binding of NF-κB; also, the drug did not affect transient expression from exogenous κB-reporter plasmids."( Furumai, R; Horinouchi, S; Ito, A; Maeda, S; Nishino, N; Ogawa, K; Saito, A; Yoshida, M, 2011)

Treatment

ExcerptReference
"Trichostatin A treatment remarkably suppressed osteogenesis, decreasing HDAC expression and enhancing histone H3 acetylation."( Fujita, T; Ishida, S; Iwata, T; Kajiya, M; Kaneda-Ikeda, E; Kurihara, H; Matsuda, S; Mizuno, N; Nagahara, T; Ouhara, K; Sasaki, S; Takahashi, K; Takeda, K; Yoshioka, M, 2023)
"Trichostatin A treatment induced CTNNA2 expression in SK-N-AS cells, and combination treatment with Trichostatin A induced retinoic acid sensitivity in retinoic acid-resistant cells."( Chung, DH; Clark, RA; Lee, S; Newton, M; Qiao, J, 2021)
"Trichostatin A treatment also resulted in cell stiffening and decreased migratory ability in KFs."( Chen, WR; Cheng, CM; Harn, HI; Ho, YT; Hsu, CK; Lee, JY; Lee, YC; Lin, HH; McGrath, JA; Ogawa, R; Shieh, SJ; Tang, MJ; Wang, YK, 2018)
"Trichostatin A treatment resulted in an increase in MKK3 phosphorylation or acetylation in myocardium."( Du, J; Liu, P; Zhang, LX; Zhao, TC; Zhuang, S, 2013)
"Trichostatin A treatment could moderately increase H3-K9 acetylation at the silenced loci; however, it had no effect on DNA and H3-K9 methylation and minimal effects on NGX6 expression."( Dai, D; Liu, J; Xu, X; Zhu, X, 2014)
"Trichostatin A treatment of donor cells significantly improved both cleavage and blastocyst rate (P<0.05) compared with the control embryos, also apoptotic index in treated cloned blastocysts was significantly decreased compared with the nontreated blastocysts (P<0.05) and was at the level of IVF counterpart."( Chauhan, MS; Madan, P; Palta, P; Revey, T; Saini, M; Selokar, NL; Singla, SK, 2014)
"Trichostatin A treatment of human epidermoid carcinoma A431 cells inhibited the EGF-induced 12(S)-lipoxygenase enzymatic activity in a dose-dependent manner that was consistent with the expression of 12(S)-lipoxygenase mRNA and protein."( Chang, WC; Chen, BK; Chen, CJ, 2008)
"Trichostatin A and ADC treatment also suppressed the cell cycle progression in ectopic endometrial stromal cells."( Guo, SW, 2010)
"Trichostatin A treatment also showed therapeutic effects on arthritis in SKG mice, when it was administered after the onset of arthritis."( Fujita, M; Kasagi, S; Kumagai, S; Matsuki, F; Misaki, K; Miyamoto, Y; Morinobu, A; Saegusa, J, 2011)
"Trichostatin A treatment results in not only histone hyperacetylation but also an increase in methylation of H3-K4, increase in dual modification of pS10/acK14, and reduction in methylation of H3-K9, revealing an extensive interplay between histone acetylation, methylation, and phosphorylation."( Allis, CD; Huang, ZQ; Li, J; Lin, Q; Strahl, BD; Wong, J; Yoon, HG, 2002)
"Trichostatin A treatment reduced the percentage of cells in S phase (10% to 23%) and increased G1 populations (10% to 40%) as determined by flow cytometry."( Bueno, R; Gilchrist, D; Jaklitsch, MT; Mukhopadhyay, NK; Sugarbaker, DJ; Weisberg, E, 2006)
"Trichostatin A treatment elevated expression of ADH1C."( Chen, HJ; Dannenberg, LO; Edenberg, HJ; Tian, H, 2006)
"Trichostatin A treatment led to a time- and dose-dependent inhibition in carcinoma cells A549 proliferation (Twenty-four hours after the treatment of TSA The inhibition rates of the A549 cells in the control group and the cells treated with TSA of the concentrations of 5, 10, 20, and 40 microg/L were 6.2%+/-1.1%, 18.5%+/-2.3%, 28.9%+/-3.6%, 39.4%+/-3.7%, and 45.6%+/-2.7% respectively 24 hours later (P<0.05): 8.1%+/-2.3%, 26.9%+/-4.2%, 35.6%+/-3.8%, 56.5%+/-6.1%, and 69.8%+/-5.3% 48 h later (P<0.05); and 10.5%+/-1.3%, 28.4%+/-3.2%, 50.5%+/-5.8%, 70.5%+/-6.9%, and 78.6%+/-4.5% 72 h later (P<0.05). "( Meng, M; Wang, CT, 2007)
"Trichostatin A treatment did not modify MBD1 binding to the ABCB1 promoter and similarly increased PCAF binding in both H69 cell lines."( Breuzard, G; Dufer, J; El-Khoury, V; Fourré, N, 2007)
"Trichostatin A treatment results in dramatic reactivation of gene expression that is preceded by histone acetylation and chromatin decondensation."( Chen, WY; Townes, TM, 2000)
"Trichostatin A treatment arrests cells at the G(2)-M phase of the cell cycle, which is consistent with the hypothesis that the proper formation of the chromatin after DNA replication may be important in signaling the progression through the cell cycle."( Milutinovic, S; Szyf, M; Zhuang, Q, 2002)
"Pretreatment with trichostatin A, a pan-histone deacetylase inhibitor that renders chromatin decondensation, significantly decreased the number of mutations in UVB-irradiated keratinocytes."( Ha, W; Liu, L; Queen, D; Shen, Y; Zeng, W, 2020)
"Pre-treatment of trichostatin A significantly hampered glomerulosclerosis and tubulointerstitial fibrosis, as did the pre-treatment with valproic acid."( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013)
"Treatment with Trichostatin A, relaxing chromatin, recovers both transcription initiation and UV-survival."( Coin, F; Eberova, J; Egly, JM; Giglia-Mari, G; Mari, PO; Nardo, T; Oksenych, V; Stefanini, M; Zhovmer, A; Ziani, S, 2013)
"Treatment with trichostatin A, a histone deacetylase inhibitor, predominantly up-regulated NDRG2 expression in the NDRG2 low-expressing cell lines (PANC-1, PCI-35, PK-45P, and AsPC-1)."( Abe, K; Egawa, S; Fukushige, S; Horii, A; Kaneko, N; Karasawa, H; Miura, K; Mizuguchi, Y; Morishita, K; Motoi, F; Nagase, H; Saiki, Y; Sasaki, I; Sase, T; Shibata, C; Sunamura, M; Unno, M; Yamamura, A, 2013)
"Pretreatment with trichostatin A decreased amylase levels by 70 % and protected against tissue injury in the pancreas. "( Hartman, H; Regnér, S; Thorlacius, H; Wetterholm, E, 2015)
"Treatment with trichostatin A (TSA) led to defective callus formation on callus-inducing medium (CIM)."( Jung, SJ; Lee, K; Park, OS; Seo, PJ, 2016)
"Treatment with Trichostatin A (TSA), a broad-spectrum HDAC inhibitor, restored their physical association, and attenuated Ang-II-induced MMP9 expression, IL-18 induction, and extracellular matrix (collagen I, collagen III and fibronectin) production."( Chandrasekar, B; Higashi, Y; Krenz, M; McDonald, KS; Noda, M; Somanna, NK; Valente, AJ, 2016)
"Treatment with trichostatin A led to enhanced acetylation of histone H3-K9 with concurrent induction of E-cadherin mRNA in 3 E-cadherin low/negative cell lines that are not DNA methylated."( Eu, KW; Hong, Y; Ismail, TM; Liu, Y; Wong, Y; Zhao, Y, 2008)
"Co-treatment with trichostatin A maintained near-normal levels of acetylation of histone core proteins in cochlear hair cells and attenuated gentamicin-induced cell death."( Chen, FQ; Schacht, J; Sha, SH, 2009)
"Treatment with trichostatin A, a classical HDAC inhibitor, also decreased pathogenesis."( Arie, T; Izawa, M; Kamakura, T; Kimura, M; Takekawa, O; Teraoka, T; Yoshida, M, 2009)
"Treatment with trichostatin A at 50 ng/mL decreased the collagen level in cells from neurogenic bladders to almost normal levels (2.1 microg/mL)."( Atala, A; Hodges, SJ; Mishra, N; Yoo, JJ, 2010)
"Treatment with trichostatin A or apicidine suppressed the proliferation in all cell lines examined, in association with increased expression of p21 and down-regulation of cyclin D1 and cyclin A expression."( Fakhry, H; Kashima, H; Ke, H; Konishi, I; Miyamoto, T; Shiozawa, T; Suzuki, A, 2010)
"Treatment with trichostatin A, which inhibits histone deacetylases, resulted in increased histone H4 acetylation accompanied by the decondensation of interphase chromatin and a decrease in both global H3K9 dimethylation and DNA methylation during mitosis in maize root tip cells. "( Huang, J; Li, J; Li, L; Ma, L; Wen, R; Yang, F; Zhang, L; Zhou, D, 2010)
"Treatment with trichostatin A and 5-azacytidine treatment caused a decrease in the mitotic index, suggesting that H4 deacetylation and DNA and H3K9 methylation may contain the necessary information for triggering mitosis in maize root tips."( Huang, J; Li, J; Li, L; Ma, L; Wen, R; Yang, F; Zhang, L; Zhou, D, 2010)
"Treatment with Trichostatin A alone had no significant effect on the expression of PCDH10 but enhanced the effect of 5'-azacytidin."( Cai, Z; Gui, Y; Li, W; Li, X; Li, Z; Tang, A; Wang, Y; Xie, J; Ye, J, 2011)
"Treatment with trichostatin A, a histone deacetylase inhibitor, blocks chromatin structural changes but not nuclear tyrosine phosphorylation by c-Abl."( Aoyama, K; Fukumoto, Y; Horiike, Y; Ishibashi, K; Kubota, S; Morinaga, T; Nakayama, Y; Takahashi, A; Yamaguchi, N; Yuki, R, 2011)
"Treatment with trichostatin A, but not other histone deacetylase inhibitors, partially restored reelin transcription and promoted the accumulation of mutant ATXN7 into nuclear inclusions."( Bekiranov, S; Dent, SY; Grant, PA; McCullough, SD; Roeder, RG; Xu, X, 2012)
"Treatment with trichostatin A, a histone deacetylase inhibitor, resulted in hTERT reactivation only in very early differentiating HT cells."( Andrews, LG; Hansen, NJ; Key, JS; Lopatina, NG; Pita, MA; Poole, JC; Saldanha, SN; Tollefsbol, TO, 2003)
"Treatment with trichostatin A, which is an inhibitor of histone deacetylase, or PML over-expression relieved Daxx-mediated transcriptional repression of p53."( Kim, EJ; Park, JS; Um, SJ, 2003)
"Treatment with trichostatin A and calphostin C led to a 50% to 90% decrease of trichostatin A- mediated upregulation of nuclear factor kappaB and p21 activation."( Cole, GW; Maxhimer, JB; Nguyen, DM; Reddy, RM; Schrump, DS; Zuo, J, 2005)
"Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis."( Bang, YJ; Jong, HS; Jung, Y; Kim, JH; Kim, TY; Lee, JH; Park, JH, 2006)
"Treatment with trichostatin A (TSA), an inhibitor of histone deacetylases, induced histone hyperacetylation of meiotic chromosomes from which endogenous BRD4, however, remained dissociated."( Arase, T; Furuya, M; Kajitani, T; Maruyama, T; Masuda, H; Nagashima, T; Ono, M; Ozato, K; Uchida, H; Yoshimura, Y, 2007)
"Treatment with trichostatin A, a potent inhibitor of the transcriptional co-repressor HDAC, partially reversed the inhibitory effect of BCL3."( Ego, T; Hishiki, T; Ohshima, T; Shimotohno, K, 2007)
"Treatment with trichostatin A, a specific inhibitor of histone deacetylase, reduces the expression of the active maternal H19 allele and this can be correlated with regional changes in acetylation within the upstream regulatory domain."( Ferguson-Smith, A; Grandjean, V; O'Neill, L; Sado, T; Turner, B, 2001)

Roles (3)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
EC 3.5.1.98 (histone deacetylase) inhibitorAn EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
trichostatin
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
antibiotic antifungal agentHeteroorganic entities that are microbial metabolites (or compounds derived from them) which have significant antifungal properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (71)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
ATAD5 protein, partialHomo sapiens (human)Potency11.53660.004110.890331.5287AID624247; AID624252; AID624253; AID686934; AID720565
PPM1D proteinHomo sapiens (human)Potency2.08210.00529.466132.9993AID1347411
Microtubule-associated protein tauHomo sapiens (human)Potency35.48130.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency17.78280.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency6.92410.016525.307841.3999AID602332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
survival motor neuron protein isoform dHomo sapiens (human)Potency1.26730.125912.234435.4813AID1458; AID1740
Interferon betaHomo sapiens (human)Potency2.08210.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HDLP (HISTONE DEACETYLASE-LIKE PROTEIN)Aquifex aeolicusIC50 (µMol)0.40000.40000.40000.4000AID977608
Chain B, HDLP (HISTONE DEACETYLASE-LIKE PROTEIN)Aquifex aeolicusIC50 (µMol)0.40000.40000.40000.4000AID977608
Chain A, Histone deacetylase 7aHomo sapiens (human)IC50 (µMol)0.30000.30000.30000.3000AID977608
Chain A, Histone deacetylase 7aHomo sapiens (human)IC50 (µMol)0.30000.30000.30000.3000AID977608
Histone deacetylase 8Schistosoma mansoniIC50 (µMol)3.62000.30341.33503.6200AID1446915
Histone deacetylase Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.35173.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)28.40000.20001.95696.3096AID1885254
Histone deacetylase 1Mus musculus (house mouse)IC50 (µMol)0.00430.00140.72308.1000AID273173; AID316880; AID90519; AID90673; AID90675; AID90680; AID90681
Histone deacetylase 1Mus musculus (house mouse)Ki0.00110.00110.03430.0676AID90677
Histone deacetylase 3Homo sapiens (human)IC50 (µMol)0.33880.00040.619610.0000AID1127324; AID1173704; AID1246509; AID1273502; AID1280315; AID1294973; AID1322059; AID1324228; AID1354393; AID1363779; AID1384761; AID1394890; AID1459968; AID1532631; AID1586079; AID1605940; AID1622918; AID1647301; AID1690108; AID1758520; AID1765326; AID1781513; AID1802398; AID1802451; AID1863435; AID1901146; AID242687; AID286454; AID316875; AID316888; AID331898; AID331899; AID366642; AID382342; AID408882; AID417646; AID420326; AID447991; AID447992; AID447994; AID456795; AID463865; AID465151; AID478330; AID488275; AID525002; AID539709; AID541646; AID568152; AID608776; AID723479; AID723726; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 3Homo sapiens (human)Ki0.08440.00020.42378.1900AID1236444; AID1479815; AID331899; AID447579; AID487226; AID496803
5-hydroxytryptamine receptor 3ACavia porcellus (domestic guinea pig)IC50 (µMol)7.69000.69004.19007.6900AID568153
Histone deacetylase 3Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
Plasma kallikreinHomo sapiens (human)IC50 (µMol)0.03400.00312.024110.0000AID269912
Integrin beta-3Homo sapiens (human)IC50 (µMol)0.02630.00010.632310.0000AID242561
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.02000.00011.774010.0000AID1354391; AID1390224
Integrin alpha-IIbHomo sapiens (human)IC50 (µMol)0.02630.00010.730910.0000AID242561
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)0.03400.00020.83363.3000AID269912
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)10.00000.00051.28547.6500AID1441630; AID1441631
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.00500.00002.015110.0000AID708216
Vitamin D3 receptorHomo sapiens (human)IC50 (µMol)0.08700.00000.43746.4300AID1915533
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)0.02800.00002.800510.0000AID1390224
Tissue factorHomo sapiens (human)IC50 (µMol)0.03200.00010.734410.0000AID269912; AID360092; AID360093; AID360094; AID360095; AID385446; AID385447
Adenosine receptor A1Bos taurus (cattle)IC50 (µMol)0.19000.00001.09106.7400AID313185
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.00500.00002.398310.0000AID708216
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)0.10000.00020.75218.0140AID80353
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.10000.00402.15557.2000AID80353
Histone deacetylase 4Homo sapiens (human)IC50 (µMol)0.85520.00061.052610.0000AID1127325; AID1173704; AID1182187; AID1246514; AID1273502; AID1530556; AID1578487; AID1622920; AID1622967; AID1781513; AID1802398; AID1802451; AID1847776; AID1901151; AID240718; AID242687; AID269912; AID286454; AID302798; AID308644; AID309968; AID313186; AID316875; AID316888; AID331616; AID331898; AID382342; AID417647; AID420326; AID447991; AID447992; AID456795; AID461092; AID463865; AID478330; AID525000; AID539709; AID541648; AID568153; AID608776; AID628435; AID695594; AID723464; AID723479; AID723726; AID764213; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 4Homo sapiens (human)Ki3.65020.00021.62559.1242AID1236446; AID1622973; AID447579; AID496804; AID760387
Histone deacetylase 2Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)0.41910.00010.55439.9000AID1127323; AID1173704; AID1173705; AID1182186; AID1246507; AID1254047; AID1273502; AID1276711; AID1280314; AID1294953; AID1322059; AID1322060; AID1322066; AID1324226; AID1354391; AID1363777; AID1384206; AID1384759; AID1390223; AID1394889; AID1401557; AID1432957; AID1459953; AID1518781; AID1525777; AID1530555; AID1532629; AID1557981; AID1578485; AID1586077; AID1589336; AID1591715; AID1605938; AID1622916; AID1622966; AID1647311; AID1651332; AID1652187; AID1659230; AID1690107; AID1709382; AID1758519; AID1764791; AID1765324; AID1781513; AID1802398; AID1802451; AID1833063; AID1863433; AID1882456; AID1901147; AID240717; AID242687; AID254791; AID269911; AID273990; AID286454; AID302797; AID308643; AID309967; AID313185; AID316875; AID316888; AID331615; AID331898; AID366640; AID382342; AID408880; AID417644; AID420325; AID420326; AID447991; AID447992; AID447993; AID456795; AID461091; AID463865; AID465149; AID478330; AID488273; AID488358; AID525003; AID538408; AID539709; AID541644; AID568150; AID608776; AID611683; AID621737; AID628437; AID650229; AID654541; AID659292; AID683274; AID695592; AID708216; AID723466; AID723479; AID723726; AID756022; AID764214; AID769934; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529; AID90661; AID90662; AID90666; AID90668
Histone deacetylase 1Homo sapiens (human)Ki0.07230.00000.49888.1900AID1236442; AID1479814; AID1622972; AID447579; AID487224; AID496801; AID760390
Splicing factor 3B subunit 3Homo sapiens (human)IC50 (µMol)0.59440.01090.93893.4810AID506784; AID507021
Histone deacetylase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.34513.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Adenosine receptor A1Sus scrofa (pig)IC50 (µMol)0.20000.20000.20000.2000AID313186
Histone deacetylase Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.35173.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Histone deacetylase 4Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
Polyamine deacetylase HDAC10Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
Histone deacetylase 3Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.35173.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Histone deacetylase-like amidohydrolaseAlcaligenaceae bacterium FB188IC50 (µMol)1.20001.00001.10001.2000AID420318
Histone deacetylase-like amidohydrolaseAlcaligenaceae bacterium FB188Ki0.70000.70003.05009.2000AID420317
Histone deacetylase 7Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
NAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)Ki226.00002.00002.00002.0000AID1423498; AID1423503
Histone deacetylase 8Mus musculus (house mouse)IC50 (µMol)0.02070.00140.02070.0400AID90519; AID90840
Histone deacetylase 7Homo sapiens (human)IC50 (µMol)0.50520.00071.02609.9000AID1127328; AID1173704; AID1246516; AID1273502; AID1578489; AID1622922; AID1781513; AID1802398; AID1802451; AID242687; AID286454; AID316875; AID316888; AID331898; AID382342; AID417650; AID420326; AID447991; AID447992; AID456795; AID463865; AID478330; AID524997; AID539709; AID541650; AID608776; AID628432; AID723479; AID723726; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 7Homo sapiens (human)Ki0.29800.00022.00059.5000AID1236448; AID447579; AID496807
Histone deacetylase 11Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
Histone deacetylase 2Homo sapiens (human)IC50 (µMol)0.64010.00010.72219.9700AID1173704; AID1173706; AID1246508; AID1273502; AID1276706; AID1294963; AID1322059; AID1324227; AID1354392; AID1363778; AID1384760; AID1401558; AID1459954; AID1578486; AID1586078; AID1605939; AID1622917; AID1630587; AID1647300; AID1651333; AID1765325; AID1781513; AID1802398; AID1802451; AID1833064; AID1863434; AID242687; AID254792; AID286454; AID316875; AID316888; AID331898; AID366641; AID367237; AID382342; AID408881; AID417645; AID420326; AID447991; AID447992; AID456795; AID463865; AID465150; AID478330; AID488274; AID525001; AID539709; AID541645; AID568151; AID608776; AID611684; AID628436; AID650228; AID659293; AID723465; AID723479; AID723726; AID756023; AID769935; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 2Homo sapiens (human)Ki0.08510.00000.47098.1900AID1236443; AID1479811; AID447579; AID487225; AID496802; AID760389
HD2 type histone deacetylase HDA106 Zea maysIC50 (µMol)0.00600.00300.17372.0000AID241474; AID273166; AID90197; AID90359; AID90682; AID90687; AID90688; AID90690; AID90691; AID90695; AID90696
HD2 type histone deacetylase HDA106 Zea maysKi0.00440.00440.06810.1318AID90199; AID90693
Polyamine deacetylase HDAC10Homo sapiens (human)IC50 (µMol)0.32660.00050.72459.9000AID1127331; AID1173704; AID1246512; AID1273502; AID1294971; AID1384758; AID1401561; AID1459974; AID1578491; AID1586085; AID1605947; AID1622925; AID1781513; AID1802398; AID1802451; AID242687; AID286454; AID316875; AID316888; AID331898; AID366645; AID382342; AID408884; AID417653; AID420326; AID447991; AID447992; AID456795; AID463865; AID465153; AID478330; AID524995; AID539709; AID541653; AID608776; AID628430; AID723479; AID723726; AID769932; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Polyamine deacetylase HDAC10Homo sapiens (human)Ki0.17190.00000.76878.1900AID1479819; AID447579; AID487231
Histone deacetylase 11 Homo sapiens (human)IC50 (µMol)0.69890.00030.92989.9000AID1127332; AID1173704; AID1246513; AID1273502; AID1294969; AID1459975; AID1532639; AID1605948; AID1622926; AID1702070; AID1781513; AID1802451; AID1898913; AID242687; AID286454; AID316875; AID316888; AID331898; AID382342; AID417654; AID420326; AID447991; AID447992; AID456795; AID463865; AID478330; AID539709; AID541654; AID608776; AID628429; AID723460; AID723479; AID723726; AID769930; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 11 Homo sapiens (human)Ki0.45250.00011.21478.1900AID1479820; AID447579
Histone deacetylase 9Mus musculus (house mouse)IC50 (µMol)0.00140.00140.00140.0014AID90519
Histone deacetylase 7Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.35173.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Histone deacetylase 6 Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.35173.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Histone deacetylase 4Rattus norvegicus (Norway rat)IC50 (µMol)0.18540.00280.35173.5120AID242559; AID242560; AID242561; AID242586; AID242587; AID242600; AID90521; AID90522
Histone deacetylase 8Homo sapiens (human)IC50 (µMol)1.29720.00070.99479.9000AID1127329; AID1173704; AID1246510; AID1254049; AID1273502; AID1276713; AID1280317; AID1294968; AID1354394; AID1363781; AID1384762; AID1394892; AID1459972; AID1529525; AID1532636; AID1586083; AID1605945; AID1622919; AID1647307; AID1651335; AID1690110; AID1702067; AID1758522; AID1765328; AID1781513; AID1802398; AID1802451; AID1833065; AID1862621; AID1863440; AID1901144; AID240720; AID242687; AID286454; AID316875; AID316888; AID331898; AID366643; AID367239; AID382342; AID408883; AID417651; AID420326; AID447991; AID447992; AID447995; AID456795; AID463865; AID465152; AID478330; AID488277; AID524996; AID539709; AID541647; AID568155; AID608776; AID611686; AID704015; AID723461; AID723479; AID723726; AID756021; AID769933; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 8Homo sapiens (human)Ki0.14050.00020.75258.1900AID1236445; AID1479813; AID1503585; AID447579; AID487228; AID496808; AID760388
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)0.25590.00000.53769.9000AID1127327; AID1173704; AID1173707; AID1246511; AID1254048; AID1273502; AID1276712; AID1280316; AID1294967; AID1322061; AID1322067; AID1324229; AID1363780; AID1384209; AID1384763; AID1394891; AID1401560; AID1424816; AID1432956; AID1459955; AID1473143; AID1518780; AID1525776; AID1528345; AID1529524; AID1530557; AID1532634; AID1557982; AID1586081; AID1591716; AID1605943; AID1622924; AID1622948; AID1647309; AID1651334; AID1659237; AID1690109; AID1709383; AID1758521; AID1764792; AID1765327; AID1781513; AID1802398; AID1802451; AID1833066; AID1862620; AID1863438; AID1882462; AID1895827; AID1901145; AID240719; AID242687; AID254794; AID269913; AID286454; AID308645; AID313187; AID316875; AID316888; AID331617; AID331898; AID331900; AID366644; AID367238; AID382342; AID408885; AID417649; AID420326; AID447991; AID447992; AID447996; AID456795; AID461093; AID463865; AID465154; AID478330; AID488276; AID524999; AID538409; AID539709; AID541652; AID568154; AID608776; AID611685; AID628433; AID695596; AID708215; AID723462; AID723479; AID723726; AID764212; AID769931; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 6Homo sapiens (human)Ki0.07300.00010.41568.1900AID1236450; AID1479812; AID331900; AID447579; AID487227; AID496806; AID760386
Histone deacetylase 9Homo sapiens (human)IC50 (µMol)0.57040.00050.94139.9000AID1127330; AID1173704; AID1246517; AID1273502; AID1578490; AID1622923; AID1781513; AID1802398; AID1802451; AID242687; AID286454; AID316875; AID316888; AID331898; AID382342; AID417652; AID420326; AID447991; AID447992; AID456795; AID463865; AID478330; AID524994; AID539709; AID541651; AID608776; AID628431; AID723479; AID723726; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 9Homo sapiens (human)Ki0.70130.00021.85209.0000AID1236449; AID447579; AID496809
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)0.53320.00070.961010.0000AID1127326; AID1173704; AID1246515; AID1273502; AID1578488; AID1622921; AID1781513; AID1802398; AID1802451; AID242687; AID286454; AID316875; AID316888; AID331898; AID382342; AID417648; AID420326; AID447991; AID447992; AID456795; AID463865; AID478330; AID524998; AID539709; AID541649; AID608776; AID628434; AID723463; AID723479; AID723726; AID80353; AID90208; AID90211; AID90350; AID90351; AID90354; AID90528; AID90529
Histone deacetylase 5Homo sapiens (human)Ki1.28600.00021.29939.5000AID1236447; AID447579; AID496805; AID760385
Histone deacetylase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.00060.00060.16880.9400AID414980
Nuclear receptor corepressor 2Homo sapiens (human)IC50 (µMol)0.01380.00170.59528.0000AID1294973; AID1363779; AID1532631; AID1622918; AID1647301; AID1901146; AID331899
Nuclear receptor corepressor 2Homo sapiens (human)Ki0.00050.00030.33253.2000AID1479815; AID331899
Histone deacetylase 6Mus musculus (house mouse)IC50 (µMol)0.03870.00060.20660.7870AID1182188; AID1390224; AID1622968; AID302799; AID309969; AID90519; AID90835
Histone deacetylase 5Mus musculus (house mouse)IC50 (µMol)0.01070.00140.01070.0200AID90519; AID90699
Histone deacetylase Zea maysIC50 (µMol)0.00040.00040.01330.0300AID273168; AID384316
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone deacetylase 4Homo sapiens (human)EC50 (µMol)2.50000.03002.35236.7000AID209973
Histone deacetylase 1Homo sapiens (human)EC50 (µMol)3.50000.03001.98776.7000AID208533; AID90679
Histone deacetylase 1Homo sapiens (human)Kd0.01370.01210.10490.2820AID1802399
Histone deacetylase 2Homo sapiens (human)Kd0.01370.01210.11300.2820AID1802399
Histone deacetylase 6Homo sapiens (human)EC50 (µMol)0.00520.00521.59986.7000AID1266100
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
unnamed protein productSaccharomyces cerevisiae (brewer's yeast)AC500.00080.00080.00080.0008AID463208
Histone deacetylase 3Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 3Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 4Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 4Homo sapiens (human)EC1000 (µMol)0.02000.02000.02000.0200AID461095
Histone deacetylase 4Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 1Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 1Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 7Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 7Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 2Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 2Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Polyamine deacetylase HDAC10Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Polyamine deacetylase HDAC10Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 11 Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 11 Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 8Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 8Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 6Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 6Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 9Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 9Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
Histone deacetylase 5Homo sapiens (human)AC500.40000.01002.70207.9000AID90344
Histone deacetylase 5Homo sapiens (human)Inhibition0.00350.00350.04170.0800AID243634
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (438)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
establishment of mitotic spindle orientationHistone deacetylase 3Homo sapiens (human)
in utero embryonic developmentHistone deacetylase 3Homo sapiens (human)
positive regulation of protein phosphorylationHistone deacetylase 3Homo sapiens (human)
chromatin organizationHistone deacetylase 3Homo sapiens (human)
transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
protein deacetylationHistone deacetylase 3Homo sapiens (human)
regulation of mitotic cell cycleHistone deacetylase 3Homo sapiens (human)
positive regulation of protein ubiquitinationHistone deacetylase 3Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 3Homo sapiens (human)
positive regulation of TOR signalingHistone deacetylase 3Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
regulation of multicellular organism growthHistone deacetylase 3Homo sapiens (human)
positive regulation of protein import into nucleusHistone deacetylase 3Homo sapiens (human)
regulation of circadian rhythmHistone deacetylase 3Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
negative regulation of JNK cascadeHistone deacetylase 3Homo sapiens (human)
spindle assemblyHistone deacetylase 3Homo sapiens (human)
establishment of skin barrierHistone deacetylase 3Homo sapiens (human)
cellular response to fluid shear stressHistone deacetylase 3Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone deacetylase 3Homo sapiens (human)
DNA repair-dependent chromatin remodelingHistone deacetylase 3Homo sapiens (human)
cornified envelope assemblyHistone deacetylase 3Homo sapiens (human)
negative regulation of cardiac muscle cell differentiationHistone deacetylase 3Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
Factor XII activationPlasma kallikreinHomo sapiens (human)
proteolysisPlasma kallikreinHomo sapiens (human)
blood coagulationPlasma kallikreinHomo sapiens (human)
zymogen activationPlasma kallikreinHomo sapiens (human)
plasminogen activationPlasma kallikreinHomo sapiens (human)
fibrinolysisPlasma kallikreinHomo sapiens (human)
positive regulation of fibrinolysisPlasma kallikreinHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Bos taurus (cattle)
response to purine-containing compoundAdenosine receptor A1Bos taurus (cattle)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
chromatin remodelingHistone deacetylase 4Homo sapiens (human)
protein deacetylationHistone deacetylase 4Homo sapiens (human)
inflammatory responseHistone deacetylase 4Homo sapiens (human)
nervous system developmentHistone deacetylase 4Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 4Homo sapiens (human)
response to denervation involved in regulation of muscle adaptationHistone deacetylase 4Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone deacetylase 4Homo sapiens (human)
protein sumoylationHistone deacetylase 4Homo sapiens (human)
B cell differentiationHistone deacetylase 4Homo sapiens (human)
positive regulation of protein sumoylationHistone deacetylase 4Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 4Homo sapiens (human)
B cell activationHistone deacetylase 4Homo sapiens (human)
regulation of protein bindingHistone deacetylase 4Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 4Homo sapiens (human)
negative regulation of glycolytic processHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
type I interferon-mediated signaling pathwayHistone deacetylase 4Homo sapiens (human)
response to interleukin-1Histone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
RNA splicing, via transesterification reactionsSplicing factor 3B subunit 3Homo sapiens (human)
mRNA splicing, via spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
regulation of DNA repairSplicing factor 3B subunit 3Homo sapiens (human)
RNA splicingSplicing factor 3B subunit 3Homo sapiens (human)
negative regulation of protein catabolic processSplicing factor 3B subunit 3Homo sapiens (human)
regulation of RNA splicingSplicing factor 3B subunit 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSplicing factor 3B subunit 3Homo sapiens (human)
U2-type prespliceosome assemblySplicing factor 3B subunit 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
base-excision repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
determination of adult lifespanNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
response to UVNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
retrotransposon silencingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid metabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of telomere maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
ketone biosynthetic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein import into nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
glucose homeostasisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of circadian rhythmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gene expression, epigeneticNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glycolytic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glucose importNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein export from nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fibroblast proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein delipidationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
cardiac muscle cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of cold-induced thermogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell population maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of chondrocyte proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein localization to plasma membraneNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of blood vessel branchingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein localization to site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 7Homo sapiens (human)
vasculogenesisHistone deacetylase 7Homo sapiens (human)
chromatin remodelingHistone deacetylase 7Homo sapiens (human)
protein deacetylationHistone deacetylase 7Homo sapiens (human)
cell-cell junction assemblyHistone deacetylase 7Homo sapiens (human)
protein sumoylationHistone deacetylase 7Homo sapiens (human)
negative regulation of interleukin-2 productionHistone deacetylase 7Homo sapiens (human)
negative regulation of osteoblast differentiationHistone deacetylase 7Homo sapiens (human)
regulation of mRNA processingHistone deacetylase 7Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 7Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionHistone deacetylase 7Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
response to amphetamineHistone deacetylase 2Homo sapiens (human)
cardiac muscle hypertrophyHistone deacetylase 2Homo sapiens (human)
chromatin remodelingHistone deacetylase 2Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 2Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 2Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 2Homo sapiens (human)
negative regulation of neuron projection developmentHistone deacetylase 2Homo sapiens (human)
dendrite developmentHistone deacetylase 2Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 2Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 2Homo sapiens (human)
response to caffeineHistone deacetylase 2Homo sapiens (human)
heterochromatin formationHistone deacetylase 2Homo sapiens (human)
response to lipopolysaccharideHistone deacetylase 2Homo sapiens (human)
positive regulation of interleukin-1 productionHistone deacetylase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHistone deacetylase 2Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 2Homo sapiens (human)
positive regulation of collagen biosynthetic processHistone deacetylase 2Homo sapiens (human)
cellular response to heatHistone deacetylase 2Homo sapiens (human)
response to nicotineHistone deacetylase 2Homo sapiens (human)
protein modification processHistone deacetylase 2Homo sapiens (human)
response to cocaineHistone deacetylase 2Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHistone deacetylase 2Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 2Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 2Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of MHC class II biosynthetic processHistone deacetylase 2Homo sapiens (human)
positive regulation of proteolysisHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
behavioral response to ethanolHistone deacetylase 2Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 2Homo sapiens (human)
response to hyperoxiaHistone deacetylase 2Homo sapiens (human)
hair follicle placode formationHistone deacetylase 2Homo sapiens (human)
negative regulation of dendritic spine developmentHistone deacetylase 2Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 2Homo sapiens (human)
fungiform papilla formationHistone deacetylase 2Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 2Homo sapiens (human)
cellular response to retinoic acidHistone deacetylase 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone deacetylase 2Homo sapiens (human)
positive regulation of male mating behaviorHistone deacetylase 2Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
cellular response to dopamineHistone deacetylase 2Homo sapiens (human)
response to amyloid-betaHistone deacetylase 2Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 2Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolyamine deacetylase HDAC10Homo sapiens (human)
DNA repairPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationPolyamine deacetylase HDAC10Homo sapiens (human)
regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
macroautophagyPolyamine deacetylase HDAC10Homo sapiens (human)
positive regulation of mismatch repairPolyamine deacetylase HDAC10Homo sapiens (human)
homologous recombinationPolyamine deacetylase HDAC10Homo sapiens (human)
negative regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
polyamine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
spermidine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
epigenetic regulation of gene expressionPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationHistone deacetylase 11 Homo sapiens (human)
oligodendrocyte developmentHistone deacetylase 11 Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 11 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of cytokine productionHistone deacetylase 9Homo sapiens (human)
response to amphetamineHistone deacetylase 9Homo sapiens (human)
inflammatory responseHistone deacetylase 9Homo sapiens (human)
heart developmentHistone deacetylase 9Homo sapiens (human)
neuron differentiationHistone deacetylase 9Homo sapiens (human)
B cell differentiationHistone deacetylase 9Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 9Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 9Homo sapiens (human)
B cell activationHistone deacetylase 9Homo sapiens (human)
cholesterol homeostasisHistone deacetylase 9Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 9Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 9Homo sapiens (human)
regulation of skeletal muscle fiber developmentHistone deacetylase 9Homo sapiens (human)
regulation of striated muscle cell differentiationHistone deacetylase 9Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor corepressor 2Homo sapiens (human)
lactationNuclear receptor corepressor 2Homo sapiens (human)
response to organonitrogen compoundNuclear receptor corepressor 2Homo sapiens (human)
regulation of cellular ketone metabolic processNuclear receptor corepressor 2Homo sapiens (human)
cerebellum developmentNuclear receptor corepressor 2Homo sapiens (human)
response to estradiolNuclear receptor corepressor 2Homo sapiens (human)
estrous cycleNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of miRNA transcriptionNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (150)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone deacetylase activityHistone deacetylase 1Mus musculus (house mouse)
transcription corepressor bindingHistone deacetylase 3Homo sapiens (human)
chromatin bindingHistone deacetylase 3Homo sapiens (human)
transcription corepressor activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase activityHistone deacetylase 3Homo sapiens (human)
protein bindingHistone deacetylase 3Homo sapiens (human)
enzyme bindingHistone deacetylase 3Homo sapiens (human)
cyclin bindingHistone deacetylase 3Homo sapiens (human)
chromatin DNA bindingHistone deacetylase 3Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 3Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 3Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 3Homo sapiens (human)
protein decrotonylase activityHistone deacetylase 3Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 3Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
serine-type endopeptidase activityPlasma kallikreinHomo sapiens (human)
protein bindingPlasma kallikreinHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 4Homo sapiens (human)
histone bindingHistone deacetylase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase activityHistone deacetylase 4Homo sapiens (human)
protein bindingHistone deacetylase 4Homo sapiens (human)
zinc ion bindingHistone deacetylase 4Homo sapiens (human)
SUMO transferase activityHistone deacetylase 4Homo sapiens (human)
potassium ion bindingHistone deacetylase 4Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 4Homo sapiens (human)
identical protein bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 4Homo sapiens (human)
molecular adaptor activityHistone deacetylase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
protein bindingSplicing factor 3B subunit 3Homo sapiens (human)
protein-containing complex bindingSplicing factor 3B subunit 3Homo sapiens (human)
U2 snRNA bindingSplicing factor 3B subunit 3Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
damaged DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleotidyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleosome bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein homodimerization activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K18 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein-arginine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA damage sensor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K56 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
TORC2 complex bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin bindingHistone deacetylase 7Homo sapiens (human)
transcription corepressor activityHistone deacetylase 7Homo sapiens (human)
histone deacetylase activityHistone deacetylase 7Homo sapiens (human)
protein kinase C bindingHistone deacetylase 7Homo sapiens (human)
protein bindingHistone deacetylase 7Homo sapiens (human)
SUMO transferase activityHistone deacetylase 7Homo sapiens (human)
protein kinase bindingHistone deacetylase 7Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 7Homo sapiens (human)
metal ion bindingHistone deacetylase 7Homo sapiens (human)
14-3-3 protein bindingHistone deacetylase 7Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 7Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 2Homo sapiens (human)
chromatin bindingHistone deacetylase 2Homo sapiens (human)
RNA bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 2Homo sapiens (human)
protein bindingHistone deacetylase 2Homo sapiens (human)
enzyme bindingHistone deacetylase 2Homo sapiens (human)
heat shock protein bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 2Homo sapiens (human)
histone bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 2Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 2Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 2Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 2Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
protein bindingPolyamine deacetylase HDAC10Homo sapiens (human)
zinc ion bindingPolyamine deacetylase HDAC10Homo sapiens (human)
deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
enzyme bindingPolyamine deacetylase HDAC10Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase bindingPolyamine deacetylase HDAC10Homo sapiens (human)
acetylputrescine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
acetylspermidine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityHistone deacetylase 11 Homo sapiens (human)
protein bindingHistone deacetylase 11 Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 11 Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein kinase C bindingHistone deacetylase 9Homo sapiens (human)
protein bindingHistone deacetylase 9Homo sapiens (human)
histone H3K14 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H3K9 deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H4K16 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 9Homo sapiens (human)
metal ion bindingHistone deacetylase 9Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA bindingNuclear receptor corepressor 2Homo sapiens (human)
chromatin bindingNuclear receptor corepressor 2Homo sapiens (human)
transcription corepressor activityNuclear receptor corepressor 2Homo sapiens (human)
Notch bindingNuclear receptor corepressor 2Homo sapiens (human)
protein bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
histone deacetylase bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (98)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmHistone deacetylase 1Mus musculus (house mouse)
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Homo sapiens (human)
cytoplasmHistone deacetylase 3Homo sapiens (human)
Golgi apparatusHistone deacetylase 3Homo sapiens (human)
cytosolHistone deacetylase 3Homo sapiens (human)
plasma membraneHistone deacetylase 3Homo sapiens (human)
mitotic spindleHistone deacetylase 3Homo sapiens (human)
histone deacetylase complexHistone deacetylase 3Homo sapiens (human)
transcription repressor complexHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Mus musculus (house mouse)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionPlasma kallikreinHomo sapiens (human)
extracellular spacePlasma kallikreinHomo sapiens (human)
plasma membranePlasma kallikreinHomo sapiens (human)
extracellular exosomePlasma kallikreinHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleusHistone deacetylase 4Homo sapiens (human)
nucleoplasmHistone deacetylase 4Homo sapiens (human)
cytoplasmHistone deacetylase 4Homo sapiens (human)
cytosolHistone deacetylase 4Homo sapiens (human)
nuclear speckHistone deacetylase 4Homo sapiens (human)
histone deacetylase complexHistone deacetylase 4Homo sapiens (human)
chromatinHistone deacetylase 4Homo sapiens (human)
transcription repressor complexHistone deacetylase 4Homo sapiens (human)
nucleoplasmHistone deacetylase 2Mus musculus (house mouse)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
SAGA complexSplicing factor 3B subunit 3Homo sapiens (human)
nucleusSplicing factor 3B subunit 3Homo sapiens (human)
nucleoplasmSplicing factor 3B subunit 3Homo sapiens (human)
spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2-type spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2 snRNPSplicing factor 3B subunit 3Homo sapiens (human)
nucleolusSplicing factor 3B subunit 3Homo sapiens (human)
U12-type spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2-type precatalytic spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
catalytic step 2 spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
nucleusSplicing factor 3B subunit 3Homo sapiens (human)
nucleoplasmHistone deacetylase 1Rattus norvegicus (Norway rat)
nucleoplasmHistone deacetylase 4Mus musculus (house mouse)
nucleoplasmHistone deacetylase 3Rattus norvegicus (Norway rat)
nucleolusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
endoplasmic reticulumNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of DNA damageNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
intracellular membrane-bounded organelleNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromosome, subtelomeric regionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusHistone deacetylase 7Homo sapiens (human)
nucleoplasmHistone deacetylase 7Homo sapiens (human)
cytoplasmHistone deacetylase 7Homo sapiens (human)
cytosolHistone deacetylase 7Homo sapiens (human)
chromosome, telomeric regionHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleoplasmHistone deacetylase 2Homo sapiens (human)
cytoplasmHistone deacetylase 2Homo sapiens (human)
NuRD complexHistone deacetylase 2Homo sapiens (human)
Sin3-type complexHistone deacetylase 2Homo sapiens (human)
histone deacetylase complexHistone deacetylase 2Homo sapiens (human)
chromatinHistone deacetylase 2Homo sapiens (human)
protein-containing complexHistone deacetylase 2Homo sapiens (human)
ESC/E(Z) complexHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleusPolyamine deacetylase HDAC10Homo sapiens (human)
nucleoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytosolPolyamine deacetylase HDAC10Homo sapiens (human)
intracellular membrane-bounded organellePolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase complexPolyamine deacetylase HDAC10Homo sapiens (human)
nucleusHistone deacetylase 11 Homo sapiens (human)
plasma membraneHistone deacetylase 11 Homo sapiens (human)
histone deacetylase complexHistone deacetylase 11 Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
nucleusHistone deacetylase 9Homo sapiens (human)
nucleoplasmHistone deacetylase 9Homo sapiens (human)
cytoplasmHistone deacetylase 9Homo sapiens (human)
histone deacetylase complexHistone deacetylase 9Homo sapiens (human)
transcription regulator complexHistone deacetylase 9Homo sapiens (human)
histone methyltransferase complexHistone deacetylase 9Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
nucleusNuclear receptor corepressor 2Homo sapiens (human)
nucleoplasmNuclear receptor corepressor 2Homo sapiens (human)
membraneNuclear receptor corepressor 2Homo sapiens (human)
nuclear matrixNuclear receptor corepressor 2Homo sapiens (human)
nuclear bodyNuclear receptor corepressor 2Homo sapiens (human)
chromatinNuclear receptor corepressor 2Homo sapiens (human)
transcription repressor complexNuclear receptor corepressor 2Homo sapiens (human)
cytosolHistone deacetylase 6Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1101)

Assay IDTitleYearJournalArticle
AID90677Binding affinity towards HDAC1 (Histone deacetylase 1) in mouse A20 cells, expressed as binding constant (pKi)2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID1532634Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in Baculovirus infected insect cells using RHKK-Ac as substrate by fluorimetric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID1394889Inhibition of human HDAC1 using RHKK(Ac) as substrate2018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID385445Effect on TNF-alpha-induced TFkappaB activation assessed as p65/p50 binding to TFkappaB in HUVEC preincubated for 4 hrs measured after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID300678Antiproliferative activity against H661 cells after 48 hrs by XTT assay2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.
AID755476Inhibition of recombinant human HDAC7 using acetyl-Lys-(trifluoroacetyl)-AMC as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID1622916Inhibition of recombinant full-length human HDAC1 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1324229Inhibition of HDAC6 (unknown origin) assessed as inhibition of fluorogenic peptide deacetylation2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1384765Selectivity index, ratio of IC50 for human HDAC2 to IC50 for human HDAC62018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1595394Inhibition of HDAC in human HeLa nuclear extract assessed as enzyme residual activity at 500 nM using Boc-Lys(acetyl)-AMC as substrate and measured after 15 mins by fluorescence assay relative to control2019European journal of medicinal chemistry, Jun-15, Volume: 172Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
AID1401640Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.52 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1628751Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1294970Inhibition of human recombinant HDAC9 using trifluoroacetyl lysine as substrate2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1127328Inhibition of human HDAC7 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID488357Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1322061Inhibition of human recombinant HDAC6 expressed in baculovirus infected insect cells using BATCP as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID764213Inhibition of human recombinant HDAC4 using p53 residues 379-382 (RHKKAc) as substrate2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1758522Inhibition of human recombinant HDAC8 using [RHKK(Ac)] fluorogenic substrate2021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID1622925Inhibition of recombinant full-length human HDAC10 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1647308Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to 991 residues) expressed in baculovirus infected insect cells using Boc-K(Ac)-AMC as substrate after 90 mins by fluorimetry analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1156707Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID446381Inhibition of SIRT2 in human MCF7 cells assessed as tubulin hyperacetylation at 0.1 uM after 16 hrs by Western blot2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).
AID1853418Inhibition of human MMP-8 at 0.5 uM2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID1384758Inhibition of human HDAC10 using RHKKAc peptide as substrate2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1628763Antiproliferative activity against human PC3 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID367241Selectivity ratio of IC50 for human recombinant histone deacetylase 8 to IC50 for human recombinant histone deacetylase 62009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID525025Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 0.1 uM by RT-PCR2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1702070Inhibition of human full length HDAC11 expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID50586Inhibitory concentration against colon HCT116 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID156319Inhibitory activity against PC-3 cell line2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.
AID1401593Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.33 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID90346Ability to inhibit recombinant human histone deacetylase 1 (HDAC-1); Potent inhibitor2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.
AID1529528Antiproliferative activity against human K562 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID516284Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH412 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID90662Inhibition against partially purified human histone deacetylase 1 (HDAC-1)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID1401632Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1 x 10'-5 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1155332Inhibition of HDAC in Plasmodium falciparum 3D7 trophozoites assessed as histone H4 hyperacetylation level at 500 nM after 3 hrs by Western blotting analysis relative to control2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID385450Inhibition of IL-1-beta-induced tissue factor activity in C57BL/6J mouse macrophages preincubated for 4 hrs assessed after 5 hrs of IL1-beta challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1363777Inhibition of C-terminal FLAG-His-tagged full length recombinant human HDAC1 expressed in Sf21 insect cells using RHKK(Ac)AMC as substrate by fluorescence-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1387537Inhibition of mouse HDAC6 expressed in 293T cells at 100 uM using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay relative to control2018ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.
AID1363779Inhibition of recombinant human HDAC3/NCOR2 expressed in baculovirus infected insect cells using RHKK(Ac)AMC as substrate by fluorescence-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1384759Inhibition of human HDAC1 using RHKKAc peptide as substrate2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1459971Inhibition of recombinant human HDAC7 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1863433Inhibition of HDAC1 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID503117Induction of p21 expression in human HeLa cells at 1 uM after 24 hrs by Western blotting2007Nature chemical biology, Sep, Volume: 3, Issue:9
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID1431818Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC32017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1862613Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID366644Inhibition of HDAC6 after 17 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID723728Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID90838Tested for inhibition of Histone deacetylase 6 induced acetylated tubulin in mammalian cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID324484Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324380Induction of light chain 3-GFP level in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID43027Cytotoxicity of compound against normal human ovarian C18013S cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID1656940Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
AID90354Inhibitory concentration against human histone deacetylase (HDAC)2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID1173707Inhibition of HDAC6 (unknown origin) after 15 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Aurones as histone deacetylase inhibitors: identification of key features.
AID358673Induction of REST/NRSF-coupled repression of luciferase tagged rat RE1/NRSE BDNF promoter activity expressed in ST14A cells at 75 nM assessed as increase in luciferase activity2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
AID1529535Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1833068Selectivity ratio of IC50 for full length recombinant C-terminal GST-fusion-tagged human HDAC2 to IC50 for full length recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 insect cells2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID230221Inhibitory concentration against HDAC6/HDAC12003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID90695Inhibition of maize Histone deacetylase 2 (HD-2) activity1999Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22
Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.
AID1589335Inhibition of HDAC1 (unknown origin) using Fluor de Lys substrate at 50 uM by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID769933Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1862615Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1862608Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1236441Antitrypanosomal activity against Trypanosoma brucei brucei 427 assessed as inhibition of parasite proliferation measured as ATP levels after 48 hrs by luciferase-based assay2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1127327Inhibition of human HDAC6 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1622966Inhibition of recombinant human HDAC1 expressed in HEK293T cells using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID408886Selectivity for HDAC6 over HDAC12008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1765332Selectivity index, ratio of IC50 for human full-length recombinant C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells to IC50 for human recombinant full length HDAC22021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID628435Inhibition of human recombinant HDAC4 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1401636Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.23 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID723464Inhibition of human HDAC4 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID408887Selectivity for HDAC10 over HDAC12008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID503530Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 0.1 uM after 12 hrs by Western blot analysis2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID408882Inhibition of HDAC32008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1127326Inhibition of human HDAC5 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1529532Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1586078Inhibition of human HDAC2 using RHKKAc as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID90840Inhibitory activity against histone deacetylase 8 prepared from mouse melanoma B16/BL6 cells2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
AID1394891Inhibition of human HDAC6 using RHKK(Ac) as substrate2018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID417069Activation of mouse Wnt3a signaling expressed in HEK293 STF cells assessed as increase in transcriptional activity after 24 hrs by luciferase reporter gene-based lactate dehydrogenase assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.
AID1532656Antiangiogenic activity in zebrafish embryo assessed as effect on blood vessel development at 10 uM administered from 24 to 50 hrs post fertilization for 24 hrs and measured after 72 hrs by alkaline phosphatase assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID670032Inhibition of Class 1 histone deacetylase in human MCF7 cells assessed as up-regulation of p21 protein level at 0.5 uM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
AID324432Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID524996Inhibition of HDAC8 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1363780Inhibition of N-terminal GST-tagged recombinant human HDAC6 expressed in baculovirus infected insect cells using RHKK(Ac)AMC as substrate by fluorescence-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID654541Inhibition of human HDAC1 after 30 mins by fluorescence assay2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Trichostatin analogues JBIR-109, JBIR-110, and JBIR-111 from the marine sponge-derived Streptomyces sp. RM72.
AID1578490Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1177040Cytotoxicity against human LO2 cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.
AID551713Inhibition of HDAC by fluorescent activity assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1557982Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID417649Inhibition of human HDAC62009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID1758525Selectivity ratio of IC50 for human recombinant HDAC8 to IC50 for human recombinant HDAC62021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID1459973Inhibition of recombinant human HDAC9 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1260640Inhibition of human recombinant HDAC4 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID456799Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID683274Inhibition of HDAC1 by fluorometric assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
AID1781512Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from
AID1622918Inhibition of recombinant full-length human HDAC3/NCOR2 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1394892Inhibition of human HDAC8 using RHKAcKAc as substrate2018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1156703Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID90338Tested for inhibitory concentration required to inhibit 50% of histone deacetylase (HDAC) from human T cell leukemia Jurkat cell2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.
AID519598Selectivity index, ratio of IC50 for neonatal foreskin fibroblasts to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1605942Inhibition of recombinant human C-terminal His-fusion tagged HDAC5 (657 to 1123 residues) expressed in baculovirus infected insect cells using fluorogenic HDAC class2a as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1833064Inhibition of full length recombinant C-terminal GST-fusion-tagged human HDAC2 expressed in insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence plate reader assay2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID541646Inhibition of human HDAC3 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1651337Selectivity ratio of IC50 for recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in insect cells to IC50 of human HDAC62020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID1401622Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1 x 10'-5 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID350020Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
AID1532636Inhibition of recombinant C-terminal His-tagged human HDAC8 (1 to 377 residues) expressed in Baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID316882Growth inhibition of human neonatal foreskin fibroblasts cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID456795Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID308643Inhibition of human HDAC12007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1423502Binding affinity to recombinant human full length SIRT6 (1 to 355 residues) expressed in Escherichia coli M15 after 20 mins in presence of NAM by fluorescence-based SDS-denaturation assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
AID1421905Cytotoxicity against human NFF cells2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID487226Inhibition of recombinant HDAC32010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID487231Inhibition of HDAC102010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID90680Inhibition of mouse Histone deacetylase 1 (HDAC1) receptor2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID1764791Inhibition of full length recombinant human HDAC1 expressed in baculovirus infected Sf9 insect cells using RHKKAc fluorogenic peptide as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID1459954Inhibition of recombinant human HDAC2 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID417651Inhibition of human HDAC82009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID299644Increase in GRP78 protein level in HEK293 cells at 600 nM by immunoblot2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID385470Effect on TNF-alpha-induced NF-kappaB activation assessed as p65/p50 binding to NF-kappaB in HUVEC at 0.3 uM preincubated for 4 hrs measured after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1630623Inhibition of recombinant C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus expression system using fluorogenic substrate at 100 uM by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID1210092Increase in NAT1 enzyme activity in 100% confluent human HeLa cells at 0.5 uM using p-aminobenzoic acid substrate after 24 hrs by HPLC method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1628760Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1557981Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID90691Inhibition of maize Histone deacetylase 22004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID764212Inhibition of human recombinant HDAC6 using p53 residues 379-382 (RHKKAc) as substrate2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID524999Inhibition of HDAC6 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID385465Induction of PMA-induced TFkappaB-dependent wild type tissue factor promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of PMA challenge by luciferase reporter assay relative to control2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1901144Inhibition of human full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell using fluorogenic HDAC class 2a substrate measured after 30 mins by fluorimetry2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1622921Inhibition of recombinant full-length human HDAC5 using Boc-Lys(trifluoroacetyl)-AMC as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1276712Inhibition of recombinant human HDAC6 by fluorimetry2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors.
AID1177041Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.
AID80353Concentration required to inhibit the partially purified HDAC enzyme by 50% obtained from H1299 cell lysate2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1709383Inhibition of recombinant human full-length N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in baculovirus infected Sf9 insect cells using RHKK(Ac)AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2021Bioorganic & medicinal chemistry, 04-01, Volume: 35Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1401602Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1 x 10'-5 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID723460Inhibition of human HDAC11 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID420318Inhibition of Bordetella / Alcaligenes strain FB188 HDAH by fluorimetric assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1182190Increase in human wild type p21 protein expression in mink Mv1Lu cells after 24 hrs by p21 promoter assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.
AID1459955Inhibition of recombinant human HDAC6 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1529510Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID417646Inhibition of human HDAC32009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID143656Cytotoxicity of compound against normal human normal neonatal foreskin fibroblasts (NFF)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID704015Inhibition of human recombinant HDAC8 using fluor de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 25 mins by microplate reader analysis2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose.
AID447996Inhibition of human recombinant HDAC6 after 30 mins by fluorimetric assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID507021Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID1628750Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID331898Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from HDAC in human HeLa nuclear cell extract by fluorescence p2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID1401608Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.37 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID652766Induction of CFTR deltaF508 mutant protein expression in cystic fibrosis patient lung cells relative to control2011ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID385446Inhibition of LPS-induced tissue factor activity in human PBMC preincubated for 4 hrs assessed after 5 hrs of LPS challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1690107Inhibition of recombinant human C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorimetry analysis2020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID1173704Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Aurones as histone deacetylase inhibitors: identification of key features.
AID611684Inhibition of human HDAC2 using rhodamine as substrate after 1 hrs by fluorescence assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
AID465154Inhibition of HDAC6 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1384209Inhibition of HDAC6 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1401557Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate after 1 to 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1901151Inhibition of recombinant human N-terminal GST-fused/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf9 insect cells using fluorogenic HDAC class 2a substrate measured after 30 mins by fluorimetry2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1401633Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.33 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1479817Inhibition of recombinant human C-terminal His-tagged HDAC5 (656 to 1122 residues) expressed in baculovirus-infected insect cells using Boc-Lys(TFA)-AMC as substrate after 60 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID360096Inhibition of IL-1-beta-induced tissue factor protein expression in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1764788Inhibition of HDAC6 in mouse Neuro2a cells assessed as fold increase in ratio of acetylated alpha-tubulin to alpha tubulin at 1 uM incubated for overnight by Western blot analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID456796Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by alamar blue assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID1898913Inhibition of HDAC11 (unknown origin) using fluorogenic peptide 382 RHKK(Ac)AM as substrate and measured by fluorescence assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1578491Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID628429Inhibition of human recombinant HDAC11 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID201971Cytotoxicity of compound against normal human melanoma SK-MEL-28 cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID1155333Inhibition of histone deacetylase in Plasmodium falciparum nuclear lysates at 1 uM by fluorescence assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID566552Inhibition of HDAC in human HeLa cells at 1 uM after 10 mins by fluorometric assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells.
AID516295Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH444 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1294967Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1591717Selectivity index, ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC62019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID1690109Inhibition of recombinant human HDAC6 using RHK-K(Ac)-AMC as substrate by fluorescence based assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID538408Inhibition of recombinant human HDAC1 using Cbz-Lys(TFAc)-AMC as substrate by fluorometric analysis2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Inhibitors selective for HDAC6 in enzymes and cells.
AID1260638Inhibition of human recombinant HDAC2 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID628431Inhibition of human recombinant HDAC9 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1431817Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC62017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1431813Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC12017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1127323Inhibition of human HDAC1 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID695596Inhibition of HDAC6 by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.
AID90529Inhibitory concentration against histone deacetylase2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID496807Inhibition of human HDAC72010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1401598Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.37 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1605959Inhibition of recombinant full length human C-terminal His-tagged HDAC3 (1 to 428 residues) expressed in baculovirus infected insect cells at 10 uM using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluo2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID8297Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID1459970Inhibition of recombinant human HDAC5 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1532646Selectivity ratio of IC50 for recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) to IC50 for recombinant C-terminal His-tagged human HDAC8 (1 to 377 residues)2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID385434Inhibition of LPS-induced tissue factor activity in HUVEC at 0.3 uM preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1532640Selectivity ratio of IC50 for recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) to IC50 for recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues)2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID1656941Cytotoxicity against human A2058 cells assessed as reduction in cell viability
AID1758520Inhibition of human recombinant HDAC3 using [RHKK(Ac)] fluorogenic substrate2021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID568155Inhibition of HDAC8 by fluorescence assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1384762Inhibition of human HDAC8 using RHKAcKAc peptide as substrate2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID408885Inhibition of HDAC62008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1479811Inhibition of full length recombinant human C-terminal GST-tagged HDAC2 expressed in baculovirus-infected insect cells using RHKK(Ac)AMC as substrate after 60 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID90520Inhibition of in vitro enzyme activity measured in partially purified rat liver Histone deacetylase preparation2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
AID519597Selectivity index, ratio of IC50 for neonatal foreskin fibroblasts to IC50 for chloroquine-resistant Plasmodium falciparum Dd22008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1127324Inhibition of human HDAC3 complexed with NCOR2 using fluorogenic tetrapeptide RHKKAc as susbtrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1127330Inhibition of human HDAC9 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1280314Inhibition of human KDAC1 using [3H]acetyl histone H4 peptide substrate incubated for 60 mins by scintillation counting method2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1503585Inhibition of C-terminal His-tagged human recombinant full-length HDAC8 expressed in baculovirus expression system assessed as reduction in 7-amino-4-methylcoumarin by fluorescence based assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
AID420317Displacement of Atto700-HA from Bordetella / Alcaligenes strain FB188 HDAH by fluorescence anisotropy2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID461092Inhibition of HDAC42010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.
AID755477Inhibition of recombinant human HDAC6 using Arg-His-Lys-Lys(Ac) as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID102521Inhibitory concentration against lung H446 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID659293Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay2012European journal of medicinal chemistry, Jun, Volume: 52A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
AID756006Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Cdh1 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID1863437Inhibition of HDAC5 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1622948Inhibition of human HDAC6 using fluorogenic HDAC substrate2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1765331Selectivity index, ratio of IC50 for human recombinant full length HDAC6 to IC50 for human recombinant full length HDAC22021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1622923Inhibition of recombinant full-length human HDAC9 using Boc-Lys(trifluoroacetyl)-AMC as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1863438Inhibition of HDAC6 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1605950Inhibition of human PI3Kbeta assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID417645Inhibition of human HDAC22009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID447579Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID1647307Inhibition of recombinant C-terminal His-tagged and N-terminal Streptavidin2-tagged human HDAC8 (1 to 377 residues) expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1765326Inhibition of human full-length recombinant HDAC3 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay2021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1236443Inhibition of human HDAC22015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1656944Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability
AID1863434Inhibition of HDAC2 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID650229Inhibition of HDAC12012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1276706Inhibition of recombinant human HDAC2 by fluorimetry2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors.
AID755480Inhibition of recombinant human HDAC2 using Arg-His-Lys-Lys(Ac) as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID503115Induction of p16 expression in human HeLa cells at 1 uM after 24 hrs by Western blotting2007Nature chemical biology, Sep, Volume: 3, Issue:9
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID1628746Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1363778Inhibition of C-terminal GST-tagged recombinant human HDAC2 expressed in baculovirus infected insect cells using RHKK(Ac)AMC as substrate by fluorescence-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID420326Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1401630Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.52 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID496806Inhibition of human HDAC62010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID90661In vitro inhibition of partially purified recombinant human Histone deacetylase 12001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Design and synthesis of a novel class of histone deacetylase inhibitors.
AID316875Inhibition of HDAC from human HeLa cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID1246510Inhibition of HDAC8 (unknown origin) using RHK(Ac)K(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID568153Inhibition of HDAC4 by fluorescence assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID525021Inhibition of HDAC in human CFBE41o- cell line assessed as total CFTR protein level including CFTR glycoform at 5 uM by immunoblot analysis2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1294973Inhibition of full length human recombinant C-terminal His-tagged HDAC3 (1 to 428 residues)/human recombinant N-terminal GST-tagged NCOR2 expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1622992Antiproliferative activity against human MCF7 cells2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1246508Inhibition of HDAC2 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1765324Inhibition of human full-length recombinant HDAC1 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay2021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1260641Inhibition of human recombinant HDAC5 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID605941Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Microbial transformation of trichostatin A to 2,3-dihydrotrichostatin A.
AID385452Inhibition of baseline tissue factor activity in non-stimulated C57BL/6J mouse macrophages after 4 hrs by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1177038Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.
AID516317Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate RB3 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID43458Inhibitory concentration against breast MCF-7 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1390226Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B-based colorimetric assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
AID420325Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1441700Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS at 10 uM preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1401600Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.52 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID273168Inhibition of maize HD1B2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1384767Selectivity index, ratio of IC50 for human HDAC8 to IC50 for human HDAC62018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID723726Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1853420Inhibition of human TACE at 0.5 uM by fluorescence based assay2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID104356Cytotoxicity against human melanoma MM96L cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID1156708Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID1354369Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
AID723462Inhibition of human HDAC6 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID488277Inhibition of HDAC82010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
On the inhibition of histone deacetylase 8.
AID1647302Inhibition of recombinant N-terminal GST-tagged/C-terminal His-tagged human HDAC4 (627 to 1084 residues) expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1586081Inhibition of human HDAC6 using RHKKAc as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID90199Experimental anti-HDAC (anti-histone deacetylase) activity of the compound2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors.
AID1862621Inhibition of HDAC8 (unknown origin) measured by fluorometry assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1605948Inhibition of human recombinant N-terminal Streptavidin2-tagged HDAC11 (1 to 347 residues) expressed in baculovirus infected insect cells using fluorogenic HDAC class 2a as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1431811Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC12017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID90681Inhibition of mouse HDAC12004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID487228Inhibition of recombinant HDAC82010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID568150Inhibition of HDAC1 by fluorescence assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1702063Inhibition of recombinant human N-terminal GST-tagged and C-terminal His-tagged HDAC4 (627 to 1084 end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID382113Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by LDH reporter assay2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy.
AID756008Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Sox2 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID105452Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID756023Inhibition of HDAC2 (unknown origin) after 30 mins by fluorometric analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID143655Cytotoxicity of compound against human normal neonatal foreskin fibroblasts (NFF) cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID1758524Selectivity ratio of IC50 for human recombinant HDAC3 to IC50 for human recombinant HDAC62021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID360090Effect on TNF-alpha-induced increase in HDAC3 binding to TFkappaB in HUVEC cells at preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by chromatin immunoprecipitation assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1702065Inhibition of recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID659292Inhibition of human HDAC1 in presence of dithiothreitol by HDAC fluorescent assay2012European journal of medicinal chemistry, Jun, Volume: 52A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
AID1324226Inhibition of HDAC1 (unknown origin) assessed as inhibition of fluorogenic peptide deacetylation2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID360094Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID723466Inhibition of human HDAC1 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1293877Competitive inhibition of HDAC in human HeLa nuclear cells at 10 to 25 uM using Boc-acetyl-lysine-AMC as substrate after 30 mins by Lineweaver-Burk plot analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID1595395Inhibition of HDAC in human HeLa nuclear extract assessed as enzyme residual activity at 50 nM using Boc-Lys(acetyl)-AMC as substrate and measured after 15 mins by fluorescence assay relative to control2019European journal of medicinal chemistry, Jun-15, Volume: 172Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
AID1630622Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus expression system using fluorogenic substrate at 100 uM by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID1586082Inhibition of human HDAC7 using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID519600Antimalarial activity against Plasmodium falciparum infected in O+ human erythrocytes assessed as reduction in parasites at trophozoites stage at 200 nM after 48 hrs by Giemsa staining based microscopy2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID417647Inhibition of human HDAC42009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID1853417Inhibition of human MMP-7 at 0.5 uM2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID71648Inhibitory concentration against friend cells proliferation2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID1862606Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1651336Selectivity ratio of IC50 for recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells to IC50 of human HDAC62020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID1862612Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID350024Increase in E-cadherin mRNA expression in human NCI-H661 cells at 300 nM by qRT-PCR relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
AID1210091Increase in NAT1 enzyme activity in 40% confluent human HeLa cells at 0.5 uM using p-aminobenzoic acid substrate after 24 hrs by HPLC method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1605939Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID756005Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Dppa4 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID316876Inhibition of human SQ20B cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID1387536Inhibition of human HDAC1 expressed in 293T cells at 100 uM using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay relative to control2018ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.
AID252223Average fold change in expression of CYP1A1 after treatment with compound of concentration 0.01 mM in human MCF-7 cells2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
AID628434Inhibition of human recombinant HDAC5 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID519587Toxicity in neonatal foreskin fibroblasts2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID541647Inhibition of human HDAC8 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID360091Inhibition of TNF-alpha-induced tissue factor activity in HUVEC at 1 uM preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1901071Nephroprotective activity against cisplatin-induced acute kidney injury in male C57BL/6 mouse assessed as serum EPO level at 10 mg/kg/day, ip2022European journal of medicinal chemistry, Feb-15, Volume: 230Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1833065Inhibition of recombinant C-terminal His-fusion tagged/N-terminal Strep2 tagged human HDAC8 (1 to 377 residues) expressed in insect cells using RHK-K(Ac)-K(Ac)-AMC as substrate measured after 60 mins by fluorescence plate reader assay2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID760387Inhibition of human recombinant HDAC4 by Michaelis-Menten equation analysis2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1656939Inhibition of mushroom tyrosinase using L-DOPA as substrate
AID366642Inhibition of HDAC3 after 17 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1702062Inhibition of recombinant human C-terminal His-tagged HDAC3 (1 to 428 end residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins b2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1210099Induction of Sp1 recruitment to NATb promoter in human HeLa cells at 0.5 uM after 24 hrs by luciferase reporter gene assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1246515Inhibition of HDAC5 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1354370Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay
AID385448Inhibition of LPS-induced tissue factor activity in C57BL/6J mouse macrophages preincubated for 4 hrs assessed after 5 hrs of LPS challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1702061Inhibition of HDAC2 (unknown origin) using fluorogenic HDAC substrate 3 incubated for 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID242560Inhibitory concentration against rat liver histone deacetylase (HDAC) with substrate 3b2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID1384760Inhibition of human HDAC2 using RHKKAc peptide as substrate2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID463864Inhibition of human HDAC in human HeLa cell nuclear extract at 50 nM after 15 mins by colorimetric assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
AID1630587Inhibition of full length recombinant human HDAC2 expressed in baculovirus expression system using fluorogenic peptide RHKK(Ac) as substrate by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID1246507Inhibition of HDAC1 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1459972Inhibition of recombinant human HDAC8 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID313186Inhibition of HDAC4 expressed in 293T cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
AID385455Effect on TNF-alpha-induced NF-kappaB activation in HUVEC preincubated for 4 hrs assessed as increase in p50 level after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1605962Inhibition of HDAC10 (unknown origin) at 10 uM using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay relative to control2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1702064Inhibition of HDAC5 (unknown origin) using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID756010Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Oct3/4 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID1605952Inhibition of human PI3Kdelta assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1833063Inhibition of full length recombinant C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf21 insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence plate reader assay2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID420321Inhibition of Bordetella / Alcaligenes strain FB188 HDAC6 by fluorescence polarization assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1280315Inhibition of human KDAC3 using [3H]acetyl histone H4 peptide substrate incubated for 60 mins by scintillation counting method2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID252221Average fold change in expression of CYP1B1 after treatment with compound of concentration 0.1 mM in human MCF-7 cells2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
AID1578487Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID611685Inhibition of human HDAC6 using rhodamine as substrate after 1 hrs by fluorescence assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
AID90699Inhibitory activity against histone deacetylase (HDAC4) prepared from mouse melanoma B16/BL6 cells2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
AID496802Inhibition of human HDAC22010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1586080Inhibition of human HDAC4 using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1363781Inhibition of C-terminal His-tagged recombinant human HDAC8 expressed in baculovirus infected insect cells using RHKK(Ac)AMC as substrate by fluorescence-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID764214Inhibition of human recombinant HDAC1 using p53 residues 379-382 (RHKKAc) as substrate2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID90679Inhibition of Histone deacetylase 1 induced acetylated histone in mammalian cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1387552Inhibition of HDAC in human HeLaS3 cells assessed as increase in histone H3K9 acetylation at 10 uM measured immediately by immunoblot analysis2018ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.
AID252219Average fold change in expression of CYP1B1 after treatment with compound of concentration 1 mM in human MCF-7 cells2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
AID1764792Inhibition of full length recombinant human HDAC6 expressed in baculovirus infected Sf9 insect cells using RHKKAc fluorogenic peptide as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID760388Inhibition of human recombinant HDAC8 by Michaelis-Menten equation analysis2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1847753Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method2021Bioorganic & medicinal chemistry, 12-15, Volume: 52From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
AID1764793Selectivity index, ratio of IC50 for recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells to recombinant full length human HDAC6 expressed in baculovirus infected Sf9 insect cells using RHKKAc fluorogenic peptide as substrate pr2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID755998Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Otx2 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID1479814Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus-infected Sf21 insect cells using RHKK(Ac)AMC as substrate after 60 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1709382Inhibition of recombinant human full-length C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf9 insect cells using RHKK(Ac)AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured af2021Bioorganic & medicinal chemistry, 04-01, Volume: 35Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1622922Inhibition of recombinant full-length human HDAC7 using Boc-Lys(trifluoroacetyl)-AMC as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID308644Inhibition of human HDAC42007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1882456Inhibition of HDAC1 (unknown origin)2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1702068Inhibition of C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1578485Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID708215Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
AID659294Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2012European journal of medicinal chemistry, Jun, Volume: 52A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
AID1246512Inhibition of HDAC10 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID525002Inhibition of HDAC3 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1479819Inhibition of recombinant human HDAC10 expressed in baculovirus-infected insect cells using fluorogenic peptide RHKKAc as substrate by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID299642Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 600 nM after 48 hrs relative to control2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID385471Effect on TNF-alpha-induced NF-kappaB activation assessed as p65/p50 binding to NF-kappaB in HUVEC at 1 uM preincubated for 4 hrs measured after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID55804Cytotoxicity of compound against normal human prostate DU145 cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID233841Selectivity as ratio of inhibitory concentration for NFF cell line versus MM96L cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID385449Inhibition of TNF-alpha-induced tissue factor activity in C57BL/6J mouse macrophages preincubated for 4 hrs assessed after 5 hrs of TNFalpha challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID769928Selectivity index, ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC62013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1847776Inhibition of HDAC4 in human HeLa cells incubated for 1 hr by mass spectrometry method2021Bioorganic & medicinal chemistry, 12-15, Volume: 52From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
AID1591716Inhibition of human recombinant HDAC6 using fluorogenic HDAC substrate 3 pre-incubated for 30 mins followed by HDAC developer addition and measured after 15 mins by fluorogenic assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID8302Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID683277Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
AID503116Induction of p27 expression in human HeLa cells at 1 uM after 24 hrs by Western blotting2007Nature chemical biology, Sep, Volume: 3, Issue:9
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID1635106Upregulation of HDAC1 inhibition/ERK signalling activation-mediated extracellular SOD protein expression in human THP1 cells at 1 uM after 24 hrs by ELISA2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Royal Jelly Constituents Increase the Expression of Extracellular Superoxide Dismutase through Histone Acetylation in Monocytic THP-1 Cells.
AID538409Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate by fluorometric analysis2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Inhibitors selective for HDAC6 in enzymes and cells.
AID90693Binding affinity against Histone deacetylase 2 (HD2) in maize, expressed as binding constant (pKi)2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID1622920Inhibition of recombinant full-length human HDAC4 using Boc-Lys(trifluoroacetyl)-AMC as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID90197Inhibitory concentration against histone deacetylase activity2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors.
AID1630621Inhibition of recombinant N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in baculovirus expression system using fluorogenic substrate at 100 uM by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID769932Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID331899Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from human HDAC3/NcoR2 by fluorescence polarization assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID1651332Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID516293Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH189 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1622973Inhibition of HDAC4 (unknown origin)2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID309970Induction of wild-type p21 promoter activation in mink Mv1Lu cells after 18 hrs by luciferase assay relative to basal level2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
AID1605955Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to contro2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1254049Inhibition of HDAC8 (unknown origin) incubated for 1 hr by fluor de lys substrate based fluorescence method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.
AID385447Inhibition of IL-1-beta-induced tissue factor activity in human PBMC preincubated for 4 hrs assessed after 5 hrs of IL1-beta challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID417654Inhibition of human HDAC112009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID1322060Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID324909Inhibition of human HDAC6 assessed as tubulin hyperacetylation in human HCT116 cells by Western blot2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
AID516296Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH409 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID366643Inhibition of HDAC8 after 17 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID269912Inhibition of HDAC42006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
AID1182186Inhibition of human HDAC1 using fluorescent substrate Ac-KGLGK(Ac)-MCA after 30 mins by fluorescence plate reader2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.
AID385467Induction of PMA-induced wild type NF-kappaB-dependent ICAM promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of PMA challenge by luciferase reporter assay relative to control2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID760385Inhibition of human recombinant HDAC5 by Michaelis-Menten equation analysis2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1628748Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1127331Inhibition of human HDAC10 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1260647Inhibition of human recombinant HDAC11 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID104054Cytotoxicity of compound against normal human breast MCF-7 cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID541648Inhibition of human HDAC4 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1479812Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus-infected Sf9 insect cells using RHKK(Ac)AMC as substrate after 90 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1401561Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate after 1 to 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1177036Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.
AID1431822Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC62017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID769927Induction of neurite outgrowth in rat PC12 cells at 10 uM after 5 days2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID309968Inhibition of human HDAC4 expressed in 293T cells2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
AID1605954Inhibition of human PI3Kbeta assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID316887Antiproliferative activity against human MKN45 cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID385451Reduction of ICAM1 mRNA level in TNF-alpha-stimulated HUVEC at 1 uM preincubated for 4 hrs assessed after 1 to 2 hrs of TNFalpha challenge by RT-PCR2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID503304Antiproliferative activity against human PC3 cells at 5 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID331900Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from human HDAC6 by fluorescence polarization assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID1622924Inhibition of recombinant full-length human HDAC6 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1758519Inhibition of human recombinant HDAC1 expressed in baculovirus infected insect cells using [RHKK(Ac)] fluorogenic substrate2021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID525008Inhibition of HDAC7 in Fdelta508 CFTR-expressing human CFBE41o- cell line assessed as increase in cAMP-stimulated iodide efflux in at 0.1 uM after 24 hrs relative to control2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID309967Inhibition of human HDAC1 expressed in 293T cells2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
AID1532649Selectivity ratio of IC50 for recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) to IC50 for recombinant C-terminal His-tagged human HDAC11 (1 to 347 residues)2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID1371055Inhibition of recombinant Trypanosoma brucei HDAC3 at 5 uM after 30 mins2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID90350Inhibitory activity against histone deacetylase (HDAC) enzyme obtained from H1299 human lung carcinoma cell lysates2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
AID1605940Inhibition of recombinant full length human C-terminal His-tagged HDAC3 (1 to 428 residues) expressed in baculovirus infected insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence 2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1479816Inhibition of recombinant human C-terminal GST-tagged HDAC4 expressed in baculovirus-infected insect cells using Boc-Lys(TFA)-AMC as substrate by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1901145Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in Sf9 insect cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorimetry2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID240034Effective concentration determined for p21 promoter assay2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
AID1156700Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID1236442Inhibition of human HDAC12015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1647306Inhibition of human HDAC9 using fluorogenic Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence based analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID447994Inhibition of human recombinant HDAC3 after 30 mins by fluorimetric assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID242587Inhibition concentration required to inhibit rat liver histone deacetylase (HDAC) in the presence of compound 5e as a substrate2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID209973Inhibition of acetylation of histone-4 in human T-24 cancer cells2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID240717Inhibition of human histone deacetylase 1 prepared from 293T cells2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
AID1260642Inhibition of human recombinant HDAC6 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID566555Inhibition of HDAC in human PC3 cells at 1 uM after 10 mins by fluorometric assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells.
AID478330Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.
AID90671Inhibitory activity afgainst maize Histone deacetylase 1-A2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID299654Increase in GRP78 protein level in HEK293 cells at 600 nM by immunoblot2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID1647311Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1260643Inhibition of human recombinant HDAC7 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1765329Selectivity index, ratio of IC50 for human recombinant full length HDAC1 to IC50 for human recombinant full length HDAC22021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1401626Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.23 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID568154Inhibition of HDAC6 by fluorescence assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1529534Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1586085Inhibition of human HDAC10 using RHKKAc as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID57526Cytotoxicity of compound against normal human melanoma DO4 cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID1401601Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 5.08 x 10'-10 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1702067Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1586077Inhibition of human HDAC1 using RHKKAc as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID417644Inhibition of human HDAC12009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID382112Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 48 hrs by LDH reporter assay2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy.
AID1622990Antiproliferative activity against human A549 cells2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1529533Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1622968Inhibition of recombinant mouse HDAC6 expressed in HEK293T cells using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1432955Selectivity ratio of IC50 for human HDAC1 to IC50 for human HDAC62017ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors.
AID488358Inhibition of HDAC12010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1431815Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC82017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID519584Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in O+ human erythrocytes by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID385443Effect on TNF-alpha-induced IkappaB degradation in HUVEC at 1 uM preincubated for 4 hrs assessed after 60 mins of TNFalpha challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1127332Inhibition of human HDAC11 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1156704Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID385466Induction of PMA-induced TFkappaB mutant-dependent tissue factor promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of PMA challenge by luciferase reporter assay relative to control2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID58061Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID539709Inhibition of human HDAC after 30 mins2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase.
AID385468Inhibition of LPS-induced tissue factor protein expression in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID652765Induction of CFTR deltaF508 mutant mRNA expression in cystic fibrosis patient lung cells relative to control2011ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1518780Inhibition of human HDAC6 using Arg-His-Lys-Lys (Ac) as substrate incubated for 2 hrs by fluorescence assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID242559Inhibitory concentration against rat liver histone deacetylase (HDAC) with substrate 3a2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID764211Selectivity ratio of IC50 for human recombinant HDAC1 to human recombinant HDAC62013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID385462Inhibition of LPS-induced wild type TFkappaB-dependent tissue factor promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of LPS challenge by luciferase reporter assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1401595Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.70 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1586084Inhibition of human HDAC9 using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID611683Inhibition of human HDAC1 using rhodamine as substrate after 1 hrs by fluorescence assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
AID541655Growth inhibition of human H460 cells after 48 hrs by SRB assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID367236Induction of histone H3 acetylation in human T24 cells2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID252225Average fold change in expression of CYP1B1 after treatment with compound of concentration 0.01 mM in human MCF-7 cells2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
AID1647310Inhibition of recombinant human C-terminal His-tagged HDAC5 (657 to 1123 residues) expressed in baculovirus infected insect cells using Boc-K(Ac)-AMC as substrate after 60 mins by fluorimetry analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID525034In vivo inhibition of HDAC2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1647300Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1210095Increase in NAT1 mRNA expression in human HeLa cells at 0.5 uM after 24 hrs by qPCR method2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1401605Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.70 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID73169Inhibitory concentration against normal fibroblast MRHF cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1155334Inhibition of Plasmodium falciparum recombinant histone deacetylase1 using HDAC substrate 3 as substrate at 1 uM by fluorescence assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID316886Antiproliferative activity against human SKBR3 cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID1479818Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to 991 residues) expressed in baculovirus-infected insect cells after 60 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID385454Reduction of tissue factor mRNA level in TNF-alpha-stimulated HUVEC at 1 uM preincubated for 4 hrs assessed after 1 to 2 hrs of TNFalpha challenge by RT-PCR2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1294953Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1384761Inhibition of human HDAC3 using RHKKAc peptide as substrate2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID106868Compound was tested for antiproliferative activity against human MKN45 cancer cell lines2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1401634Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.11 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1630624Inhibition of full length recombinant human HDAC11 expressed in baculovirus expression system using fluorogenic substrate at 100 uM by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID1881883Activation of PKM2 (unknown origin) Leu353, Glu397, Phe26, Gly315 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID764209Partition coefficient, log D of the compound at pH 7.4 by Avdeef-Tsinman potentiometric titration method2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID695598Inhibition of HDAC assessed as induction of p21 promoter expression by cell-based assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.
AID541656Growth inhibition of human HCT116 cells after 48 hrs by SRB assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID269915Selectivity for HDAC6 over HDAC42006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
AID769930Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1182188Inhibition of mouse HDAC6 using fluorescent substrate Ac-KGLGK(Ac)-MCA after 30 mins by fluorescence plate reader2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.
AID1246516Inhibition of HDAC7 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID350025Increase in semaphoring 3F mRNA expression in human NCI-H661 cells at 300 nM by qRT-PCR relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
AID538413Selectivity index, ratio of IC50 for recombinant human HDAC1 to IC50 for recombinant human HDAC62010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Inhibitors selective for HDAC6 in enzymes and cells.
AID503527Inhibition of HDAC in human GM15850 cells assessed as increase in histone H3 lysine 9 acetylation of FXN gene at 0.1 uM after 96 hrs by chromatin immunoprecipitation assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1390224Inhibition of recombinant mouse HDAC6 expressed in HEK293T cells co-expressing mouse HDA2 using Ac-KGLGK(Ac)-MCA as substrate after 30 mins in presence of DTT by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
AID1246509Inhibition of HDAC3 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1557983Selectivity index, ratio of IC50 for recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate prei2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID769920Induction iof GAP-43 protein expression in rat PC12 cells after 48 hrs by Western blotting analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID568152Inhibition of HDAC3 by fluorescence assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1431814Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC12017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1586079Inhibition of human HDAC3 using RHKKAc as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1431816Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC32017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1781509Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from
AID1623248Inhibition of HDAC in HEK293 cells assessed as increase in histone H3 acetylation at Lys27 residues at 10 uM incubated for 24 hrs by Western blot analysis relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164The P-glycoprotein inhibitor diltiazem-like 8-(4-chlorophenyl)-5-methyl-8-[(2Z)-pent-2-en-1-yloxy]-8H-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3-one inhibits esterase activity and H3 histone acetylation.
AID1431820Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC62017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID103356Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID756021Inhibition of HDAC8 (unknown origin) after 30 mins by fluorometric analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID1518779Selectivity ratio of IC50 for human HDAC1 to IC50 for human HDAC62019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1863439Inhibition of HDAC7 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1401627Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.12 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1173705Inhibition of HDAC1 (unknown origin) after 15 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Aurones as histone deacetylase inhibitors: identification of key features.
AID723465Inhibition of human HDAC2 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1605953Inhibition of human PI3Kalpha assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to contro2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1155322Selectivity index, ratio of IC50 for erythrocytes (unknown origin) to IC50 for Plasmodium falciparum2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID764210Selectivity ratio of IC50 for human recombinant HDAC4 to human recombinant HDAC62013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID208533Concentration of compound required for acetylation of histone-4 in human T24 cancer cells2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Design and synthesis of a novel class of histone deacetylase inhibitors.
AID1781511Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from
AID708216Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
AID1882462Inhibition of HDAC6 (unknown origin)2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1155321Cytotoxicity against erythrocytes (unknown origin)2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1371070Antiparasitic activity against tachyzoite stage of Toxoplasma gondii2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1401592Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1 x 10'-5 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1556848Inhibition of HDAC8 (unknown origin) using R-H-K(Ac)-K(Ac)-AFC as substrate at 10 uM by fluorescence based assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Selenocoumarins as new multitarget antiproliferative agents: Synthesis, biological evaluation and in silico calculations.
AID302799Inhibition of mouse recombinant HDAC6 expressed in 293 cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
AID456800Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D62010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID1628756Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1401635Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.70 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID695594Inhibition of HDAC4 by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.
AID1401607Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.12 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1765328Inhibition of human full-length recombinant C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assa2021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID620532Reactivation of MeCp2 mutant expression in human GM11272 cells at 1 to 100 nM by PCR method2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.
AID541645Inhibition of human HDAC2 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1354394Inhibition of HDAC8 (unknown origin) by ELISA
AID488276Inhibition of HDAC62010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
On the inhibition of histone deacetylase 8.
AID1529531Antiproliferative activity against human U87 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1384766Selectivity index, ratio of IC50 for human HDAC3 to IC50 for human HDAC62018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1628754Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1529529Antiproliferative activity against human K562R cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID621738Antiproliferative activity against human HCT116 cells by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
AID488274Inhibition of HDAC22010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
On the inhibition of histone deacetylase 8.
AID1390227Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B-based colorimetric assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
AID91803Cytotoxicity of compound against normal human ovarian JAM cell line2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
AID1236450Inhibition of human HDAC62015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1901147Inhibition of recombinant human full-length C-terminal Flag-His6-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using fluorogenic HDAC substrate measured after 30 mins by fluorimetry2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID524995Inhibition of HDAC10 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1885254Inhibition of KDM4E (unknown origin)2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Recent Advances with KDM4 Inhibitors and Potential Applications.
AID1833069Selectivity ratio of IC50 for recombinant C-terminal His-fusion tagged/N-terminal Strep2 tagged human HDAC8 (1 to 377 residues) expressed in insect cells to IC50 full length recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus infected S2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID242600Inhibitory concentration against rat liver histone deacetylase (HDAC) with substrate 12a2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID1390225Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B-based colorimetric assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
AID1371053Antitrypanosomal activity against Trypanosoma brucei brucei measured after 22 hrs by fluorescence-based Alamar blue viability assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1401606Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.23 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1459974Inhibition of recombinant human HDAC10 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1236444Inhibition of human HDAC32015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1765325Inhibition of human full-length recombinant HDAC2 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay2021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID408883Inhibition of HDAC82008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID568156Inhibition of HDAC assessed as increase of histone H3 acetylation2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID316888Inhibition of HDAC from human SNU16 cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID408881Inhibition of HDAC22008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1155340Inhibition of HDAC in Plasmodium falciparum 3D7 trophozoites assessed as histone H3 hyperacetylation level at 500 nM after 3 hrs by Western blotting analysis relative to control2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1901070Nephroprotective activity against cisplatin-induced acute kidney injury in male C57BL/6 mouse assessed as plasma SCr concentration at 10 mg/kg/day, ip2022European journal of medicinal chemistry, Feb-15, Volume: 230Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1862611Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1781508Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from
AID269911Inhibition of HDAC12006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
AID1322066Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID1578488Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1628762Antiproliferative activity against human MDA-MB-231 cells by WST8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1322067Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID1210100Induction of Sp1 (GC>TA) mutant recruitment to NATb promoter in human HeLa cells at 0.5 uM after 24 hrs by luciferase reporter gene assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1156705Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID764208Intrinsic aqueous solubility of the compound at pH 7.4 by Avdeef-Tsinman potentiometric titration method2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID331617Inhibition of human HDAC6 expressed in 293T cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells.
AID344918Inhibition of 2-oxoglutarate-dependent human JMJD2E preincubated for 30 mins by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1622993Antiproliferative activity against human SKBR3 cells2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID525022Inhibition of HDAC in human CFBE41o- cell line assessed as increase in total CFTR protein level including CFTR glycoform at 0.1 uM by immunoblot analysis2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1690113Selectivity index, ratio of IC50 for recombinant human HDAC8 to IC50 for recombinant human HDAC62020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID1622971Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID414980Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID1384206Inhibition of HDAC1 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1690111Selectivity index, ratio of IC50 for recombinant human C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells to IC50 for recombinant human HDAC62020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID1623249Inhibition of HDAC in human HepG2 cells assessed as increase in histone H3 acetylation at Lys27 residues at 10 uM incubated for 24 hrs by Western blot analysis relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164The P-glycoprotein inhibitor diltiazem-like 8-(4-chlorophenyl)-5-methyl-8-[(2Z)-pent-2-en-1-yloxy]-8H-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3-one inhibits esterase activity and H3 histone acetylation.
AID81709Inhibitory concentration against human colon cancer HCT116 cell proliferation2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID1895827Inhibition of HDAC6 (unknown origin)2021European journal of medicinal chemistry, Dec-15, Volume: 226Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
AID1591715Inhibition of human recombinant HDAC1 using fluorogenic HDAC substrate 3 pre-incubated for 30 mins followed by HDAC developer addition and measured after 15 mins by fluorogenic assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID1651333Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID208400Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID90211Inhibitory activity against Histone deacetylase (HDAC) in K 562 erythroleukemia cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Heterocyclic ketones as inhibitors of histone deacetylase.
AID90673Inhibitory activity against histone deacetylases (HDAC1) prepared from mouse melanoma B16/BL6 cells2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
AID1853419Inhibition of human MMP-14 at 0.5 uM2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID411793Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
AID1853414Inhibition of human MMP-1 at 0.5 uM2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID1260637Inhibition of human recombinant HDAC1 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1605951Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1605945Inhibition of recombinant C-terminal His-fusion tagged and N-terminal Streptavidin2-tagged human HDAC8 (1 to 377 residues) expressed in insect cells using fluorogenic peptide p53 residues 379-382 (RHK(Ac)K(Ac)AMC) as substrate measured after 1 to 2 hrs by2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1173706Inhibition of HDAC2 (unknown origin) after 15 mins by fluorescence assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Aurones as histone deacetylase inhibitors: identification of key features.
AID1401623Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.33 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1605946Inhibition of HDAC9 (unknown origin) using fluorogenic HDAC class 2a as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID302801Selectivity for human HDAC6 over human HDAC42007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
AID566558Inhibition of HDAC in human LNCAP cells at 1 uM after 10 mins by fluorometric assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells.
AID487227Inhibition of recombinant HDAC62010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID385439Effect on TNF-alpha-induced NF-kappaB activation in HUVEC preincubated for 4 hrs assessed as increase in p65 level after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1210103Induction of acetylated histone H4 recruitment to NATb promoter in human HeLa cells at 0.5 uM after 24 hrs by ChIP assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID769929Selectivity index, ratio of IC50 for human recombinant HDAC8 to IC50 for human recombinant HDAC62013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID102520Inhibitory concentration against lung A549 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1863440Inhibition of HDAC8 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1423498Inhibition of full length SIRT6 (unknown origin) using acetylated H3K9 peptide as substrate after 2 hrs in presence of NAD2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
AID316885Antiproliferative activity against human A549 cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID516283Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH754 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1156701Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID420329Inhibition of HDAC from RT extract2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID541650Inhibition of human HDAC7 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1847754Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay2021Bioorganic & medicinal chemistry, 12-15, Volume: 52From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
AID628432Inhibition of human recombinant HDAC7 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID568151Inhibition of HDAC2 by fluorescence assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID417653Inhibition of human HDAC102009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID331615Inhibition of human HDAC1 expressed in 293T cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells.
AID628437Inhibition of human recombinant HDAC1 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1578486Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID240719Inhibition of human histone deacetylase 6 prepared from 293T cells2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
AID241474Inhibitory concentration against maize histone deacetylase 22005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1901067Antiproliferative activity against human HK-2 cells assessed as decrease in cell viability at 0.78 uM measured after 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1394893Selectivity index, ratio of IC50 for human HDAC1 to IC50 for human HDAC62018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID541649Inhibition of human HDAC5 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1862616Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1628747Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1394890Inhibition of human HDAC3 using RHKK(Ac) as substrate2018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1155320Antimalarial activity against Plasmodium falciparum infected in erythrocytes after 2 hrs2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1651335Inhibition of recombinant human C-terminal His-tagged HDAC8 (1 to 377 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID1622967Inhibition of recombinant human HDAC4 expressed in HEK293T cells using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1765330Selectivity index, ratio of IC50 for human recombinant full length HDAC3 to IC50 for human recombinant full length HDAC22021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID324536Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 5.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID384317Inhibition of maize histone deacetylase 1A2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
AID516298Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate H0058-1-818 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID525030Inhibition of HDAC7 in human CFBE41o- cell line assessed as correction of mutant Fdelta508 CFTR trafficking to cell surface as glycoform at 0.1 uM by Immunoblot analysis2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1236445Inhibition of human HDAC82015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1280317Inhibition of human KDAC8 using [3H]acetyl histone H4 peptide substrate incubated for 60 mins by scintillation counting method2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1651334Inhibition of human HDAC6 using fluorogenic-(RHKKAc) as substrate by fluorescence assay2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID81711Concentration required to inhibit the HCT116 cell growth by 50%.2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1432956Inhibition of human HDAC6 using RHKKAc as substrate by fluorescence assay2017ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors.
AID316881Inhibition of human MM96L cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID1441632Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 50 uM by SYPRO orange dye-based thermofluor assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID503525Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 16 acetylation of FXN gene at 0.1 uM after 96 hrs by chromatin immunoprecipitation assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID254794Inhibitory concentration against histone deacetylase 62005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Design and synthesis of phthalimide-type histone deacetylase inhibitors.
AID44724Inhibitory concentration against bladder T24 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1479820Inhibition of recombinant human N-terminal His-tagged HDAC11 (1 to 347 residues) expressed in baculovirus-infected insect cells using RHKK(Ac)AMC as substrate by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID417650Inhibition of human HDAC72009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID1280316Inhibition of human KDAC6 using [3H]acetyl histone H4 peptide substrate incubated for 60 mins by scintillation counting method2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1758521Inhibition of human recombinant HDAC6 expressed in baculovirus infected insect cells using [RHKK(Ac)] fluorogenic substrate2021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID723463Inhibition of human HDAC5 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID769931Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1371054Inhibition of recombinant Trypanosoma brucei HDAC1 at 5 uM after 30 mins2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1702066Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1628749Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1605944Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to 991 residues) expressed in baculovirus infected insect cells using fluorogenic HDAC class2a as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID90515Effective concentration in histone deacetylases (HDAC) using p21 promoter assay2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
AID252220Average fold change in expression of CYP1A1 after treatment with compound of concentration 0.1 mM in human MCF-7 cells2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
AID1503589Inhibition of HDAC in human HN13 cells assessed as reduction in histone H3 Lys9 acetylation incubated for 24 hrs by immunofluorescence assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
AID80246Inhibitory activity against HCT116 human colon cell growth2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
AID384316Inhibition of maize histone deacetylase 1B2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
AID1586083Inhibition of human HDAC8 using RHKAcKAc as substrate by fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 1621-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1690110Inhibition of recombinant human HDAC8 using RHK-K(Ac)-AMC as substrate by fluorescence based assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID385469Inhibition of TNF-alpha-induced tissue factor protein expression in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID302798Inhibition of human recombinant HDAC4 expressed in 293 cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
AID506770Displacement of [3H]probe from SAP130 in human WiDr cell immunoprecipitate sample assessed as radioactive intensity at 500 nM after 1 hr by scintillation counting relative to control2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID1605947Inhibition of HDAC10 (unknown origin) using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1635107Upregulation of HDAC1 inhibition/ERK signalling activation-mediated extracellular SOD mRNA expression in human THP1 cells at 1 uM after 24 hrs by RT-PCR method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Royal Jelly Constituents Increase the Expression of Extracellular Superoxide Dismutase through Histone Acetylation in Monocytic THP-1 Cells.
AID90666Inhibitory activity on partially purified recombinant human Histone deacetylase 1 (HDAC-1)2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID461093Inhibition of HDAC62010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.
AID503526Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 8 acetylation of FXN gene at 0.1 uM after 96 hrs by chromatin immunoprecipitation assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1459969Inhibition of recombinant human HDAC4 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID70208Inhibitory concentration against normal epithelial HMEC cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID385461Effect on LPS-induced wild type NF-kappaB-dependent ICAM1 promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of LPS challenge by luciferase reporter assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID240720Inhibition of human histone deacetylase 8 prepared from 293T cells2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
AID506784Inhibition of SAP130 mediated cell growth in human WiDr cells2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID1862620Inhibition of HDAC6 (unknown origin) measured by fluorometry assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID516299Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate H00581-1941 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID503694Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 12 acetylation of FXN gene at 0.1 uM after 96 hrs by chromatin immunoprecipitation assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID447995Inhibition of human recombinant HDAC8 after 30 mins by fluorimetric assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID254792Inhibitory concentration against histone deacetylase 22005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Design and synthesis of phthalimide-type histone deacetylase inhibitors.
AID1236446Inhibition of human HDAC42015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID299649Increase in protein disulfide isomerase level in HEK293 cells at 600 nM by immunoblot2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID1622919Inhibition of recombinant full-length human HDAC8 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID465149Inhibition of HDAC1 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1605957Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells at 10 uM using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 h2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1273502Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Can Small Chemical Modifications of Natural Pan-inhibitors Modulate the Biological Selectivity? The Case of Curcumin Prenylated Derivatives Acting as HDAC or mPGES-1 Inhibitors.
AID541653Inhibition of human HDAC10 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1401628Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.37 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1294971Inhibition of human recombinant HDAC10 using RHK-K(Ac)-AMC as substrate2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID316891Inhibition of HDAC2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID1210094Increase in NATa promoter activity in human HeLa cells at 0.5 uM after 24 hrs by qPCR method2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID503682Inhibition of HDAC in human GM15850 cells assessed as increase in histone H3 lysine 14 acetylation of FXN gene at 0.1 uM after 96 hrs by chromatin immunoprecipitation assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID541652Inhibition of human HDAC6 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1401639Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.57 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID90835Inhibitory activity against histone deacetylase 6 prepared from mouse melanoma B16/BL6 cells2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
AID488273Inhibition of HDAC12010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
On the inhibition of histone deacetylase 8.
AID461095Inhibition of HDAC4 assessed as induction of p21 promotor activity by cell based assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.
AID611686Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
AID1847752Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay2021Bioorganic & medicinal chemistry, 12-15, Volume: 52From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
AID367237Inhibition of human recombinant histone deacetylase 22009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID1401610Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.52 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID695592Inhibition of HDAC1 by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.
AID360095Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID90208Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells.1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
AID755997Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Lhx1 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID1853415Inhibition of human MMP-2 at 0.5 uM2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID90675In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID1628752Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1532642Selectivity ratio of IC50 for human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) to IC50 for recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues)2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID78390Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID331618Induction of p21 expression in human HeLa cells after 24 hrs2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells.
AID1401594Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.11 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1622994Antiproliferative activity against human MKN45 cells2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID516288Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B5788 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID90690In vitro for anti-HD2 (Histone deacetylase 2) activity in maize2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID269913Inhibition of HDAC62006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
AID1182187Inhibition of human HDAC4 using fluorescent substrate Ac-KGLGK(Ac)-MCA after 30 mins by fluorescence plate reader2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.
AID302797Inhibition of human recombinant HDAC1 expressed in NIH3T3 cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
AID1628745Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID161227Inhibitory concentration against prostate DU145 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID525020Inhibition of HDAC in human CFBE41o- cell line assessed as total CFTR protein level including CFTR glycoform at 1 uM by immunoblot analysis2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID769924Induction of neurite outgrowth in human SH-SY5Y cells at 10 uM after 5 days2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID488275Inhibition of HDAC32010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
On the inhibition of histone deacetylase 8.
AID1656945Mixed-type of inhibition of mushroom tyrosinase using varying level of L-DOPA as substrate by Dixon plot analysis
AID274171Antiproliferative activity against HCT116 cells2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
AID1401629Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.57 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID496808Activity of human HDAC82010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID465150Inhibition of HDAC2 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID769914Inhibition of HDAC6 in rat PC12 cells assessed as acetylation of histone H3 at 10 uM after 48 hrs by Western blotting analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID628433Inhibition of human recombinant HDAC6 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1210101Induction of Sp1 recruitment to NATb promoter in human HeLa cells nuclear extracts at 0.5 uM after 24 hrs by EMSA method2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1622970Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1862614Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1690112Selectivity index, ratio of IC50 for recombinant human HDAC3 to IC50 for recombinant human HDAC62020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID760390Inhibition of human recombinant HDAC1 by Michaelis-Menten equation analysis2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID90521Inhibitory activity against histone deacetylase (HDAC)2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition.
AID1529526Inhibition of human recombinant HDAC11 after 30 mins using fluorogenic substrate by fluorimetric assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID670029Inhibition of HDAC1 in human MCF7 cells assessed as up-regulation of acetylated histone H3 protein level at 0.5 uM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
AID90701Inhibition of Histone deacetylase 4 in mammalian cells2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1915533Agonist activity at Vitamin D receptor (unknown origin) by fluorescence polarization assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID417648Inhibition of human HDAC52009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID385463Inhibition of TNFalpha induced wild type TFkappaB-dependent tissue factor promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of TNFalpha challenge by luciferase reporter assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1628757Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID465153Inhibition of HDAC10 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1424816Inhibition of human recombinant HDAC6 using RHKKAcAMC as substrate by fluorescence assay2018European journal of medicinal chemistry, May-25, Volume: 152Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
AID769916Inhibition of HDAC6 in rat PC12 cells assessed as induction of alpha-tubulin acetylation at 10 uM after 48 hrs by Western blotting analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1628753Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1324227Inhibition of HDAC2 (unknown origin) assessed as inhibition of fluorogenic peptide deacetylation2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1294969Inhibition of human recombinant N-terminal His-tagged HDAC11 (1 to 347 residues) expressed in insect cells/baculovirus expression system using RHK-K(Ac)-AMC as substrate by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1421931Selectivity index, ratio of IC50 for human NFF cells to IC50 for Plasmodium falciparum2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID525001Inhibition of HDAC2 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1833066Inhibition of full length recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 insect cells using RHK-K(Ac)-AMC as substrate measured after 90 mins by fluorescence plate reader assay2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID1605938Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by flu2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1690108Inhibition of recombinant human HDAC3 using RHK-K(Ac)-AMC as substrate by fluorescence based assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID385460Effect on TNF-alpha-induced wild type NF-kappaB-dependent ICAM1 promoter expression in HUVEC preincubated for 4 hrs assessed after 6 hrs of TNFalpha challenge by luciferase reporter assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1394895Selectivity index, ratio of IC50 for human HDAC8 to IC50 for human HDAC62018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1431819Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC82017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID600531Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 20 ug/ml after 24 hrs by Western blot analysis2009Journal of natural products, Jul, Volume: 72, Issue:7
Cytotoxic triterpenoids from the stems of Microtropis japonica.
AID1529524Inhibition of human recombinant HDAC6 after 30 mins using fluorogenic substrate by fluorimetric assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID309969Inhibition of mouse HDAC6 expressed in 293T cells2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
AID1863441Inhibition of HDAC9 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1401638Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.37 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1254047Inhibition of HDAC1 (unknown origin) incubated for 1 hr by fluor de lys substrate based fluorescence method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.
AID723730Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1532631Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID447993Inhibition of human recombinant HDAC1 after 30 mins by fluorimetric assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID1479813Inhibition of recombinant human C-terminal His-tagged HDAC8 (1 to 377 residues) expressed in baculovirus-infected insect cells using RHK(Ac)K(Ac)AMC as substrate after 60 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1322068Selectivity index, ratio of IC50 for HDAC1 in human SHSY5Y cells to IC50 for HDAC6 in human SHSY5Y cells2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID1441630Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA preincubated for 10 mins followed by substrate addition measured after 10 mins2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID273990Inhibition of HDAC12007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor.
AID1384764Selectivity index, ratio of IC50 for human HDAC1 to IC50 for human HDAC62018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID302800Selectivity for human HDAC6 over human HDAC12007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
AID1432957Inhibition of human HDAC1 using RHKKAc as substrate by fluorescence assay2017ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors.
AID1862610Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1863442Inhibition of HDAC10 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1446915Inhibition of Schistosoma mansoni KDAC8 using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID324910Inhibition of human HDAC1 assessed as histone hyperacetylation in human HCT116 cells by Western blot2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
AID252218Average fold change in expression of CYP1A1 after treatment with compound of concentration 1 mM in human MCF-7 cells2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
AID254791Inhibitory concentration against histone deacetylase 12005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Design and synthesis of phthalimide-type histone deacetylase inhibitors.
AID1635111Inhibition of HDAC1 in human THP1 cells assessed as increase in histone H3 acetylation level at 1 uM after 12 hrs by Western blot analysis relative to control2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Royal Jelly Constituents Increase the Expression of Extracellular Superoxide Dismutase through Histone Acetylation in Monocytic THP-1 Cells.
AID496805Inhibition of human HDAC52010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1266100Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1401611Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 5.08 x 10'-10 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1354391Inhibition of human HDAC1 by ELISA
AID1656942Cytotoxicity against human A549 cells assessed as reduction in cell viability
AID90528Inhibition of histone deacetylase (HDAC) activity in HeLa cell nuclear extract2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides.
AID769935Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1758523Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC62021European journal of medicinal chemistry, May-05, Volume: 217Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID360097Inhibition of HOSCN-induced tissue factor protein expression in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID90359Concentration required for inhibition of histone deacetylase HD2 in vitro.2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
AID269914Selectivity for HDAC6 over HDAC12006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
AID496803Inhibition of human HDAC32010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID456798Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID756007Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Rex1 expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID1605941Inhibition of recombinant human N-terminal GST-tagged and C-terminal His-tagged HDAC4 expressed in baculovirus infected insect cells using fluorogenic HDAC class2a as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID385464Induction of PMA-induced wild type TFkappaB-dependent tissue factor promoter expression in HUVEC at 100 nM preincubated for 4 hrs assessed after 6 hrs of PMA challenge by luciferase reporter assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID90351Concentration required to inhibit human Histone deacetylase (HDAC) enzyme by 50%2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1529525Inhibition of human recombinant HDAC8 after 30 mins using fluorogenic substrate by fluorimetric assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID408880Inhibition of HDAC12008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID408884Inhibition of HDAC102008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1276711Inhibition of recombinant human HDAC1 by fluorimetry2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors.
AID1630619Inhibition of recombinant C-terminal His-tagged/N-terminal GST-tagged human HDAC4 (627 to 1084 residues) expressed in baculovirus expression system using fluorogenic substrate at 100 uM by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID456797Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID628430Inhibition of human recombinant HDAC10 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1853422Inhibition of human HDAC8 at 0.5 uM by fluorometric method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID503693Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 5 acetylation of FXN gene at 0.1 uM after 96 hrs by chromatin immunoprecipitation assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID90522Inhibitory concentration against rat liver Histone deacetylase2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID516291Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B3939 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1324228Inhibition of HDAC3 (unknown origin) assessed as inhibition of fluorogenic peptide deacetylation2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID90687Inhibitory concentration against maize Histone deacetylase 22003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID273167Inhibition of maize HD1A2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID242687Inhibitory concentration against human histone deacetylase (HDAC) from HeLa cells with substrate 5a2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID313187Inhibition of HDAC6 expressed in 293T cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
AID756022Inhibition of HDAC1 (unknown origin) after 30 mins by fluorometric analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID385442Increase in acetylated histone H3 level in HUVEC preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by Western blot2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1236448Inhibition of human HDAC72015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID760389Inhibition of human recombinant HDAC2 by Michaelis-Menten equation analysis2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1294965Inhibition of human recombinant N-terminal GST-tagged C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in insect cells using Boc-K(TFA)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID302099Antiproliferative activity against H661 cells after 48 hrs2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
AID1833067Selectivity ratio of IC50 for full length recombinant C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf21 insect cells to IC50 for full length recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 in2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID1210102Induction of Sp1 recruitment to NATb promoter in human HeLa cells at 0.5 uM after 24 hrs by ChIP assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID525003Inhibition of HDAC1 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID80076Inhibitory activity against H1299 human lung carcinoma cell growth2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
AID308645Inhibition of human HDAC62007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID90688Inhibitory activity against maize Histone deacetylase 2 at 1 mM2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID358670Induction of REST/NRSF-coupled repression of luciferase tagged rat RE1/NRSE BDNF promoter activity expressed in ST14A cells assessed as increase in luciferase activity2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
AID243634In vitro inhibition against human Histone deacetylase2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors.
AID1254048Inhibition of HDAC6 (unknown origin) incubated for 1 hr by fluor de lys substrate based fluorescence method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.
AID1127325Inhibition of human HDAC4 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1322065Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID1182189Ratio of IC50 for mouse HDAC6 to IC50 for human HDAC12014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.
AID650228Inhibition of HDAC22012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1431821Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC82017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID90696Inhibition of maize histone deacetylase 22004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID417652Inhibition of human HDAC92009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
AID1322062Selectivity index, ratio of IC50 for human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells to IC50 for human recombinant HDAC6 expressed in baculovirus infected insect cells2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID1401599Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.57 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1156699Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID541651Inhibition of human HDAC9 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID516285Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH535 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID500916Inhibition of heat-induced AML1-ETO protein expression in heterozygous transgenic zebrafish embryo at 0.5 uM by Western blot analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1530556Inhibition of recombinant human HDAC4 using Boc-Lys(trifluoroacetyl)-AMC as substrate by homogeneous fluorescence release assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1630620Inhibition of recombinant C-terminal His-tagged human HDAC5 catalytic domain (656 to 1122 residues) expressed in baculovirus expression system using fluorogenic substrate at 100 uM by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID447991Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID309971Selectivity for human HDAC4 over human HDAC12007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
AID1423499Binding affinity to recombinant human full length SIRT6 (1 to 355 residues) expressed in Escherichia coli M15 after 20 mins by fluorescence-based SDS-denaturation assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
AID1293871Inhibition of HDAC in mouse C127-LT cells assessed as activation of EGFP expression at 200 nM after 24 hrs by fluorescence microscopy2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID525000Inhibition of HDAC4 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID708214Selectivity index, ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC62012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
AID605940Antifungal activity against Saccharomyces cerevisiae ATCC 9763 by microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Microbial transformation of trichostatin A to 2,3-dihydrotrichostatin A.
AID367240Selectivity ratio of IC50 for human recombinant histone deacetylase 2 to IC50 for human recombinant histone deacetylase 62009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID414981Antimalarial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID524994Inhibition of HDAC9 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID242561Inhibitory concentration against rat liver histone deacetylase (HDAC) with substrate 5a2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID1401631Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 5.08 x 10'-10 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1529564Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1294968Inhibition of human recombinant C-terminal His-tagged HDAC8 (1 to 377 residues) expressed in insect cells using RHK-K(Ac)-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID360092Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1622969Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID775831Inhibition of HDAC2 (unknown origin)-mediated deacetylation at 10 uM preincubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID274170Antiproliferative activity against H1299 cells2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
AID201624Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1622972Inhibition of HDAC1 (unknown origin)2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID519602Antimalarial activity against Plasmodium falciparum infected in O+ human erythrocytes assessed as reduction in parasites at schizonts stage at 200 nM after 48 hrs by Giemsa staining based microscopy2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1659230Inhibition of human HDAC12020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
AID723479Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID385456Effect on TNF-alpha-induced SP1 protein level in HUVEC preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1294963Inhibition of full length human recombinant C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID755481Inhibition of recombinant human HDAC1 using Arg-His-Lys-Lys(Ac) as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID1651338Selectivity ratio of IC50 for recombinant human C-terminal His-tagged HDAC8 (1 to 377 residues) expressed in insect cells to IC50 of human HDAC62020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis and biological evaluation of 2-quinolineacrylamides.
AID1635110Inhibition of HDAC1 in human THP1 cells assessed as increase in histone H4 acetylation level at 1 uM after 12 hrs by Western blot analysis relative to control2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Royal Jelly Constituents Increase the Expression of Extracellular Superoxide Dismutase through Histone Acetylation in Monocytic THP-1 Cells.
AID463865Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
AID80247Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID1622917Inhibition of recombinant full-length human HDAC2 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID273173Inhibition of mouse HDAC12006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1605943Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1125 residues) expressed in baculovirus infected insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID628436Inhibition of human recombinant HDAC2 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1530557Inhibition of recombinant human HDAC6 using RHK-K(Ac) as substrate by homogeneous fluorescence release assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1246517Inhibition of HDAC9 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID226263Fold selectivity for classI HDAC2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1652187Inhibition of human recombinant HDAC1 using fluorogenic substrate incubated for 30 mins by fluorescence based assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1863435Inhibition of HDAC3 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1595396Inhibition of HDAC in human HeLa nuclear extract assessed as enzyme residual activity at 5 nM using Boc-Lys(acetyl)-AMC as substrate and measured after 15 mins by fluorescence assay relative to control2019European journal of medicinal chemistry, Jun-15, Volume: 172Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
AID1459968Inhibition of recombinant human HDAC3 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID516297Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH771 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID239792Selectivity for class I HDACs as ratio of IC50 for maize histone deacetylase 1-A and 1-B2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID43462Inhibitory concentration against breast MDA-MB-231 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID496809Inhibition of human HDAC92010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID456801Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-resistant Plasmodium falciparum W22010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID516289Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B5763 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1246514Inhibition of HDAC4 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID524822Inhibition of HDAC7 in human primary bronchial epithelial cells assessed as induction of mutant Fdelta508 CFTR protein apical surface localization at 0.1 uM2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID760386Inhibition of human recombinant HDAC6 by Michaelis-Menten equation analysis2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID366641Inhibition of HDAC2 after 17 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1518781Inhibition of human HDAC1 using Arg-His-Lys-Lys (Ac) as substrate incubated for 2 hrs by fluorescence assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID367235Induction of alpha tubulin acetylation in human T24 cells2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID525035Inhibition of CFTR transcription assessed as decrease of CFTR protein level at 50 uM by immunoblot method2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1454738Decrease in alcohol intake in rat assessed as ethanol intake at 2 mg/kg, ip administered daily during last 3 days of 10 day period of two-bottel choice paradigm (Rvb = 7 g/kg)2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1765327Inhibition of human full-length recombinant HDAC6 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay2021European journal of medicinal chemistry, Oct-15, Volume: 222A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1473143Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 90 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID385458Inhibition of TNF-alpha-induced p65 binding to TFkappaB in HUVEC preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by chromatin immunoprecipitation assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID71776Tested in vivo for the inhibition of proliferation of friend leukemic cells2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
AID350022Inhibition of HDAC in human NCI-H661 cells assessed as induction of alpha-tubulin acetylation at 300 nM after 6 hrs by Western blot analysis2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
AID1431812Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC32017European journal of medicinal chemistry, Feb-15, Volume: 127Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID242586Inhibitory concentration against rat liver histone deacetylase (HDAC) with substrate 5b2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Subtype selective substrates for histone deacetylases.
AID83150Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID755478Inhibition of recombinant human HDAC4 using acetyl-Lys-(trifluoroacetyl)-AMC as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID1702069Inhibition of N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1605960Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1125 residues) expressed in baculovirus infected insect cells at 10 uM using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence as2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1605961Inhibition of recombinant C-terminal His-fusion tagged and N-terminal Streptavidin2-tagged human HDAC8 (1 to 377 residues) expressed in insect cells at 10 uM using fluorogenic peptide p53 residues 379-382 (RHK(Ac)K(Ac)AMC) as substrate measured after 1 to2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1293876Inhibition of HDAC in human HeLa nuclear extract assessed as accumulation of acetylated histone H3 after 24 hrs by western blot analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID1901069Nephroprotective activity against cisplatin-induced acute kidney injury in male C57BL/6 mouse assessed as plasma BUN concentration at 10 mg/kg/day, ip2022European journal of medicinal chemistry, Feb-15, Volume: 230Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID1532639Inhibition of recombinant C-terminal His-tagged human HDAC11 (1 to 347 residues) expressed in Baculovirus infected insect cells using RHKK-Ac as substrate by fluorimetric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID1589336Inhibition of HDAC1 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1260646Inhibition of human recombinant HDAC10 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1401596Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.23 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID524997Inhibition of HDAC7 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID313185Inhibition of HDAC1 expressed in 293T cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
AID1628755Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1276713Inhibition of recombinant human HDAC8 by fluorimetry2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors.
AID519709Antimalarial activity against Plasmodium falciparum infected in O+ human erythrocytes assessed as reduction in parasites at ring stage at 200 nM after 48 hrs by Giemsa staining based microscopy2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1354393Inhibition of HDAC3 (unknown origin) by ELISA
AID1401558Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate after 1 to 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID608776Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure-based optimization of click-based histone deacetylase inhibitors.
AID50591Inhibitory concentration against colon SW48 cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID274375Inhibition of SIRT2 in A549 cells assessed as ability to induce hyperacetylation of tubulin by Western blot analysis at 0.1 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID1578489Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1605949Inhibition of human PI3Kalpha assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID516294Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate NIH34 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1628761Antiproliferative activity against human HL60 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1656943Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
AID1702060Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence based assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID461091Inhibition of HDAC12010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.
AID1901052Inhibition of HDAC in human HK-2 cells assessed as increase in histone H3 expression acetylation at 5 uM measured by western blot analysis2022European journal of medicinal chemistry, Feb-15, Volume: 230Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID274169Antiproliferative activity against H661 cells2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
AID1394894Selectivity index, ratio of IC50 for human HDAC3 to IC50 for human HDAC62018European journal of medicinal chemistry, Apr-25, Volume: 1501-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1401603Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.33 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID90668Inhibitory concentration against recombinant human Histone deacetylase 12003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID1210096Effect on NAT1 mRNA stability in human HeLa cells assessed as slope of mRNA decay curve at 0.5 uM after 24 hrs in presence of transcription inhibitor actinomycin D by qPCR method (Rvb = -0.78 +/- 0.02/hr)2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1401641Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 5.08 x 10'-10 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID756009Inhibition of HDAC8 in C57BL/6 mouse embryonic fibroblasts assessed as upregulation of Nanog expression after 24 hrs by qPCR analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity.
AID90682Inhibition of in vitro enzyme activity measured in a highly purified maize Histone deacetylase 2 preparation2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
AID487225Inhibition of recombinant HDAC22010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID1622926Inhibition of recombinant full-length human HDAC11 using RHKK(Ac) as substrate measured after 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1628758Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID1210098Induction of NATb Sp1 site in human HeLa cells at 0.5 uM after 24 hrs by luciferase reporter gene assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID516282Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH200 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1529527Antiproliferative activity against human A549 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID316880Inhibition of mouse liver HDAC12008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID465151Inhibition of HDAC3 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1529530Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID385453Decrease in thioglycolate-induced tissue factor activity in C57BL/6J mouse macrophage at 1 mg/kg, ip preincubated for 4 hrs assessed after 5 hrs of thioglycolate challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID367239Inhibition of human recombinant histone deacetylase 82009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID516290Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH198 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1421930Antiplasmodial activity against Plasmodium falciparum2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID350021Inhibition of HDAC in human NCI-H661 cells assessed as induction of histone H4 acetylation at 300 nM after 6 hrs by Western blot analysis2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
AID1210097Induction of NATb 3657 bp fragment upstream of exon 4 in human HeLa cells at 0.5 uM after 24 hrs by luciferase reporter gene assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID1423500Binding affinity to recombinant human full length SIRT6 (1 to 355 residues) expressed in Escherichia coli M15 after 20 mins in presence of ADP-ribose by fluorescence-based SDS-denaturation assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
AID1647301Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminaL GST-tagged human recombinant NCOR2 (395 to 489 residues) expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 60 mins b2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1246511Inhibition of HDAC6 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID769934Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID1384763Inhibition of human HDAC6 using RHKKAc peptide as substrate2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID385457Effect on TNF-alpha-induced Egr1 protein level in HUVEC preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by Western blotting2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID286454Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Design and synthesis of a potent histone deacetylase inhibitor.
AID366645Inhibition of HDAC10 after 17 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1260644Inhibition of human recombinant HDAC8 at 20 uM using Ac-RHK(Ac)K(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID382342Inhibition of human HDAC in HeLa cells by flour de lys assay2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
AID503668Cytotoxicity against human GM15850 cells at 5 uM after 96 hrs by trypan blue exclusion assay2006Nature chemical biology, Oct, Volume: 2, Issue:10
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1236449Inhibition of human HDAC92015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID506769Displacement of [3H]probe from SAP130 in human WiDr cells assessed as radioactive intensity at 500 nM after 1 hr by scintillation counting relative to control2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID331616Inhibition of human HDAC4 expressed in 293T cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells.
AID240718Inhibition of human histone deacetylase 4 prepared from 293T cells2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
AID385441Increase in acetylated histone H4 level in HUVEC preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by Western blot2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID90672Inhibitory activity against maize Histone deacetylase 1-B2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1528345Inhibition of human N-terminal GST-tagged HDAC6 expressed in baculovirus infected insect cells using RHKKAc as substrate2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
AID541654Inhibition of human HDAC11 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID541644Inhibition of human HDAC1 by fluorimetric assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1628759Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
AID519604Inhibition of HDAC in Plasmodium falciparum Dd2 infected in O+ human erythrocytes assessed as alteration of histone acetylation at 500 nM after 3.5 hrs by Westen blot2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID241538Inhibitory concentration against maize histone deacetylase 1-B (class I HDAC)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1294964Inhibition of human recombinant N-terminal GST-tagged HDAC7 (518 to 991 residues) expressed in insect cells using Boc-K(TFA)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1529562Antiproliferative activity against human HT-29 cells assessed as cell viability after 72 hrs by MTS assay relative to control2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1210090Increase in NAT1 enzyme activity in human HeLa cells at 0.5 uM using p-aminobenzoic acid substrate after 24 hrs by HPLC method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID273166Inhibition of maize HD22006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1781510Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from
AID1387553Inhibition of HDAC in human HeLaS3 cells assessed as increase in histone H3K9 acetylation at 10 uM treated for 16 hrs followed by compound washout and measured up to 24 hrs by immunoblot analysis2018ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.
AID487224Inhibition of recombinant HDAC12010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID723461Inhibition of human HDAC8 by fluorescence assay2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1441631Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1401625Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 3.70 x 10'-7 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID516287Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate B4506 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1525777Inhibition of HADC1 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1459953Inhibition of recombinant human HDAC1 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1322059Inhibition of HDAC1/HDAC2/HDAC3 in human HeLa nuclear extracts using MAL as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
AID1401604Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.11 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1647309Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 90 mins by fluorimetry analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1294966Inhibition of human recombinant C-terminal His-tagged HDAC5 (657 to 1123 residues) expressed in insect cells using Boc-K(TFA)-AMC as substrate incubated for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID385440Effect on TNF-alpha-induced NF-kappaB activation in HUVEC preincubated for 4 hrs assessed as increase in c-Rel level after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1294961Inhibition of HDAC1 in human HeLa cells assessed as hyperacetylation of histone H3 at 2 uM incubated for 24 hrs by Western blot analysis2016European journal of medicinal chemistry, Jun-30, Volume: 116Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID385459Inhibition of TNF-alpha-induced p65 binding to ICAM1 NF-kappaB in HUVEC preincubated for 4 hrs assessed after 0.5 hrs of TNFalpha challenge by chromatin immunoprecipitation assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID544397Inhibition of Plasmodium falciparum 3D7 histone deacetylase infected in human erythrocytes assessed as alteration of histone H3 acetylation at 100 nM after 3.5 hrs by SDS-PAGE2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1246513Inhibition of HDAC11 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID496801Inhibition of human HDAC12010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID465152Inhibition of HDAC8 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID519583Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in O+ human erythrocytes by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1764798Inhibition of class1 HDAC in mouse Neuro2a cells assessed as fold increase in ratio of acetylated histone H3 to histone H4 at 1 uM incubated for overnight by Western blot analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID1156702Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID385444Effect on TNF-alpha-induced TFkappaB activation assessed as p65/c-Rel binding to TFkappaB in HUVEC preincubated for 4 hrs measured after 0.5 hrs of TNFalpha challenge by electrophoretic shift mobility assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1401637Inhibition of HDAC10 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.12 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.06 to 107.72%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1532629Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID201882Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.
AID1605958Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells at 10 uM using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay relative t2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1441699Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID568157Inhibition of HDAC assessed as increase of histone H4 acetylation2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1390223Inhibition of recombinant human HDAC1 expressed in HEK293T cells using Ac-KGLGK(Ac)-MCA as substrate after 30 mins in presence of DTT by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
AID1862622Inhibition of HDAC11 (unknown origin) measured by fluorometry assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID80362In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Design and synthesis of a novel class of histone deacetylase inhibitors.
AID1659237Inhibition of human HDAC6 (unknown origin)2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
AID1853416Inhibition of human MMP-3 at 0.5 uM2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID1384768Selectivity index, ratio of IC50 for human HDAC10 to IC50 for human HDAC62018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1177037Cytotoxicity against human U2OS cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.
AID1236447Inhibition of human HDAC52015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID1459975Inhibition of recombinant human HDAC11 using fluorogenic substrate by fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 1253-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID90349Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1177039Cytotoxicity against human HeLa cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.
AID90344Induction of p21 using Histone deacetylase inhibitors2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1210093Increase in NATb promoter activity in human HeLa cells at 0.5 uM after 24 hrs by qPCR method2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
AID316883Selectivity index, ratio of IC50 for human MM96L cells to IC50 for human NFF cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Histone deacetylase inhibitors: from bench to clinic.
AID1781513Inhibition of HDAC in human HeLa nuclear extract using Fluor de Lys as substrate incubated for 20 mins by fluorometric assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from
AID1401624Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 1.11 x 10'-6 M after 1 to 2 hrs by fluorescence assay (Rvb = 96.3 to 101.70%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID621737Inhibition of HDAC1 by fluorescent activity assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
AID1127329Inhibition of human HDAC8 using fluorogenic tetrapeptide RHKKAc as substrate2014European journal of medicinal chemistry, May-22, Volume: 79Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1853421Inhibition of human HDAC3 at 0.5 uM by fluorometric method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID1525776Inhibition of HADC6 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1605956Inhibition of human PI3Kdelta assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to contro2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1479815Inhibition of full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged recombinant human NCOR2 (395 to 489 residues) expressed in baculovirus-infected insect cells using RHKK(Ac)AMC as substrate after 60 mins by fluorimeter2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1901146Inhibition of C-terminal His-tagged human HDAC3 (1 to 428 residues)/N-terminal GST tagged human NCOR2 (395 to 489) expressed in baculovirus infected Sf9 insect cells using fluorogenic HDAC substrate measured after 30 mins by fluorimetry2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID360093Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay2007The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID755475Inhibition of recombinant human HDAC8 using Arg-His-Lys(Ac)-Lys(Ac) as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID500920Inhibition of Hsp70 expression in heterozygous transgenic zebrafish embryo at 0.5 uM by Western blot analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID366640Inhibition of HDAC1 after 17 hrs2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID516292Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype B isolate NIH184 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1863436Inhibition of HDAC4 (unknown origin) by colorimetric method2022European journal of medicinal chemistry, Oct-05, Volume: 240Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1423501Binding affinity to recombinant human full length SIRT6 (1 to 355 residues) expressed in Escherichia coli M15 after 20 mins in presence of ADP-ribose and acetylated H3K9 peptide by fluorescence-based SDS-denaturation assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
AID1156706Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
AID1423503Inhibition of human SIRT6 preincubated for 5 mins in presence of substrate followed enzyme addition measured after 5 to 10 mins in presence of NAD by fluorescence spectrophotometry2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development.
AID1709384Selectivity index, ratio of IC50 for inhibition of recombinant human full-length C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf9 insect cells to IC50 for inhibition of recombinant human full-length N-terminal GST2021Bioorganic & medicinal chemistry, 04-01, Volume: 35Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID90519Inhibitory concentration against partially purified mouse histone deacetylase (HDAC)2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Histone deacetylase inhibitors.
AID421211Antitumor activity against mouse ML1 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID1401597Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.12 x 10'-8 M after 1 to 2 hrs by fluorescence assay (Rvb = 93.78 to 100%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID755479Inhibition of HDAC3/NCOR2 (unknown origin) using Arg-His-Lys-Lys(Ac) as substrate assessed as residual activity at 3.3 x 10'-5 M after 2 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural basis for the design and synthesis of selective HDAC inhibitors.
AID1266099Inhibition of HDAC6 in human HeLa cells assessed as tubulin acetylation incubated for overnight by immunofluorescence microscopic analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1260645Inhibition of human recombinant HDAC9 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID384318Selectivity for IC50 of maize histone deacetylase 1B over IC50 of maize histone deacetylase 1A2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
AID367238Inhibition of human recombinant histone deacetylase 62009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
AID496780Inhibition of shATP citrate lyase-induced cell differentiation in mouse C2C12 assessed as myosin heavy chain expression at 100 nM2010Nature chemical biology, Mar, Volume: 6, Issue:3
Carbon metabolism-mediated myogenic differentiation.
AID1401609Inhibition of HDAC2 (unknown origin) using RHKK(Ac)AMC as substrate assessed as remaining activity at 4.57 x 10'-9 M after 1 to 2 hrs by fluorescence assay (Rvb = 94.78 to 103.8%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID241537Inhibitory concentration against maize histone deacetylase 1-A (class IIa HDAC)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID516286Antimicrobial activity against fluconazole-resistant Cryptococcus gattii serotype C isolate NIH257 at 64 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Heteroresistance of Cryptococcus gattii to fluconazole.
AID1862609Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors.
AID1845905Reversal of HIV-1 latency infected in human J-Lat Tat-GFP Clone A7 cells assessed as increase in GFP expressing cells at 100 nM incubated for 72 hrs by flow cytometry analysis relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 213HIV latency reversal agents: A potential path for functional cure?
AID670035Inhibition of HDAC6 in human MCF7 cells assessed as change in tubulin acetylation level at 0.5 uM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
AID1401560Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate after 1 to 2 hrs by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1202473Antiproliferative activity against human A549 cells assessed as shrunken and sharp shape at 0.4 uM after 24 hrs by phase contrast microscopy2015European journal of medicinal chemistry, , Volume: 96Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents.
AID1354392Inhibition of human HDAC2 by ELISA
AID1530555Inhibition of recombinant human HDAC1 using RHK-K(Ac) as substrate by homogeneous fluorescence release assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1260639Inhibition of human recombinant HDAC3 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID447992Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
AID524998Inhibition of HDAC5 by in vitro deacetylation assay2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID496804Inhibition of human HDAC42010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1802398Enzymatic HDAC Activity Assay from Article 10.1074/jbc.M113.490706: \\Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.\\2013The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37
Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
AID1802451HDAC Cell-Free Assays from Article 10.1074/jbc.M113.472563: \\The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.
AID1802399Proteros Reporter Displacement Assay from Article 10.1074/jbc.M113.490706: \\Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.\\2013The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37
Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2008The Journal of biological chemistry, Apr-25, Volume: 283, Issue:17
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346090Human histone deacetylase 9 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346032Human histone deacetylase 6 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346066Human histone deacetylase 5 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346134Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346104Human histone deacetylase 4 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346131Human histone deacetylase 7 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346068Human histone deacetylase 8 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346077Human histone deacetylase 3 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID1346082Human histone deacetylase 2 (3.5.1.- Histone deacetylases (HDACs))2010Nature chemical biology, Mar, Volume: 6, Issue:3
Chemical phylogenetics of histone deacetylases.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Inside HDAC with HDAC inhibitors.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1999Nature, Sep-09, Volume: 401, Issue:6749
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB1999Nature, Sep-09, Volume: 401, Issue:6749
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,311)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (0.15)18.7374
1990's147 (4.44)18.2507
2000's1563 (47.21)29.6817
2010's1424 (43.01)24.3611
2020's172 (5.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.21%)5.53%
Reviews57 (1.69%)6.00%
Case Studies4 (0.12%)4.05%
Observational1 (0.03%)0.25%
Other3,296 (97.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies[NCT03838926]Phase 142 participants (Anticipated)Interventional2018-09-27Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
entinostat[no description available]medium700benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
entinostat[no description available]medium701benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sodium butyrate[no description available]medium80organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
sodium butyrate[no description available]medium81organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide[no description available]high90benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
vorinostat[no description available]high2480dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
trapoxin a[no description available]medium50
hc toxin[no description available]medium40
pyroxamide[no description available]medium20aromatic amide
suberoyl bis-hydroxamic acid[no description available]medium130hydroxamic acid
laq824[no description available]medium100
romidepsin[no description available]medium70cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
tubacin[no description available]medium2401,3-oxazoles
psammaplin a[no description available]medium50
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone[no description available]medium121oligopeptide
sk-7041[no description available]medium50
scriptaid[no description available]medium300isoquinolines
cinnamoylhydroxamic acid[no description available]medium10
bl1521[no description available]high40enamide;
hydroxamic acid;
monocarboxylic acid amide		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
valproate sodium[no description available]medium30organic sodium saltgeroprotector
benzo(a)pyrene[no description available]medium20ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite
ag-1296[no description available]medium10quinoxaline derivative
albuterol[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
aminoglutethimide[no description available]medium10dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
bicalutamide[no description available]medium20(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
caffeine[no description available]medium40purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
celecoxib[no description available]medium30organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ciglitazone[no description available]medium40aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
ciprofibrate[no description available]medium10cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clenbuterol[no description available]medium20amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
clofibrate[no description available]medium10aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clotrimazole[no description available]medium20conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
fenofibrate[no description available]medium10aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
gemfibrozil[no description available]medium10aromatic etherantilipemic drug
go 6976[no description available]medium60indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
isoproterenol[no description available]medium40catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
ketoconazole[no description available]medium10dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
beta-lapachone[no description available]medium10benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
letrozole[no description available]medium10nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one[no description available]medium130chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
milrinone[no description available]medium10bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
niclosamide[no description available]medium20benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
patulin[no description available]medium20furopyran;
gamma-lactone;
lactol		antimicrobial agent;
Aspergillus metabolite;
carcinogenic agent;
mutagen;
mycotoxin;
Penicillium metabolite
pd 153035[no description available]medium20aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
pd 158780[no description available]medium10aromatic amine;
bromobenzenes;
diamine;
pyridopyrimidine;
secondary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pd 98059[no description available]medium70aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pioglitazone[no description available]medium20aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
propranolol[no description available]medium20naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
quetiapine[no description available]medium10dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
raloxifene[no description available]medium101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
risperidone[no description available]medium101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rofecoxib[no description available]medium10butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
rolipram[no description available]medium10pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
imatinib[no description available]medium30aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
terfenadine[no description available]medium10diarylmethane
thalidomide[no description available]medium10phthalimides;
piperidones
troglitazone[no description available]medium20chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
zm 336372[no description available]medium10benzamides
zonisamide[no description available]medium101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
rotenone[no description available]medium50organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
camptothecin[no description available]medium90delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
levamisole[no description available]medium106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
paclitaxel[no description available]medium220taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
paroxetine[no description available]medium10aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
lovastatin[no description available]medium50delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
simvastatin[no description available]medium30delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
pravastatin[no description available]medium203-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
aromasil[no description available]medium1017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
atorvastatin[no description available]medium20aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
ziprasidone[no description available]medium101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
mevastatin[no description available]medium302-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
sertraline[no description available]medium10dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
rosiglitazone[no description available]medium20aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
fulvestrant[no description available]medium7017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
tadalafil[no description available]medium30benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
valdecoxib[no description available]medium10isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cyc 202[no description available]medium602,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
angiotensin ii[no description available]medium80amino acid zwitterion;
angiotensin II		human metabolite
sb 203580[no description available]medium70imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
wortmannin[no description available]medium50acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
acetylleucyl-leucyl-norleucinal[no description available]medium20aldehyde;
tripeptide		cysteine protease inhibitor
tretinoin[no description available]medium620retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
cerivastatin[no description available]medium10dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin[no description available]medium10dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
y 27632[no description available]medium10aromatic amide
epothilone a[no description available]medium20epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
h 89[no description available]medium20N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
benzyloxycarbonylleucyl-leucyl-leucine aldehyde[no description available]medium180amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
cinnarizine[no description available]medium10diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
tamoxifen[no description available]medium180stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
toremifene[no description available]medium30aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
sc 560[no description available]medium10aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
apigenin[no description available]medium30trihydroxyflavoneantineoplastic agent;
metabolite
genistein[no description available]medium1407-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
sirolimus[no description available]medium110antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
brefeldin a[no description available]medium10macrolide antibioticPenicillium metabolite
geldanamycin[no description available]medium301,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
lysophosphatidic acid[no description available]medium201-acyl-sn-glycerol 3-phosphate
bay 11-7082[no description available]medium20nitrile;
sulfone		apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium20dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
tanespimycin[no description available]medium601,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
gw 1929[no description available]medium10benzophenones
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole[no description available]medium10aryl sulfide
ci 940[no description available]medium20hydroxy polyunsaturated fatty acid;
leptomycin		antifungal agent;
bacterial metabolite
pifithrin-alpha[no description available]medium10
clozapine[no description available]medium30benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
sildenafil[no description available]medium20piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
olanzapine[no description available]medium10benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
vardenafil[no description available]medium20imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
valproic acid[no description available]medium1670branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
valproic acid[no description available]medium1671branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
n1-(2-aminophenyl)-n7-phenylheptanediamide[no description available]medium20
bml 210[no description available]medium10dicarboxylic acid diamideantineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
niacinamide[no description available]medium240pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
bisindolylmaleimide i[no description available]medium30
2-(1-(2-(1-methylpyrrolidino)ethyl)-1h-indol-3-yl)maleimide[no description available]medium10
bisindolylmaleimide iv[no description available]medium10indoles;
maleimides
bisindolylmaleimide v[no description available]medium10indoles
indirubin-3'-monoxime[no description available]medium10
1-(2-naphthalenyl)-2-propen-1-one[no description available]medium10naphthalenes
nsc 664704[no description available]medium10indolobenzazepine;
lactam;
organobromine compound		cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid[no description available]medium10aromatic amine
ro 31-8220[no description available]medium40imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
staurosporine[no description available]medium30indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
paullone[no description available]medium10indolobenzazepine;
lactam		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
3,3',4,5'-tetrahydroxystilbene[no description available]medium10catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
sirtinol[no description available]medium80aldimine;
benzamides;
naphthols		anti-inflammatory agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Sir2 inhibitor
rottlerin[no description available]medium10aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
methyl 2,5-dihydroxycinnamate[no description available]medium10cinnamate ester;
hydroquinones;
methyl ester		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
geroprotector;
human urinary metabolite;
plant metabolite
3-nitropropionic acid[no description available]medium10C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin
4-phenylbutyric acid[no description available]medium120monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
trans-2-en-valproate[no description available]medium10methyl-branched fatty acid
fr 901464[no description available]medium10acetate ester;
cyclic hemiketal;
monocarboxylic acid amide;
pyrans;
spiro-epoxide		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
spliceostatin a[no description available]medium10
tacrolimus[no description available]medium10macrolide lactambacterial metabolite;
immunosuppressive agent
lactacystin[no description available]medium40lactam;
S-substituted L-cysteine
e 7107[no description available]medium10
4-phenyl-3-furoxancarbonitrile[no description available]medium101,2,5-oxadiazole;
benzenes;
N-oxide;
nitrile		geroprotector;
nitric oxide donor;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
1-(4-methanesulfonamidophenoxy)-3-(n-methyl-3,4-dichlorophenylethylamino)-2-propanol[no description available]medium10sulfonamide
amiodarone[no description available]medium101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
2,2-bis(4-glycidyloxyphenyl)propane[no description available]medium10diarylmethane
bay-k-8644[no description available]medium10(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
bepridil[no description available]medium20pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
verapamil[no description available]medium40aromatic ether;
nitrile;
polyether;
tertiary amino compound
cypermethrin[no description available]medium10aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound		agrochemical;
molluscicide;
pyrethroid ester acaricide;
pyrethroid ester insecticide
dipyridamole[no description available]medium10piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
fluspirilene[no description available]medium10diarylmethane
fpl 64176[no description available]medium10carboxylic ester;
pyrroles		calcium channel agonist
n-(2-aminoethyl)-5-isoquinolinesulfonamide[no description available]medium10
loperamide[no description available]medium10monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
ml 9[no description available]medium10naphthalenes;
sulfonic acid derivative
nicardipine[no description available]medium10benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
propafenone[no description available]medium30aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
sb 202190[no description available]medium30imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
dpi 201-106[no description available]medium10diarylmethane
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate[no description available]medium10trihydroxybenzoic acid
trifluoperazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
cantharidin[no description available]medium10cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
indirubin[no description available]medium10
pimozide[no description available]medium10benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
nigericin[no description available]medium10polycyclic etherantibacterial agent;
antimicrobial agent;
bacterial metabolite;
potassium ionophore
etoposide[no description available]medium210beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
castanospermine[no description available]medium10indolizidine alkaloidanti-HIV-1 agent;
anti-inflammatory agent;
EC 3.2.1.* (glycosidase) inhibitor;
metabolite
niguldipine[no description available]medium10diarylmethane
aloxistatin[no description available]medium20epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor
chelerythrine chloride[no description available]medium10
calpeptin[no description available]medium10amino acid amide
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole[no description available]medium10ether;
imidazoles;
monomethoxybenzene		TRP channel blocker
paxilline[no description available]medium30diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
24-hydroxycholesterol[no description available]medium1024-hydroxycholesterolbiomarker;
human blood serum metabolite;
mouse metabolite
ilomastat[no description available]medium20hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
tanshinone ii a[no description available]medium20abietane diterpenoid
monensin[no description available]medium20cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
cyclopamine[no description available]medium10piperidinesglioma-associated oncogene inhibitor
thapsigargin[no description available]medium20butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
aphidicolin[no description available]medium40tetracyclic diterpenoidantimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite
gw9662[no description available]medium10benzamides
flunarizine[no description available]medium10diarylmethane
quinine[no description available]medium20cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
caffeic acid phenethyl ester[no description available]medium20alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
cyclosporine[no description available]medium20homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
cytochalasin b[no description available]medium20cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
cytochalasin d[no description available]medium10
latrunculin b[no description available]medium10cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
bafilomycin a1[no description available]medium20cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
ca 074 methyl ester[no description available]medium10
grayanotoxin iii[no description available]medium10
alpha-cyclopiazonic acid[no description available]medium10alpha-cyclopiazonic acids
chloroquine[no description available]medium190aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
azelaic bishydroxamic acid[no description available]medium20
belinostat[no description available]high140hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide[no description available]medium30benzamides
mocetinostat[no description available]medium90aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
azumamide e[no description available]medium20
salicylhydroxamic acid[no description available]medium10hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
fenofibrate[no description available]medium60benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor
mefloquine hydrochloride[no description available]medium30organofluorine compound;
piperidines;
quinolines;
secondary alcohol
quinacrine[no description available]medium10acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
1,3-dipropyl-8-cyclopentylxanthine[no description available]medium10oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1-aminoindan-1,5-dicarboxylic acid[no description available]medium10
astemizole[no description available]medium20benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
aricine[no description available]medium10cinchona alkaloid
moclobemide[no description available]medium10benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
n-acetyl-4-nitrophenylserinol[no description available]medium10
oxiracetam[no description available]medium10organonitrogen compound;
organooxygen compound
pentamidine[no description available]medium30aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pronethalol[no description available]medium10naphthalenes
pyrimethamine[no description available]medium10aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone[no description available]medium10cyclodepsipeptide
cycloheximide[no description available]medium210antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
phanquinone[no description available]medium10orthoquinones
diphenan[no description available]medium10diarylmethane
2-phenylacetamide[no description available]medium10monocarboxylic acid amidemouse metabolite
tetraphenylborate[no description available]medium10
cycloguanil hydrochloride[no description available]medium10hydrochloride;
organic molecular entity
emetine[no description available]medium20isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
dequalinium chloride[no description available]medium10organic chloride saltantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor
gentian violet[no description available]medium20organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
Berberine chloride (TN)[no description available]medium10organic molecular entity
9,10-dimethylanthracene[no description available]medium10
c 137[no description available]medium10
buquinolate[no description available]medium10
propranolol glycol[no description available]medium10
thionine[no description available]medium10
neocuproine[no description available]medium10phenanthrolineschelator;
copper chelator
mefloquine hydrochloride[no description available]medium10hydrochloride
toxoflavin[no description available]medium20carbonyl compound;
pyrimidotriazine		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor
selfotel[no description available]medium10non-proteinogenic alpha-amino acid
plasmenylserine[no description available]medium10O-phosphoserineEC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor;
EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2,2',2''-terpyridine[no description available]medium10terpyridineschelator
cletoquine[no description available]medium10
lycorine[no description available]medium10indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor
bathophenanthroline[no description available]medium10benzenes;
phenanthrolines		chelator
fascaplysine[no description available]medium10
tryptanthrine[no description available]medium20alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
ethylhydrocupreine[no description available]medium10aromatic ether;
cinchona alkaloid		EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
cinchonine[no description available]medium10(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
7-chloro-4-aminoquinoline[no description available]medium10aminoquinoline
mmv665852[no description available]medium10
1,3,4,10-Tetrahydro-9(2H)-acridinone[no description available]medium10acridines
wr 158122[no description available]medium10
dihydroergocristine[no description available]medium10ergot alkaloidadrenergic antagonist;
vasodilator agent
3',4'-dichlorobenzamil[no description available]medium10guanidines;
pyrazines
cleistanthin b[no description available]medium10beta-D-glucoside;
cleistanthins;
monosaccharide derivative		alpha-adrenergic antagonist;
antihypertensive agent;
diuretic
n-acetyltyramine[no description available]medium10acetamides;
tyramines		animal metabolite;
Aspergillus metabolite;
bacterial metabolite;
marine metabolite;
quorum sensing inhibitor
1,3-di(4-imidazolinophenoxyl)propane[no description available]medium10
7h-pyrido(4,3-c)carbazole[no description available]medium10
cl 246738[no description available]medium10
celastrol methyl ester[no description available]medium10carboxylic ester
2-phenyl-4-oxohydroquinoline[no description available]medium10
cypripedin[no description available]medium10phenanthrol
respinomycin d[no description available]medium10
azacrin[no description available]medium10
acetoxycycloheximide[no description available]medium10
(R)-Roemerine[no description available]medium10isoquinoline alkaloid
anisomycin[no description available]medium50monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
2-guanidine-4-methylquinazoline[no description available]medium10
jatrorrhizine chloride[no description available]medium10
puromycin[no description available]medium20puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
quinidine[no description available]medium20cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
epothilone b[no description available]medium20epothilone;
epoxide		antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent
dactinomycin[no description available]medium100actinomycinmutagen
1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione[no description available]medium10pyrimidotriazine
jp-1302[no description available]medium20
7-hydroxy-2-methoxy-1,4-phenanthrenedione[no description available]medium10
cgp 60474[no description available]medium10substituted aniline
2-[2-hydroxy-6,7-dimethoxy-4-(4-morpholinyl)-1-naphthalenyl]-N-phenylacetamide[no description available]medium10naphthols
N4-(3-chlorophenyl)-6-methyl-N2-(phenylmethyl)pyrimidine-2,4-diamine[no description available]medium10aralkylamine
2,6-bis(benzimidazol-2-yl)pyridine[no description available]medium10benzimidazoles
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine[no description available]medium10
N-[4-(1-azepanyl)phenyl]-2-chloroacetamide[no description available]medium10anilide
N-(4-methylphenyl)carbamic acid (cyclopentylideneamino) ester[no description available]medium10toluenes
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine)[no description available]medium10benzimidazoles
1,4,8-trimethyl-12-quinolino[2,3-b]quinolinamine[no description available]medium10aminoquinoline
2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone[no description available]medium10aromatic amide;
heteroarene
1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone[no description available]medium10quinolines
stk295900[no description available]medium10
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole[no description available]medium10benzimidazoles
N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine[no description available]medium10aromatic ether
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline[no description available]medium10benzimidazoles
4-(1-adamantyl)-2-methyl-1,3-thiazole[no description available]medium10thiazoles
2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile[no description available]medium10piperazines;
pyridines
1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea[no description available]medium10pyrazoles;
ring assembly
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine[no description available]medium10quinazolines
polysulfide rubber[no description available]medium10
4-(4-nitrophenyl)-N-prop-2-enyl-1-piperazinecarbothioamide[no description available]medium10piperazines
zd 6474[no description available]medium30aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamide[no description available]medium10indoles
N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide[no description available]medium10aromatic amide;
heteroarene
2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
trichomonacid[no description available]medium10
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine[no description available]medium20triazolopyrimidines
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethyl)-3-oxo-1H-isoindole-4-carboxamide[no description available]medium10isoindoles
penicillin v[no description available]medium101,1'-diethyl-2,2'-cyanine;
quinolines
hydrocortisone acetate, (11beta)-isomer[no description available]medium10
xib 4035[no description available]medium20
10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one[no description available]medium10pyridochromene
lumefantrine[no description available]medium10fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial
suloctidil[no description available]medium10
edatrexate[no description available]medium10glutamic acid derivative
cgp 71683 a[no description available]medium10
artenimol[no description available]medium10
aee 788[no description available]medium106-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
tomaymycin[no description available]medium10tomaymycin
amodiaquine hydrochloride[no description available]medium10
gramicidin a[no description available]medium10
N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide[no description available]medium10benzenes
rs 39604[no description available]medium10hydrochlorideserotonergic antagonist
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea[no description available]medium10quinazolines
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester[no description available]medium40carbamate ester
butyric acid[no description available]medium690fatty acid 4:0;
straight-chain saturated fatty acid		human urinary metabolite;
Mycoplasma genitalium metabolite
quinolinic acid[no description available]medium10pyridinedicarboxylic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite;
NMDA receptor agonist
succinic acid[no description available]medium20alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid		anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent
2,5-pyridinedicarboxylic acid[no description available]medium10pyridinedicarboxylic acid
3,4-pyridinedicarboxylic acid[no description available]medium10pyridinedicarboxylic acid
2,4-pyridinedicarboxylic acid[no description available]medium10pyridinedicarboxylic acid
3,5-pyridinedicarboxylic acid[no description available]medium10pyridinedicarboxylic acid
dipicolinic acid[no description available]medium10pyridinedicarboxylic acidbacterial metabolite
fumaric acid[no description available]medium10butenedioic acidfood acidity regulator;
fundamental metabolite;
geroprotector
oxalylglycine[no description available]medium20amino dicarboxylic acid;
N-acylglycine		EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor
carvedilol[no description available]medium20carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
chlorpromazine[no description available]medium20organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
cifenline[no description available]medium10diarylmethane
citalopram[no description available]medium102-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
ketamine[no description available]medium20cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
maprotiline[no description available]medium10anthracenes
midazolam[no description available]medium20imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
venlafaxine[no description available]medium10cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
pefloxacin[no description available]medium10fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
tropisetron[no description available]medium10indolyl carboxylic acid
kaempferol[no description available]medium207-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
acenocoumarol[no description available]medium10C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
bithionol[no description available]medium10aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol		antifungal agrochemical;
antiplatyhelmintic drug
dichlorophen[no description available]medium10bridged diphenyl fungicide;
diarylmethane
indomethacin[no description available]medium30aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
nimesulide[no description available]medium10aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide[no description available]medium10aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
6-bromoindirubin-3'-oxime[no description available]medium10
dinoprostone[no description available]medium80prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
16,16-dimethylprostaglandin e2[no description available]medium10cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol		anti-ulcer drug;
gastrointestinal drug;
radiation protective agent
dicumarol[no description available]medium10hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
panobinostat[no description available]high280cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
7-amino-4-methylcoumarin[no description available]medium407-aminocoumarinsfluorochrome
2,3-dihydroxybenzoic acid[no description available]medium10dihydroxybenzoic acidhuman xenobiotic metabolite;
plant metabolite
gamma-aminobutyric acid[no description available]medium60amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
anthranilic acid[no description available]medium10aminobenzoic acidhuman metabolite;
mouse metabolite
citric acid, anhydrous[no description available]medium10tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
salicylic acid[no description available]medium20monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
hippuric acid[no description available]medium10N-acylglycinehuman blood serum metabolite;
uremic toxin
3,4-dihydroxyphenylacetic acid[no description available]medium20catechols;
dihydroxyphenylacetic acid		human metabolite
propionic acid[no description available]medium10saturated fatty acid;
short-chain fatty acid		antifungal drug
mandelic acid[no description available]medium102-hydroxy monocarboxylic acid;
benzenes		antibacterial agent;
human xenobiotic metabolite
oxyquinoline[no description available]medium10monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
baclofen[no description available]medium10amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
kojic acid[no description available]medium204-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
4-phenylbutyric acid, sodium salt[no description available]medium20organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug
valine[no description available]medium20L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
isobutyric acid[no description available]medium40branched-chain saturated fatty acid;
fatty acid 4:0;
methyl-branched fatty acid		Daphnia magna metabolite;
plant metabolite;
volatile oil component
n-pentanoic acid[no description available]medium10short-chain fatty acid;
straight-chain saturated fatty acid		plant metabolite
vanillic acid[no description available]medium10methoxybenzoic acid;
monohydroxybenzoic acid		plant metabolite
isovaleric acid[no description available]medium20branched-chain saturated fatty acid;
methylbutyric acid;
short-chain fatty acid		mammalian metabolite;
plant metabolite
2-hydroxybutyric acid[no description available]medium102-hydroxy monocarboxylic acid;
hydroxybutyric acid		algal metabolite;
human metabolite
indole-2-carboxylic acid[no description available]medium10indolyl carboxylic acid
3,4-dihydroxyphenylpropionic acid[no description available]medium10(dihydroxyphenyl)propanoic acidantioxidant;
human xenobiotic metabolite
tartaric acid[no description available]medium10tartaric acidEscherichia coli metabolite
e-z cinnamic acid[no description available]medium20cinnamic acidplant metabolite
ferulic acid[no description available]medium20ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
3-coumaric acid[no description available]medium103-coumaric acid
sorbic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
sorbic acid
caffeic acid[no description available]medium10caffeic acidgeroprotector;
mouse metabolite
chlorogenic acid[no description available]medium20cinnamate ester;
tannin		food component;
plant metabolite
sodium lactate[no description available]medium10lactate salt;
organic sodium salt		food acidity regulator;
food preservative
ursolic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
n(1),n(11)-diethylnorspermine[no description available]medium10
n(1), n(12)-diethylspermine[no description available]medium10polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine		antineoplastic agent
n(1),n(14)-bis(ethyl)homospermine[no description available]medium10
mdl 27695[no description available]medium10
be 4-4-4-4[no description available]medium10
cgc 11047[no description available]medium10
vinblastine[no description available]medium10
amphotericin b[no description available]medium40antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
colforsin[no description available]medium30acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
su 11248[no description available]medium40monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
ci 994[no description available]medium50acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
givinostat[no description available]medium40carbamate ester
fluconazole[no description available]medium20conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
gliotoxin[no description available]medium20dipeptide;
organic disulfide;
organic heterotetracyclic compound;
pyrazinoindole		antifungal agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
immunosuppressive agent;
mycotoxin;
proteasome inhibitor
rhizoxin[no description available]medium101,3-oxazoles;
epoxide;
macrolide antibiotic		antimitotic;
antineoplastic agent;
metabolite
haloperidol[no description available]medium20aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol[no description available]medium10piperidines
atenolol[no description available]medium10ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
metoprolol[no description available]medium20aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
ranitidine[no description available]medium10aralkylamine
pyrimidin-2-one beta-ribofuranoside[no description available]medium110pyrimidine ribonucleosides
decitabine[no description available]medium37902'-deoxyribonucleoside
decitabine[no description available]medium37922'-deoxyribonucleoside
rg108[no description available]medium30indolyl carboxylic acid
mitomycin[no description available]medium20mitomycinalkylating agent;
antineoplastic agent
phloretic acid[no description available]medium10hydroxy monocarboxylic acidplant metabolite
s-adenosylhomocysteine[no description available]medium40adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide		cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
tubastatin a[no description available]high260hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide[no description available]medium30
pci 34051[no description available]medium100indolecarboxamide
niacin[no description available]medium10pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
edetic acid[no description available]medium20ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
acetazolamide[no description available]medium10monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
deferiprone[no description available]medium204-pyridonesiron chelator;
protective agent
deferoxamine[no description available]medium30acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
tropolone[no description available]medium10alpha-hydroxy ketone;
cyclic ketone;
enol		bacterial metabolite;
fungicide;
toxin
captopril[no description available]medium20alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
zileuton[no description available]medium101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
clioquinol[no description available]medium21monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clioquinol[no description available]medium20monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
beta-thujaplicin[no description available]medium10cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
atovaquone[no description available]medium20hydroxy-1,2-naphthoquinone
pyronaridine[no description available]medium20aminoquinoline
artesunate[no description available]medium20artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
pracinostat[no description available]high50benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
npi 2358[no description available]medium102,5-diketopiperazines;
benzenes;
imidazoles;
olefinic compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
aureusidin[no description available]medium10hydroxyauroneplant metabolite
4'-chloroaurone[no description available]medium10
3',4'-dihydroxyaurone[no description available]medium10catechols;
hydroxyaurone		EC 3.5.1.98 (histone deacetylase) inhibitor
trichostatin c[no description available]medium40O-amino sugar;
trichostatin
trichostatin rk[no description available]medium40
quisinostat[no description available]medium40indoles
abexinostat[no description available]medium30benzofurans
srt1720[no description available]medium20
n-hydroxy-2,2-diphenylacetamide[no description available]medium10
dasatinib[no description available]medium301,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
curcumin[no description available]medium180aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
largazole[no description available]medium50
berberine[no description available]medium10alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
cynaropicrin[no description available]medium10sesquiterpene lactone
piperolactam a[no description available]medium10alkaloid
5'-o-caffeoylquinic acid[no description available]medium10cinnamate ester;
cyclitol carboxylic acid		plant metabolite
narcissin flavonol[no description available]medium10disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
trihydroxyflavone
indigo carmine[no description available]medium10
methyl 3,5-di-o-caffeoyl quinate[no description available]medium10
sebacic acid[no description available]medium10alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		human metabolite;
plant metabolite
10-hydroxycapric acid[no description available]medium10omega-hydroxy-medium-chain fatty acid;
straight-chain saturated fatty acid
pi103[no description available]medium40aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
buparlisib[no description available]medium10aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
santacruzamate a[no description available]medium10organonitrogen compound;
organooxygen compound
mdv 3100[no description available]medium10(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
bortezomib[no description available]medium140amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
bpr0l075[no description available]medium10
ubenimex[no description available]medium20
sc 57461[no description available]medium10
resminostat[no description available]medium30
cudc 101[no description available]medium20
acy-1215[no description available]medium110pyrimidinecarboxylic acid
rg2833[no description available]medium20
nintedanib[no description available]medium20
surfactin c[no description available]medium10cyclodepsipeptide;
lipopeptide antibiotic;
macrocyclic lactone		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
metabolite;
platelet aggregation inhibitor;
surfactant
resveratrol[no description available]medium90resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
n-(3-((2-hydroxynaphthalen-1-ylmethylene)amino)phenyl)-2-phenylpropionamide[no description available]medium20
oxamniquine[no description available]medium10aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
dimethyl 2-(2-nitrobenzylidene)malonate[no description available]medium10
4-[4-(3-methyl-4-nitrophenoxy)butoxy]benzonitrile[no description available]medium10aromatic ether;
C-nitro compound
N-[2-(1-azepanyl)-1,3-benzothiazol-6-yl]carbamic acid ethyl ester[no description available]medium10benzothiazoles
u-11634[no description available]medium10
rgfp966[no description available]medium20
irinotecan[no description available]medium50carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
rhodamine 123[no description available]medium10organic chloride salt;
xanthene dye		fluorochrome
sorafenib[no description available]medium30(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
nexavar[no description available]medium10organosulfonate salt
dextromethorphan[no description available]medium106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
gdc 0941[no description available]medium20indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
vs-5584[no description available]medium10
cudc-907[no description available]medium30
cnf 2024[no description available]medium202-aminopurines;
aromatic ether;
organochlorine compound;
pyridines		antineoplastic agent;
Hsp90 inhibitor
isocombretastatin a-4[no description available]medium20
diallyl disulfide[no description available]medium20organic disulfideantifungal agent;
antineoplastic agent;
plant metabolite
harmine[no description available]medium10harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
mi-192[no description available]medium10
methylene blue[no description available]medium10organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
epoxomicin[no description available]medium20morpholines;
tripeptide		proteasome inhibitor
chlorotonil a[no description available]medium10
5-carboxy-8-hydroxyquinoline[no description available]medium20quinolines
bix 01294[no description available]medium30piperidines
unc 0638[no description available]medium40quinazolines
ex 527[no description available]medium50carbazoles;
monocarboxylic acid amide;
organochlorine compound
colchicine[no description available]medium50alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
e 7010[no description available]medium10sulfonamide
fosbretabulin[no description available]medium30stilbenoid
chidamide[no description available]medium20benzamides
temozolomide[no description available]medium20imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
pk 11195[no description available]medium10aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
jtv519[no description available]medium10
alprazolam[no description available]medium10organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
dan 2163[no description available]medium10aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amlexanox[no description available]medium10monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
benzbromarone[no description available]medium101-benzofurans;
aromatic ketone		uricosuric drug
bufexamac[no description available]medium10aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cadralazine[no description available]medium10organic molecular entity
cetirizine[no description available]medium10ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlorcyclizine[no description available]medium10diarylmethane
fenbendazole[no description available]medium10aryl sulfide;
benzimidazoles;
carbamate ester		antinematodal drug
homochlorocyclizine[no description available]medium10diarylmethane
hydroxyzine[no description available]medium10hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ifenprodil[no description available]medium10piperidines
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone[no description available]medium10naphthalenes
ketoprofen[no description available]medium10benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mebendazole[no description available]medium10aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mephenesin[no description available]medium10aromatic ether;
glycerol ether
oxibendazole[no description available]medium10benzimidazoles;
carbamate ester
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine[no description available]medium10
perphenazine[no description available]medium10N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
pimobendan[no description available]medium10benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
ag 1879[no description available]medium10aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
ropinirole[no description available]medium10indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole[no description available]medium10aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
zotepine[no description available]medium10dibenzothiepine;
tertiary amino compound		alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug
benziodarone[no description available]medium10aromatic ketone
cyclizine[no description available]medium10N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
trehalose[no description available]medium10trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
triclocarban[no description available]medium10dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
4-tert-octylphenol[no description available]medium10alkylbenzene
ethamivan[no description available]medium10methoxybenzenes;
phenols
methysergide[no description available]medium10ergoline alkaloid
podophyllotoxin[no description available]medium10furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
etonitazene[no description available]medium10
clothiapine[no description available]medium10dibenzothiazepine
benperidol[no description available]medium10aromatic ketone
7-hydroxychlorpromazine[no description available]medium10phenothiazines
thenalidine[no description available]medium10dialkylarylamine;
tertiary amino compound
bromocriptine[no description available]medium10indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
dexchlorpheniramine[no description available]medium10chlorphenamine
dv 1006[no description available]medium10
climbazole[no description available]medium10aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes
triadimenol[no description available]medium10aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
amonafide[no description available]medium10isoquinolines
flupirtine[no description available]medium10aminopyridine
chaetochromin[no description available]medium10
enoximone[no description available]medium10aromatic ketone
aripiprazole[no description available]medium10aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
indocate[no description available]medium10
N(4)-acetylsulfathiazole[no description available]medium101,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite
2,3-trimethylene-4-quinazolone[no description available]medium10quinazolines
1,3-dimethyluric acid[no description available]medium10oxopurinemetabolite
danofloxacin[no description available]medium10quinolines
nitrefazole[no description available]medium10imidazoles
methotrimeprazine[no description available]medium10phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
honokiol[no description available]medium20biphenyls
9-methoxyellipticine[no description available]medium10
3-aminophenoxazone[no description available]medium10phenoxazine
3-deazaneplanocin[no description available]medium60
2-chlorodiazepam[no description available]medium10
Polycartine B[no description available]medium10phenazines
aminoquinuride dihydrochloride[no description available]medium10
thioproperazine mesylate[no description available]medium10phenothiazines
n(6)-(delta(2)-isopentenyl)adenine[no description available]medium106-isopentenylaminopurinecytokinin
4-methyl-N-(phenylmethyl)benzenesulfonamide[no description available]medium10sulfonamide
zpck[no description available]medium10
sr141716[no description available]medium10amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
fingolimod[no description available]medium10aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
tesmilifene[no description available]medium10diarylmethane
sr 27897[no description available]medium10indolyl carboxylic acid
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine[no description available]medium10leucine derivative
norketamine[no description available]medium10organochlorine compound
indatraline[no description available]medium10indanes
methotrexate[no description available]medium60dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
salvinorin a[no description available]medium10organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide[no description available]medium10
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide[no description available]medium10phenylindole
l 741626[no description available]medium10piperidines
dx 8951[no description available]medium10pyranoindolizinoquinoline
tipifarnib[no description available]medium10imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
avasimibe[no description available]medium10monoterpenoid
l 163191[no description available]medium10
dizocilpine[no description available]medium10secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
s-benzylcysteine[no description available]medium10S-aryl-L-cysteine zwitterion
chelidonine[no description available]medium10alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
lapatinib[no description available]medium30furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
roxindole[no description available]medium10indolesalpha-adrenergic antagonist;
serotonergic drug
conidendrin[no description available]medium10
Porfiromycine[no description available]medium10mitomycin
nsc 95397[no description available]medium101,4-naphthoquinones
4-methyl-2-quinazolinamine[no description available]medium10
2-glycineamide-5-chlorophenyl-2-pyrryl ketone[no description available]medium10
niguldipine hydrochloride[no description available]medium10
2,5-bis(5-hydroxymethyl-2-thienyl)furan[no description available]medium10thiophenes
ritonavir[no description available]medium101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
bardoxolone methyl[no description available]medium10cyclohexenones
Destruxin B[no description available]medium10cyclodepsipeptide
tosylphenylalanyl chloromethyl ketone[no description available]medium20alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
sitafloxacin[no description available]medium10fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
2'-c-methylcytidine[no description available]medium10
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one[no description available]medium10benzodiazepine
tenatoprazole[no description available]medium10imidazopyridine
s 1033[no description available]medium10(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
5-[(2-fluoroanilino)methyl]-8-quinolinol[no description available]medium10hydroxyquinoline
benidipine[no description available]medium10
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one[no description available]medium10quinazolines
chlorprothixene[no description available]medium10chlorprothixene
jrf 12[no description available]medium10
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester[no description available]medium10methoxybenzenes;
substituted aniline
3-hydroxypyridine, sodium salt[no description available]medium10
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide[no description available]medium10naphthalenecarboxamide
5-[(2-bromoanilino)methyl]-8-quinolinol[no description available]medium10hydroxyquinoline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide[no description available]medium10
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline[no description available]medium10aromatic amine
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide[no description available]medium10piperidinecarboxamide
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol[no description available]medium10hydroxyquinoline
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide[no description available]medium10acetamides;
anilide
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide[no description available]medium10aromatic amide;
thiophenes
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone[no description available]medium10dimethoxybenzene
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide[no description available]medium10aromatic amide
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide[no description available]medium10aromatic ether
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione[no description available]medium10maleimides
Src Inhibitor-1[no description available]medium10aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one[no description available]medium10dimethoxybenzene
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide[no description available]medium10quinolines
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine[no description available]medium10pyrroles
bi-78d3[no description available]medium10aryl sulfide
kartogenin[no description available]medium10
vx-745[no description available]medium10aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide[no description available]medium10indoles
nih-12848[no description available]medium10
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide[no description available]medium10quinazolines
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone[no description available]medium10benzimidazoles
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile[no description available]medium10imidazopyridine
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one[no description available]medium10aromatic ketone
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester[no description available]medium10oxopurine
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester[no description available]medium10organonitrogen compound;
organosulfur compound
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide[no description available]medium10quinolines
LSM-1924[no description available]medium10organic heterotricyclic compound;
organooxygen compound
ferrostatin-1[no description available]medium10ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine[no description available]medium10C-nitro compound
rabeprazole(1-)[no description available]medium10organic nitrogen anion
ncgc00099374[no description available]medium10
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide[no description available]medium10benzamides
luteolin[no description available]medium103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
cyclosporine[no description available]medium10
mycophenolate mofetil[no description available]medium10carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
bruceantin[no description available]medium10triterpenoid
chrysin[no description available]medium107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
daidzein[no description available]medium307-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
neticonazole[no description available]medium10aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide		antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine[no description available]medium10endocannabinoid;
N-acylethanolamine 22:6
n-oleoylethanolamine[no description available]medium10endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
alpha-zearalenol[no description available]medium10macrolide
su 9516[no description available]medium10
sb 277011[no description available]medium10
sb 223412[no description available]medium10
sr 59230a[no description available]medium10tetralins
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide[no description available]medium10pyrimidines
kn 62[no description available]medium10piperazines
MeJA[no description available]medium10Jasmonate derivatives
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-[no description available]medium10
pd 161570[no description available]medium10
palbociclib[no description available]medium10aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621[no description available]medium10sulfonamide
virginiamycin factor s1[no description available]medium10cyclodepsipeptide;
macrolide antibiotic		antibacterial drug;
bacterial metabolite
fenoterol[no description available]medium10hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
gw-5074[no description available]medium10
belotecan[no description available]medium10pyranoindolizinoquinoline
norgestimate[no description available]medium10ketoxime;
steroid ester;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
b 43[no description available]medium10aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine[no description available]medium10
methiazole[no description available]medium10benzimidazoles;
carbamate ester
sb 218795[no description available]medium10quinolines
bvt.948[no description available]medium10
fk 866[no description available]medium20benzamides;
N-acylpiperidine
a 38503[no description available]medium10
parthenolide[no description available]medium10sesquiterpene lactonedrug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
krn 633[no description available]medium10
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid[no description available]medium10organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
gw 501516[no description available]medium101,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
dolastatin 10[no description available]medium101,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
spc-839[no description available]medium10
midostaurin[no description available]medium10benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
valnemulin[no description available]medium10
nu 7026[no description available]medium20organic heterotricyclic compound;
organooxygen compound
osi 930[no description available]medium10aromatic amide
ticagrelor[no description available]medium10aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor
l 692585[no description available]medium10peptide
nnc 26-9100[no description available]medium10aminopyridine
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine[no description available]medium10
tivozanib[no description available]medium10aromatic ether
hki 272[no description available]medium10nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide[no description available]medium10
tae226[no description available]medium20morpholines
gw0742[no description available]medium10monocarboxylic acid
u 18666a[no description available]medium20hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
sb 525334[no description available]medium10quinoxaline derivative
bx795[no description available]medium10ureas
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea[no description available]medium10
bay 61-3606[no description available]medium10pyrimidines
sd-208[no description available]medium10
crenolanib[no description available]medium10aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cj 033466[no description available]medium10
cc 401[no description available]medium10pyrazoles;
ring assembly
PB28[no description available]medium10aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
arterolane[no description available]medium10
cariprazine[no description available]medium10
krp-203[no description available]medium10
regorafenib[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
at 7867[no description available]medium10monochlorobenzenes;
piperidines;
pyrazoles		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester[no description available]medium10pyrroloquinoline
ptc 124[no description available]medium10oxadiazole;
ring assembly
degrasyn[no description available]medium10
bi 2536[no description available]medium20
azd 1152[no description available]medium10anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug
carfilzomib[no description available]medium20epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
idelalisib[no description available]medium20aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
motesanib[no description available]medium10pyridinecarboxamide
pf-562,271[no description available]medium10indoles
gliocladin c[no description available]medium10
sb 706504[no description available]medium10
ku-0060648[no description available]medium10dibenzothiophenes
bgt226[no description available]medium10aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
n-desmethyldanofloxacin[no description available]medium10
azd 1152-hqpa[no description available]medium10anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor
CDN1163[no description available]medium10aromatic ether;
quinolines;
secondary carboxamide		SERCA activator
gsk 269962a[no description available]medium10
pha 848125[no description available]medium10
nvp-bhg712[no description available]medium10benzamides
pf 04217903[no description available]medium10quinolines
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one[no description available]medium10aromatic ketone
ph 797804[no description available]medium10aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
purfalcamine[no description available]medium10
bms 754807[no description available]medium10pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ponatinib[no description available]medium10(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
quizartinib[no description available]medium10benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
PP121[no description available]medium10aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
navitoclax[no description available]medium20aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
gsk 650394[no description available]medium10phenylpyridine
dcc-2036[no description available]medium10organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
cabozantinib[no description available]medium10aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
TAK-580[no description available]medium101,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one[no description available]medium10chromones
pf 3758309[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol[no description available]medium10benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine[no description available]medium10aryl sulfide;
thienopyrimidine
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine[no description available]medium10aryl sulfide;
thienopyrimidine
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine[no description available]medium10aryl sulfide;
thienopyrimidine
baricitinib[no description available]medium10azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine[no description available]medium10quinazolines
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone[no description available]medium20organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide[no description available]medium10hydroxyquinoline
p505-15[no description available]medium10
mrt67307[no description available]medium10aromatic amine
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide[no description available]medium10piperazines
ribociclib[no description available]medium10
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone[no description available]medium10aromatic ketone;
thienopyrimidine
pha 793887[no description available]medium10piperidinecarboxamide
gsk 2334470[no description available]medium10indazoles
ml228 probe[no description available]medium101,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound		hypoxia-inducible factor pathway activator
pf-03882845[no description available]medium10
jq1 compound[no description available]medium20carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
pf-04620110[no description available]medium10
gsk525762a[no description available]medium20benzodiazepine
birinapant[no description available]medium10dipeptide
torin 1[no description available]medium10N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
abt-199[no description available]medium10aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea[no description available]medium10ureas
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide[no description available]medium10(trifluoromethyl)benzenes
ncgc00242364[no description available]medium10quinazolines
gsk1210151a[no description available]medium20imidazoquinoline
hs-173[no description available]medium10
sr1664[no description available]medium10indolecarboxamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide[no description available]medium10
methacycline[no description available]medium10
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid[no description available]medium10quinolines
agi-5198[no description available]medium10
cep-32496[no description available]medium10
epz004777[no description available]medium10N-glycosyl compound
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid[no description available]medium10organonitrogen heterocyclic compound
entecavir[no description available]medium10benzamides;
N-acylpiperidine
gkt137831[no description available]medium10
vx-509[no description available]medium10
vx-970[no description available]medium10sulfonamide
gs-9973[no description available]medium10
amg 925[no description available]medium10
gne-618[no description available]medium10
g007-lk[no description available]medium10
volitinib[no description available]medium10
ML355[no description available]medium10benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor
acp-196[no description available]medium10aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343[no description available]medium30aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
agi-6780[no description available]medium10
khs101[no description available]medium10
cb-839[no description available]medium10
gsk-j4[no description available]medium10organonitrogen heterocyclic compound
pf-06424439[no description available]medium10
etp-46464[no description available]medium10
onc201[no description available]medium10
kai407[no description available]medium10
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine[no description available]medium10
enasidenib[no description available]medium101,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
oicr-9429[no description available]medium10
lly-507[no description available]medium10
at 9283[no description available]medium10
hypoxanthine[no description available]medium10nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
1-hydroxyphenazine[no description available]medium10phenazines
ro 24-7429[no description available]medium10benzodiazepine
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide[no description available]medium10catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor
ver 52296[no description available]medium10aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
rvx 208[no description available]medium20
bmn 673[no description available]medium10
verapamil hydrochloride[no description available]medium10
vincaleukoblastine[no description available]medium10acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
spiruchostatin a[no description available]medium10
acy-738[no description available]medium20
2-((1-(3-fluorophenyl)cyclohexyl)amino)-n-hydroxypyrimidine-5-carboxamide[no description available]medium20
clomipramine[no description available]medium10dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
digoxin[no description available]medium20cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
bibw 2992[no description available]medium10aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
cx 4945[no description available]medium10
4,5,6,7-tetrabromo-2-azabenzimidazole[no description available]medium20
bendamustine[no description available]medium10benzimidazoles
n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide[no description available]medium10
levofloxacin[no description available]medium109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
erlotinib[no description available]medium10aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
cholecalciferol[no description available]medium50D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
casein kinase ii[no description available]medium40
abemaciclib[no description available]medium10
osimertinib[no description available]medium10acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
azacitidine[no description available]medium5150N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
azacitidine[no description available]medium5152N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
indolactam v[no description available]medium10indoles
12-deoxyphorbol 13-acetate[no description available]medium10phorbol estermetabolite
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide[no description available]medium10
cl 075[no description available]medium10
az 505[no description available]medium10
epz-6438[no description available]medium10
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide[no description available]medium10quinazolines
memantine hydrochloride[no description available]medium10hydrochlorideantidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
tacrine[no description available]medium10acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one[no description available]medium10
spermidine[no description available]medium10polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
benserazide[no description available]medium10carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
indoprofen[no description available]medium10gamma-lactam;
isoindoles;
monocarboxylic acid		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
vitamin k 3[no description available]medium201,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
metformin[no description available]medium20guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
nalidixic acid[no description available]medium101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
cysteine[no description available]medium10cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
alanine[no description available]medium30alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine[no description available]medium110L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methionine[no description available]medium20aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
phenylalanine[no description available]medium20amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
threonine[no description available]medium40amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
tryptophan[no description available]medium30erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoleucine[no description available]medium10aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
vitamin k5[no description available]medium10naphthols
fructose-1,6-diphosphate[no description available]medium10D-fructofuranose 1,6-bisphosphatemouse metabolite
hematoxylin[no description available]medium10organic heterotetracyclic compound;
oxacycle;
polyphenol;
tertiary alcohol		histological dye;
plant metabolite
syringic acid[no description available]medium10benzoic acids;
dimethoxybenzene;
phenols		plant metabolite
3-hydroxyflavone[no description available]medium10flavonols;
monohydroxyflavone
epigallocatechin gallate[no description available]medium50flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
5-hydroxyflavone[no description available]medium10flavones
epicatechin[no description available]medium10catechin;
polyphenol		antioxidant
6-hydroxyflavone[no description available]medium10hydroxyflavonoid
alkannin[no description available]medium10hydroxy-1,4-naphthoquinone
neoeriocitrin[no description available]medium104'-hydroxyflavanones;
disaccharide derivative;
flavanone glycoside;
neohesperidoside;
trihydroxyflavanone		plant metabolite
oxymatrine[no description available]medium10alkaloid;
tertiary amine oxide
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
taxifolin[no description available]medium10taxifolinmetabolite
micheliolide[no description available]medium10sesquiterpene lactone
shikonin[no description available]medium10hydroxy-1,4-naphthoquinone
triiodothyronine, reverse[no description available]medium103,3',5'-triiodothyronine;
amino acid zwitterion
6-[(2-fluorophenyl)methyl]-2,4-dimethyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
quercetin 3-o-glucopyranoside[no description available]medium10beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
fisetin[no description available]medium103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
myricetin[no description available]medium107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
scutellarein[no description available]medium10tetrahydroxyflavonemetabolite
wogonin[no description available]medium10dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
polydatin[no description available]medium10beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
iridin[no description available]medium104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
7-hydroxyflavone[no description available]medium10hydroxyflavonoid
dexmedetomidine[no description available]medium10medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
(E)-3-(2-Hydroxyphenyl)-2-propenal[no description available]medium10cinnamaldehydes
(-)-catechin-3-O-gallate[no description available]medium10flavans;
gallate ester;
polyphenol		metabolite
beta-elemene[no description available]medium10beta-elemeneantineoplastic agent
abt-737[no description available]medium10aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline[no description available]medium10benzenes;
sulfonamide
imipenem, anhydrous[no description available]medium10beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
batimastat[no description available]medium10hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
fg-4592[no description available]medium10aromatic ether;
isoquinolines;
N-acylglycine		EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
ciclopirox[no description available]medium10cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
di-n-desethylamiodarone[no description available]medium10
deferasirox[no description available]medium10benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide[no description available]medium10hydroxyquinoline
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin[no description available]medium201,4-benzoquinones;
ansamycin;
carbamate ester;
secondary amino compound;
tertiary amino compound		Hsp90 inhibitor
7,8,9,10-tetrahydroazepino(2,1-b)quinazolin-12(6h)-one[no description available]medium10
lithium chloride[no description available]medium40inorganic chloride;
lithium salt		antimanic drug;
geroprotector
benzene[no description available]medium60aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
hydroquinone[no description available]medium20benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
hydroxyurea[no description available]medium110one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
lysine[no description available]medium1030aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
carbamates[no description available]medium20amino-acid anion
docetaxel anhydrous[no description available]medium50secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
clay[no description available]medium10
silicon[no description available]medium10carbon group element atom;
metalloid atom;
nonmetal atom
phosphorus[no description available]medium10monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
chitosan[no description available]medium20
D-fructopyranose[no description available]medium10cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
glutaminase[no description available]medium10
glutamine[no description available]medium20amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
dacarbazine[no description available]medium10dacarbazine
transforming growth factor beta[no description available]medium340
aldosterone[no description available]medium1011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
quinazolines[no description available]medium120azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
bix 01294[no description available]medium50
chetomin[no description available]medium20indoles;
organic disulfide;
organic heteropentacyclic compound		Chaetomium metabolite;
immunosuppressive agent
fasudil[no description available]medium10isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
1-(5-isoquinolinesulfonyl)-2-methylpiperazine[no description available]medium20isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor
aminoimidazole carboxamide[no description available]medium20aminoimidazole;
monocarboxylic acid amide		mouse metabolite
aica ribonucleotide[no description available]medium101-(phosphoribosyl)imidazolecarboxamide;
aminoimidazole		cardiovascular drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
microcystin[no description available]medium10peptide
arginine[no description available]medium40arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
gold[no description available]medium10copper group element atom;
elemental gold
fluorescein-5-isothiocyanate[no description available]medium10fluorescein isothiocyanate
vanadates[no description available]medium40trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
carbocyanines[no description available]medium20cyanine dye;
organic iodide salt		fluorochrome
taurine[no description available]medium10amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
folic acid[no description available]medium20folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
pyrroles[no description available]medium70pyrrole;
secondary amine
isoflurane[no description available]medium10organofluorine compoundinhalation anaesthetic
interleukin-8[no description available]medium130
oxamflatin[no description available]medium40
emodin[no description available]medium10trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
morin[no description available]medium107-hydroxyflavonol;
pentahydroxyflavone		angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
sodium arsenite[no description available]medium20arsenic molecular entity;
inorganic sodium salt		antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide
oxadiazoles[no description available]medium10
lead[no description available]medium10carbon group element atom;
elemental lead;
metal atom		neurotoxin
cadmium[no description available]medium10cadmium molecular entity;
zinc group element atom
melatonin[no description available]medium30acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
benzofurans[no description available]medium20
ovalbumin[no description available]medium50
sulforaphane[no description available]medium80isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
cytidine[no description available]medium90cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sulfamethoxazole[no description available]medium10isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
pivalyloxymethyl butyrate[no description available]medium10
trapoxin a[no description available]medium190epoxide;
homodetic cyclic peptide;
ketone		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
fungal metabolite
dimethyl sulfoxide[no description available]medium80sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
thiophenes[no description available]medium30mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
leucine[no description available]medium10amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
u 0126[no description available]medium50aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
glycerol[no description available]medium30alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
leptin[no description available]medium30
rtki cpd[no description available]medium10
indazoles[no description available]medium30indazole
adenine[no description available]medium306-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytochalasin d[no description available]medium20
nocodazole[no description available]medium100aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
jasplakinolide[no description available]medium10cyclodepsipeptide;
phenols		actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
hydroxylamine[no description available]medium10hydroxylaminesalgal metabolite;
bacterial xenobiotic metabolite;
EC 1.1.3.13 (alcohol oxidase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
nitric oxide donor;
nucleophilic reagent
benzoic acid[no description available]medium10benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
morphine[no description available]medium50morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
adenosine[no description available]medium60adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
myelin oligodendrocyte glycoprotein (35-55)[no description available]medium20
malondialdehyde[no description available]medium40dialdehydebiomarker
phenylephrine[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
benzamide[no description available]medium10benzamides
anacardic acid[no description available]medium70hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
chlorine[no description available]medium20halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
lycopene[no description available]medium10acyclic caroteneantioxidant;
plant metabolite
silver[no description available]medium20copper group element atom;
elemental silver		Escherichia coli metabolite
myelin basic protein[no description available]medium10
fibrin[no description available]medium10peptide
quercetin[no description available]medium707-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
acetyl coenzyme a[no description available]medium20acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite
deoxycytidine[no description available]medium200pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
gemcitabine[no description available]medium120organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ag-490[no description available]medium20catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
chir 99021[no description available]medium10aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
2,3-bis(4-hydroxyphenyl)-propionitrile[no description available]medium10nitrile;
phenols		estrogen receptor agonist
cyclin d1[no description available]medium260
epirubicin[no description available]medium10aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
2-naphthol[no description available]medium60naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
zolpidem[no description available]medium10imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
carbon tetrachloride[no description available]medium10chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
ascorbic acid[no description available]medium40ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
etomoxir[no description available]medium10aromatic ether
kn 93[no description available]medium10monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
chlorambucil[no description available]medium10aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
hydroxyhydroquinone[no description available]medium10benzenetriolmouse metabolite
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine[no description available]medium10N-substituted diamine;
pyridines;
tertiary amino compound		apoptosis inducer;
chelator;
copper chelator
methyl methanesulfonate[no description available]medium30methanesulfonate esteralkylating agent;
apoptosis inducer;
carcinogenic agent;
genotoxin;
mutagen
activins[no description available]medium60
bromates[no description available]medium10bromine oxoanion;
monovalent inorganic anion
3-hydroxybutyric acid[no description available]medium10(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid		human metabolite
3-methylcholanthrene[no description available]medium20ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
pyruvic acid[no description available]medium202-oxo monocarboxylic acidcofactor;
fundamental metabolite
ldn 193189[no description available]medium10pyrimidines
atropine[no description available]medium10
lactoferrin[no description available]medium10
metribolone[no description available]medium2017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
silybin[no description available]medium30
nutlin-3a[no description available]medium20stilbenoid
tetradecanoylphorbol acetate[no description available]medium240acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
pyrazines[no description available]medium100diazine;
pyrazines		Daphnia magna metabolite
apicidin[no description available]medium170
palmitic acid[no description available]medium20long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
thiazoles[no description available]medium1501,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
n-acetylmannosamine[no description available]medium10
endothelin-1[no description available]medium50
bq 123[no description available]medium10cyclic peptide
apyrase[no description available]medium10
afimoxifene[no description available]medium50phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite
stilbenes[no description available]medium40stilbene
pyrimidine dimers[no description available]medium20
2,4-thiazolidinedione[no description available]medium10thiazolidenedione
lactic acid[no description available]medium202-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
lipoteichoic acid[no description available]medium10
catechin[no description available]medium40catechinantioxidant;
plant metabolite
5-methyldeoxycytidine[no description available]medium102'-deoxycytidine
ginsenosides[no description available]medium10
ginsenoside m1[no description available]medium1012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
hepatoprotective agent;
plant metabolite
cytochalasin e[no description available]medium10cytochalasan alkaloidmetabolite
acetylglucosamine[no description available]medium10N-acetyl-D-glucosamineepitope
pseurotin[no description available]medium10azaspiro compound;
lactam;
oxaspiro compound		metabolite
peptones[no description available]medium10
pyrazolanthrone[no description available]medium10anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
sq-23377[no description available]medium30cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
calpastatin[no description available]medium10polypeptideEC 3.4.22.52 (calpain-1) inhibitor;
EC 3.4.22.53 (calpain-2) inhibitor
calpain[no description available]medium10
hydrogen sulfite[no description available]medium20sulfur oxoanionhuman metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sulfites[no description available]medium100divalent inorganic anion;
sulfur oxide;
sulfur oxoanion
phenyl acetate[no description available]medium70benzenes;
phenyl acetates
fomepizole[no description available]medium10pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
arachidonic acid[no description available]medium30icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
1-methyl-4-phenylpyridinium[no description available]medium30pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin
amyloid beta-peptides[no description available]medium10
aluminum tetrasulfophthalocyanine[no description available]medium10
neuropeptide y[no description available]medium20
naltrexone[no description available]medium10cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
emerin[no description available]medium10
cytochrome c-t[no description available]medium130
cytidine triphosphate[no description available]medium30cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
5-aza-2'-deoxycytidine-5'-triphosphate[no description available]medium30
gentamicin[no description available]medium30
antibiotic g 418[no description available]medium20
piperidines[no description available]medium30
nad[no description available]medium30organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
phenanthrenes[no description available]medium20
3-methyladenine[no description available]medium10
quercetin 3-o-glucuronide[no description available]medium10beta-D-glucosiduronic acid;
quercetin O-glycoside		antidepressant;
antioxidant;
metabolite
chaetocin[no description available]medium30
dorsomorphin[no description available]medium10aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
betulinic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
methylselenic acid[no description available]medium10one-carbon compound;
organoselenium compound		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
human xenobiotic metabolite
digoxigenin[no description available]medium1012beta-hydroxy steroid;
14beta-hydroxy steroid;
3beta-hydroxy steroid;
3beta-sterol		hapten;
plant metabolite
staurosporine[no description available]medium70ammonium ion derivative
natriuretic peptide, c-type[no description available]medium10
olmesartan[no description available]medium10biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
atrial natriuretic factor[no description available]medium60polypeptide
3,4,5,3',4'-pentachlorobiphenyl[no description available]medium10pentachlorobiphenyl;
trichlorobenzene
wnt-c59[no description available]medium10
angiogenin[no description available]medium10
glucagon-like peptide 1[no description available]medium10
acadesine[no description available]medium101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
natriuretic peptide, brain[no description available]medium20polypeptide
thermozymocidin[no description available]medium10alpha-amino fatty acid;
hydroxy monocarboxylic acid;
non-proteinogenic alpha-amino acid;
sphingoid		antifungal agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor;
fungal metabolite;
immunosuppressive agent
cesium carbonate[no description available]medium10
cesium[no description available]medium10alkali metal atom
trifluoromethanesulfonic acid[no description available]medium10one-carbon compound;
perfluoroalkanesulfonic acid
iodine[no description available]medium10halide anion;
monoatomic iodine		human metabolite
carbonates[no description available]medium10carbon oxoanion
taurocholic acid[no description available]medium10amino sulfonic acid;
bile acid taurine conjugate		human metabolite
ceruletide[no description available]medium10oligopeptidediagnostic agent;
gastrointestinal drug
carbachol[no description available]medium20ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
galactosamine[no description available]medium10D-galactosamine;
primary amino compound		toxin
leupeptins[no description available]medium170
staurosporine aglycone[no description available]medium10
perindopril[no description available]medium10alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
acetylcysteine[no description available]medium120acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
garcinol[no description available]medium20
unc 0321[no description available]medium10quinazolines
calcitriol[no description available]medium160D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
aspirin[no description available]medium10benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
cbb1007[no description available]medium10
5'-methylthioadenosine[no description available]medium20thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1,2-bis(isothiazol-5-yl)disulfane[no description available]medium10
hydroxyindoleacetic acid[no description available]medium10indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
fumonisin b1[no description available]medium10diester;
fumonisin;
primary amino compound;
triol		carcinogenic agent;
metabolite
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
pf 04929113[no description available]medium10
givinostat hydrochloride[no description available]medium31
ribavirin[no description available]medium101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
aminolevulinic acid[no description available]medium104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
tamibarotene[no description available]medium20dicarboxylic acid monoamide;
retinoid;
tetralins		antineoplastic agent;
retinoic acid receptor alpha/beta agonist
allantoin[no description available]medium10imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
pectins[no description available]medium20D-galactopyranuronic acid
glucose, (beta-d)-isomer[no description available]medium30D-glucopyranoseepitope;
mouse metabolite
gibberellins[no description available]medium10
artemisinin[no description available]medium20organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
1-methylcyclopropene[no description available]medium10cycloalkene;
cyclopropenes		agrochemical;
plant growth regulator
oxytocin[no description available]medium30heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
alizarin[no description available]medium30dihydroxyanthraquinonechromophore;
dye;
plant metabolite
guanine[no description available]medium402-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
8-hydroxyguanine[no description available]medium10oxopurine
fluorouracil[no description available]medium60nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
dactolisib[no description available]medium20imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
corticosterone[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
palladium[no description available]medium20metal allergen;
nickel group element atom;
platinum group metal atom
cabazitaxel[no description available]medium10tetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent
amikacin[no description available]medium10alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
fc 75[no description available]medium10alkyltetrahydrofuran;
organofluorine compound
lomustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
urea[no description available]medium10isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
s-nitrosoglutathione[no description available]medium10glutathione derivative;
nitrosothio compound		bronchodilator agent;
nitric oxide donor;
platelet aggregation inhibitor;
signalling molecule
s-nitroso-n-acetylpenicillamine[no description available]medium10nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent
4-butyrolactone[no description available]medium20butan-4-olidemetabolite;
neurotoxin
sphingosine[no description available]medium30sphing-4-eninehuman metabolite;
mouse metabolite
sphingosine 1-phosphate[no description available]medium20sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
phosphoserine[no description available]medium70non-proteinogenic alpha-amino acid;
O-phosphoamino acid;
serine derivative		human metabolite
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
deacylcortivazol[no description available]medium10
epidermal growth factor[no description available]medium100
glutamic acid[no description available]medium30glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
kainic acid[no description available]medium20dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
cocaine[no description available]medium40benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
demecolcine[no description available]medium10alkaloid;
secondary amino compound		antineoplastic agent;
microtubule-destabilising agent
tributyrin[no description available]medium30butyrate ester;
triglyceride		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug;
protective agent
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium10(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
mevalonic acid[no description available]medium103,5-dihydroxy-3-methylpentanoic acid
gastrins[no description available]medium10
finasteride[no description available]medium103-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
thiazolyl blue[no description available]medium70organic bromide saltcolorimetric reagent;
dye
fluorobenzenes[no description available]medium10monofluorobenzenesNMR chemical shift reference compound
n-methylaspartate[no description available]medium30amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
5-aza-2'-deoxycytidine-5'-monophosphate[no description available]medium50
diethylstilbestrol[no description available]medium20olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
hydroxychloroquine[no description available]medium10aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
azoxymethane[no description available]medium10
leptomycin b[no description available]medium80
deoxycholic acid[no description available]medium20bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
beta carotene[no description available]medium10carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
okadaic acid[no description available]medium130ketal
5-methylcytosine[no description available]medium40methylcytosine;
pyrimidines		human metabolite
cytosine[no description available]medium110aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
carbonyl cyanide m-chlorophenyl hydrazone[no description available]medium10hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
sulindac sulfide[no description available]medium20aryl sulfide;
monocarboxylic acid;
organofluorine compound		antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug
sulindac[no description available]medium40monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
osteoprotegerin[no description available]medium10long-chain fatty acid
hes1 protein, human[no description available]medium10
dihydrotestosterone[no description available]medium3017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
u 73122[no description available]medium10aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
triazoles[no description available]medium101,2,3-triazole
deoxyuridine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
arsenic[no description available]medium40metalloid atom;
pnictogen		micronutrient
arsenic trioxide[no description available]medium30
lewis x antigen[no description available]medium10
thromboplastin[no description available]medium10
sphingosine kinase[no description available]medium10
bucladesine[no description available]medium403',5'-cyclic purine nucleotide
homocystine[no description available]medium10amino acid zwitterion;
homocystines		human metabolite
phenylethyl alcohol[no description available]medium10benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite
carbobenzoxy-leucyl-leucyl-norvalinal[no description available]medium10peptide
concanavalin a[no description available]medium10
elastin[no description available]medium20oligopeptide
mifepristone[no description available]medium603-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
carboxycinnamic acid bishydroxamide[no description available]medium40
kg 501[no description available]medium10
dichlororibofuranosylbenzimidazole[no description available]medium40
discodermolide[no description available]medium10
4-(2-aminoethyl)benzenesulfonylfluoride[no description available]medium10
uridine diphosphate[no description available]medium10pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
dinitrofluorobenzene[no description available]medium30C-nitro compound;
organofluorine compound		agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
gliclazide[no description available]medium10
glycyrrhizic acid[no description available]medium10enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
dapi[no description available]medium40indolesfluorochrome
mitoxantrone[no description available]medium20dihydroxyanthraquinoneanalgesic;
antineoplastic agent
imatinib mesylate[no description available]medium60methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
geldanamycin[no description available]medium50
plicamycin[no description available]medium40
sodium acetate, anhydrous[no description available]medium30organic sodium saltNMR chemical shift reference compound
losartan potassium[no description available]medium30
5'-azacytidine 5'-monophosphate[no description available]medium20
cytidine monophosphate[no description available]medium20cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
organophosphonates[no description available]medium10divalent inorganic anion;
phosphite ion
brp-lpa[no description available]medium10
3'-c-methyladenosine[no description available]medium10
fenretinide[no description available]medium10monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
bisbenzimidazole[no description available]medium30bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
tranylcypromine[no description available]medium202-phenylcyclopropan-1-amine
triiodothyronine[no description available]medium902-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
trypan blue[no description available]medium20
vx680[no description available]medium10N-arylpiperazine
calicheamicin gamma(1)i[no description available]medium10calicheamicin;
enediyne antibiotic;
organoiodine compound		antineoplastic agent;
metabolite
muscimol[no description available]medium10alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
capecitabine[no description available]medium10carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
abscisic acid[no description available]medium302-trans-abscisic acid
alkenes[no description available]medium20
heparitin sulfate[no description available]medium10
oleic acid[no description available]medium10octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
inositol[no description available]medium10cyclitol;
hexol
retinol[no description available]medium10retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
eticlopride[no description available]medium10salicylamides
theophylline[no description available]medium20dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
levodopa[no description available]medium10amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
salvin[no description available]medium10abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid		angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
tyrosine[no description available]medium60amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
saracatinib[no description available]medium10aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
thiopental sodium[no description available]medium10organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor
ellipticine[no description available]medium10indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
4-iodo-6-phenylpyrimidine[no description available]medium10biaryl;
organoiodine compound;
pyrimidines		antineoplastic agent;
apoptosis inducer;
macrophage migration inhibitory factor inhibitor
lithium[no description available]medium30alkali metal atom
nickel[no description available]medium60metal allergen;
nickel group element atom		epitope;
micronutrient
monorden[no description available]medium20cyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols		antifungal agent;
metabolite;
tyrosine kinase inhibitor
sordarin[no description available]medium10
memantine[no description available]medium10adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
naloxone[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
acetyl-aspartyl-glutamyl-valyl-aspartal[no description available]medium10tetrapeptideprotease inhibitor
2-aminosuberic acid[no description available]medium10
hydralazine[no description available]medium11azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
raloxifene hydrochloride[no description available]medium20hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
citrulline[no description available]medium10amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite
ornithine[no description available]medium10non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
glycolipids[no description available]medium10
6-phenylhexyl isothiocyanate[no description available]medium10
ondansetron[no description available]medium10carbazoles
cyclic gmp[no description available]medium103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
nitroglycerin[no description available]medium10nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
flesinoxan[no description available]medium10
diazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
e 4031[no description available]medium10sulfonamide
erlotinib hydrochloride[no description available]medium10hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
andrographolide[no description available]medium10carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
13-hydroxy-9,11-octadecadienoic acid[no description available]medium10octadecadienoic acid
c.i. 42510[no description available]medium10
l 451167[no description available]medium10
bromodeoxyuridine[no description available]medium80pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
homocysteine[no description available]medium30amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite
prostratin[no description available]medium20
propidium[no description available]medium20phenanthridines;
quaternary ammonium ion		fluorochrome;
intercalator
lignans[no description available]medium10
diphenyleneiodonium[no description available]medium10organic cation
piperaquine[no description available]medium10aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial
artesunic acid[no description available]medium10
mefloquine[no description available]medium10
amodiaquine[no description available]medium10aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
cytidylyl-3'-5'-guanosine[no description available]medium30(3'->5')-dinucleotide
adenosine-3',5'-cyclic phosphorothioate[no description available]medium10nucleoside 3',5'-cyclic phosphorothioate
ethylene[no description available]medium10alkene;
gas molecular entity		plant hormone;
refrigerant
sodium selenite[no description available]medium10inorganic sodium salt;
selenite salt		nutraceutical
transferrin[no description available]medium10
hexamethylene bisacetamide[no description available]medium50acetamides
estradiol dipropionate[no description available]medium10steroid ester
itraconazole[no description available]medium10aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
flucytosine[no description available]medium10aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
terbinafine[no description available]medium10acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
isobutyramide[no description available]medium10carboximidic acid
hc toxin[no description available]medium60homodetic cyclic peptide;
tetrapeptide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
metabolite;
phytotoxin
metallothionein[no description available]medium50
bromochloroacetic acid[no description available]medium302-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
sodium oxybate[no description available]medium40
phenobarbital[no description available]medium10barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
ammonium hydroxide[no description available]medium10azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
amanitins[no description available]medium40
2-acetylaminofluorene[no description available]medium202-acetamidofluorenesantimitotic;
carcinogenic agent;
epitope;
mutagen
thyroxine[no description available]medium202-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
darglitazone[no description available]medium10
s-adenosylmethionine[no description available]medium30organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
flavone[no description available]medium10flavonesmetabolite;
nematicide
glycogen[no description available]medium30
oligonucleotides[no description available]medium50
phytoestrogens[no description available]medium20
dihydrogenistin[no description available]medium10beta-D-glucoside;
hydroxyisoflavanone;
monosaccharide derivative		plant metabolite
cyanamide[no description available]medium10nitrile;
one-carbon compound		EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor
sodium bisulfite[no description available]medium30inorganic sodium salt;
sulfite salt		allergen;
food antioxidant;
food colour retention agent;
mutagen;
reducing agent
tetracycline[no description available]medium40
galactose[no description available]medium10D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
uridine diphosphate n-acetylglucosamine[no description available]medium10
benomyl[no description available]medium10aromatic amide;
benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		acaricide;
anthelminthic drug;
antifungal agrochemical;
microtubule-destabilising agent;
tubulin modulator
warfarin[no description available]medium20benzenes;
hydroxycoumarin;
methyl ketone
agar[no description available]medium30
phosphotyrosine[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine		Escherichia coli metabolite;
immunogen
icrf 193[no description available]medium10
razoxane[no description available]medium10N-alkylpiperazine
dimethylformamide[no description available]medium10formamides;
volatile organic compound		geroprotector;
hepatotoxic agent;
polar aprotic solvent
1-methyl-3-isobutylxanthine[no description available]medium103-isobutyl-1-methylxanthine
o-(chloroacetylcarbamoyl)fumagillol[no description available]medium10carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide		angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
sesquiterpenes[no description available]medium10
ly 117018[no description available]medium101-benzothiophenes;
aromatic ketone;
N-alkylpyrrolidine;
phenols		bone density conservation agent;
estrogen receptor antagonist;
estrogen receptor modulator
9-methylguanine[no description available]medium10
ethacrynic acid[no description available]medium10aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
n-epsilon-acetyllysine[no description available]medium10acetyl-L-lysine;
amino acid zwitterion;
N(6)-acyl-L-lysine		human metabolite
alcian blue[no description available]medium10
mg 262[no description available]medium10
formaldehyde[no description available]medium20aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chelerythrine[no description available]medium10benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
procainamide[no description available]medium20benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
15-deoxyprostaglandin j2[no description available]medium20
prostaglandin d2[no description available]medium20prostaglandins Dhuman metabolite;
mouse metabolite
ethylmaleimide[no description available]medium10maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
thymidine[no description available]medium40pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
ucn 1028 c[no description available]medium10
barbituric acid[no description available]medium10barbituratesallergen;
xenobiotic
ro 41-5253[no description available]medium10aromatic ether;
benzoic acids;
sulfone;
thiochromane		apoptosis inducer;
retinoic acid receptor alpha antagonist
suramin[no description available]medium10naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
4-aminopyridine[no description available]medium10aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
bicuculline[no description available]medium10benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
fluo-3[no description available]medium10xanthene dyefluorochrome
xanthenes[no description available]medium10xanthene
promegestone[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid		antineoplastic agent;
progesterone receptor agonist;
progestin
melphalan[no description available]medium10L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
cyanoginosin lr[no description available]medium10microcystinbacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
environmental contaminant;
xenobiotic
ig 10[no description available]medium10
chlamydocin[no description available]medium10
isoflurophate[no description available]medium10dialkyl phosphate
tautomycin[no description available]medium10
calyculin a[no description available]medium10
oxazoles[no description available]medium101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
biochanin a[no description available]medium104'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
acth (7-38)[no description available]medium10
arginine[no description available]medium20
toluene[no description available]medium20methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
pifithrin[no description available]medium20aromatic ketone
1,25(oh)2-16-ene-23-yne-26,27-hexafluoro-19-nor-d3[no description available]medium10
ganciclovir[no description available]medium102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide[no description available]medium10isoquinolines;
sulfonamide
dexamethasone 21-methanesulfonate[no description available]medium10
lometrexol[no description available]medium10
ulipristal[no description available]medium1020-oxo steroid
seocalcitol[no description available]medium10
alpha-synuclein[no description available]medium10
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone[no description available]medium20
cyproterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
dinoprost[no description available]medium10monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
phenethyl isothiocyanate[no description available]medium10isothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
muramidase[no description available]medium20
hoe 33342[no description available]medium10
purvalanol a[no description available]medium10purvalanol
eflornithine[no description available]medium10alpha-amino acid;
fluoroamino acid		trypanocidal drug
cholic acid[no description available]medium1012alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
phloretin[no description available]medium10dihydrochalconesantineoplastic agent;
plant metabolite
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid[no description available]medium10
phosphorus radioisotopes[no description available]medium10
aclarubicin[no description available]medium10aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
7-nitroindazole[no description available]medium10
boric acid[no description available]medium10boric acidsastringent
fingolimod hydrochloride[no description available]medium10hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
bryostatin 1[no description available]medium20
pervanadate[no description available]medium10
n(6),n(6)-dimethyladenine[no description available]medium10tertiary amine
phorbolol myristate acetate[no description available]medium10
sodium propionate[no description available]medium10organic sodium saltantifungal drug;
food preservative
triamcinolone acetonide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
gefitinib[no description available]medium10aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
desoximetasone[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
ru24858[no description available]medium10
copper sulfate[no description available]medium10metal sulfateemetic;
fertilizer;
sensitiser
bathocuproine disulfonate[no description available]medium10arenesulfonic acid;
phenanthrolines		chelator
1,10-phenanthroline[no description available]medium10phenanthrolineEC 2.7.1.1 (hexokinase) inhibitor;
EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
pyrrolidine dithiocarbamate[no description available]medium10dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
1,7-phenanthroline[no description available]medium10phenanthroline
3-hydroxy-3-methylglutaryl-coenzyme a[no description available]medium103-hydroxy-3-methylglutaryl-CoA;
3-hydroxy fatty acyl-CoA		human metabolite;
mouse metabolite
bay 11-7085[no description available]medium10benzenes;
nitrile;
sulfone		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor
dicarbethoxydihydrocollidine[no description available]medium10dihydropyridine;
ethyl ester		hepatic steatosis inducing agent
dihydropyridines[no description available]medium10
pca 4248[no description available]medium10dihydropyridine
shu 508[no description available]medium10
dehydroepiandrosterone[no description available]medium1017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
tetraiodothyroacetic acid[no description available]medium102-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid		apoptosis inducer;
human metabolite;
thyroid hormone
deoxyglucose[no description available]medium10
nitrites[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
1-phenyl-2-decanoylamino-3-morpholino-1-propanol[no description available]medium10
herboxidiene[no description available]medium10
cysteine[no description available]medium10cysteiniumfundamental metabolite
3-bromopropionic acid[no description available]medium10
cobalt[no description available]medium10cobalt group element atom;
metal allergen		micronutrient
cobaltous chloride[no description available]medium10cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator
ng-nitroarginine methyl ester[no description available]medium10alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
arginine butyrate[no description available]medium10
butyrolactone i[no description available]medium10butenolide
alvocidib[no description available]medium10dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
valinomycin[no description available]medium10cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
ecteinascidin 743[no description available]medium10acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
moxestrol[no description available]medium103-hydroxy steroid
ethinyl estradiol[no description available]medium1017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
2-methylbutanoic acid[no description available]medium20methylbutyric acidbacterial metabolite;
human metabolite
cyclosporin c[no description available]medium10
erythrosine[no description available]medium10
1-o-hexadecyl-2-o-methylglycerol[no description available]medium10
2',7'-dichlorodihydrofluorescein diacetate[no description available]medium10
methylnitrosourea[no description available]medium10N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
allyl isothiocyanate[no description available]medium10alkenyl isothiocyanate;
isothiocyanate		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lachrymator;
metabolite
n-butyl mercaptan[no description available]medium10alkanethiol
isothiocyanic acid[no description available]medium10hydracid;
one-carbon compound
benzidine[no description available]medium10biphenyls;
substituted aniline		carcinogenic agent
rifampin[no description available]medium10cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
chloramphenicol[no description available]medium10C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
ecdysterone[no description available]medium1014alpha-hydroxy steroid;
20-hydroxy steroid;
22-hydroxy steroid;
25-hydroxy steroid;
2beta-hydroxy steroid;
3beta-sterol;
ecdysteroid;
phytoecdysteroid		animal metabolite;
plant metabolite
ponasterone a[no description available]medium1014alpha-hydroxy steroid;
20-hydroxy steroid;
22-hydroxy steroid;
2beta-hydroxy steroid;
3beta-hydroxy steroid;
6-oxo steroid;
phytoecdysteroid
fostriecin[no description available]medium102-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor
caseins[no description available]medium10
phorbol-12-myristate[no description available]medium10
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene[no description available]medium10BODIPY compound
pulmicort[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
12-o-retinoylphorbol-13-acetate[no description available]medium10
octanoic acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
caprylates[no description available]medium10fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
inositol 1,4,5-trisphosphate[no description available]medium10myo-inositol trisphosphatemouse metabolite
carbamazepine[no description available]medium10dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
dipropylacetamide[no description available]medium10fatty amidegeroprotector;
metabolite;
teratogenic agent
agn 194310[no description available]medium10
depudecin[no description available]medium10polyketideEC 3.5.1.98 (histone deacetylase) inhibitor;
fungal metabolite
metronidazole[no description available]medium10C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
methane[no description available]low00alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
indoleacetamide[no description available]low00indoles;
monocarboxylic acid amide;
N-acylammonia		bacterial metabolite;
fungal metabolite;
plant metabolite
fosmidomycin[no description available]medium00hydroxamic acid;
phosphonic acids		antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor
glycocyamine[no description available]low00guanidinoacetic acids;
zwitterion		bacterial metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
rat metabolite
indole-3-acetaldehyde[no description available]low00indoleacetaldehydebacterial metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
nitrous oxide[no description available]low00gas molecular entity;
nitrogen oxide		analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent
1-octanol[no description available]low00octanol;
primary alcohol		antifungal agent;
bacterial metabolite;
fuel additive;
kairomone;
plant metabolite
2,4-dichlorobenzoic acid[no description available]low00chlorobenzoic acid;
dichlorobenzene		bacterial metabolite
2-aminophenol[no description available]low00aminophenolbacterial metabolite
kanamycin a[no description available]low00kanamycinsbacterial metabolite
tubercidin[no description available]medium00antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
methylethyl ketone[no description available]low00butanone;
dialkyl ketone;
methyl ketone;
volatile organic compound		bacterial metabolite;
polar aprotic solvent
pyocyanine[no description available]low00iminium betaine;
phenazines		antibacterial agent;
bacterial metabolite;
biological pigment;
virulence factor
acetopyrrothine[no description available]low00acetamides;
dithiolopyrrolone antibiotic		angiogenesis inhibitor;
antibacterial agent;
antifungal agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite;
protein synthesis inhibitor;
toxin
2,4-di-tert-butylphenol[no description available]low00alkylbenzene;
phenols		antioxidant;
bacterial metabolite;
marine metabolite
3-hydroxybenzoic acid[no description available]low00monohydroxybenzoic acidbacterial metabolite;
plant metabolite
isoamylamine[no description available]low00primary aliphatic aminebacterial metabolite;
plant metabolite
dodecanol[no description available]low00dodecanol;
primary alcohol		bacterial metabolite;
cosmetic;
insect attractant;
insecticide;
pheromone;
plant metabolite
1-tridecanol[no description available]low00long-chain primary fatty alcohol;
tridecanol		bacterial metabolite;
human metabolite;
plant metabolite
D-tryptophan[no description available]low00D-alpha-amino acid;
tryptophan zwitterion;
tryptophan		bacterial metabolite
diazooxonorleucine[no description available]low00amino acid zwitterion;
diazo compound;
ketone;
non-proteinogenic L-alpha-amino acid		analgesic;
antibacterial agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
bacterial metabolite;
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor;
EC 3.5.1.2 (glutaminase) inhibitor;
EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor;
EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor;
EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor;
glutamine antagonist
ephedrine[no description available]low00phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
4-hydroxyphenyllactic acid[no description available]low002-hydroxy carboxylic acid;
phenols		bacterial metabolite;
human metabolite
beta-cyclocitral[no description available]low00monoterpenoidbacterial metabolite
indole-3-carbaldehyde[no description available]low00heteroarenecarbaldehyde;
indole alkaloid;
indoles		bacterial metabolite;
human xenobiotic metabolite;
marine metabolite;
plant metabolite
octadecane[no description available]low00long-chain alkanebacterial metabolite;
plant metabolite
toyocamycin[no description available]medium00antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
2,5-dimethylfuran[no description available]low00furansantifungal agent;
bacterial metabolite;
fuel;
fumigant;
human urinary metabolite;
Maillard reaction product;
plant metabolite
2-nonanol[no description available]low00nonanol;
secondary alcohol		bacterial metabolite;
flavouring agent;
pheromone;
plant metabolite;
rat metabolite;
volatile oil component
pyrrolnitrin[no description available]low00alkaloid;
C-nitro compound;
monochlorobenzenes;
pyrroles		antifungal drug;
bacterial metabolite
tetramethylpyrazine[no description available]low00alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
vancomycin[no description available]low00glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
spectinomycin[no description available]low00cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
beta-hydroxymyristic acid[no description available]low003-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
long-chain fatty acid		bacterial metabolite;
human metabolite
2,4-diacetylphloroglucinol[no description available]low00aromatic ketone;
benzenetriol;
diketone;
methyl ketone		antifungal agent;
bacterial metabolite
gamma-dodecalactone[no description available]low00gamma-lactonebacterial metabolite;
fungal metabolite;
volatile oil component
2-ethylfuran[no description available]low00furans;
volatile organic compound		bacterial metabolite;
fragrance;
Maillard reaction product;
plant metabolite
2-pentylfuran[no description available]low00furansAspergillus metabolite;
bacterial metabolite;
flavouring agent;
human urinary metabolite;
insect repellent;
plant growth stimulator;
volatile oil component
streptomycin[no description available]low00antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
vidarabine[no description available]low00beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
acetylpyruvic acid[no description available]low00beta-diketone;
dioxo monocarboxylic acid		bacterial metabolite
dimethyldiselenide[no description available]low00organoselenium compoundbacterial metabolite;
human xenobiotic metabolite;
mammalian metabolite;
plant metabolite
2,3,5-trimethylpyrazine[no description available]low00pyrazinesanimal metabolite;
bacterial metabolite;
flavouring agent;
pheromone;
plant metabolite
1-deoxynojirimycin[no description available]low002-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
daunorubicin[no description available]low00aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
4-anisaldehyde[no description available]low00benzaldehydesbacterial metabolite;
human urinary metabolite;
insect repellent;
plant metabolite
tetradecanal[no description available]low002,3-saturated fatty aldehyde;
long-chain fatty aldehyde		bacterial metabolite;
plant metabolite
pyoluteorin[no description available]low00aromatic ketone;
beta-hydroxy ketone;
diol;
organochlorine compound;
organochlorine pesticide;
polyketide;
pyrroles;
resorcinols		antibacterial agent;
antifungal agent;
apoptosis inducer;
bacterial metabolite;
marine metabolite
enterobactin[no description available]low00catechols;
crown compound;
macrotriolide;
polyphenol		bacterial metabolite;
siderophore
norvaline[no description available]low002-aminopentanoic acid;
L-alpha-amino acid zwitterion		bacterial metabolite;
hypoglycemic agent;
neuroprotective agent
2-eicosanol[no description available]low00icosanol;
secondary fatty alcohol		bacterial metabolite
sulfur[no description available]low00elemental sulfur;
homomonocyclic compound		bacterial metabolite;
fungal metabolite
aureothricin[no description available]low00dithiolopyrrolone antibiotic;
secondary carboxamide		angiogenesis inhibitor;
antibacterial agent;
bacterial metabolite;
EC 2.7.7.6 (RNA polymerase) inhibitor
1-methylhydantoin[no description available]low00imidazolidine-2,4-dionebacterial metabolite
12-aminododecanoic acid[no description available]low00medium-chain fatty acid;
omega-amino fatty acid		bacterial metabolite
indole-3-carboxylic acid[no description available]low00indol-3-yl carboxylic acidbacterial metabolite;
human metabolite
oxetanocin a[no description available]low00diol;
nucleoside analogue;
oxetanes;
primary alcohol		anti-HIV agent;
antibacterial agent;
bacterial metabolite
nucleocidin[no description available]low006-aminopurines;
adenosines;
diol;
organofluorine compound;
sulfamate ester		antibacterial agent;
bacterial metabolite;
nucleoside antibiotic;
protein synthesis inhibitor;
trypanocidal drug
leupeptin[no description available]low00aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
furanomycin[no description available]low00dihydrofuran;
non-proteinogenic L-alpha-amino acid		antibacterial agent;
antimicrobial agent;
bacterial metabolite
glucosaminic acid[no description available]low00amino acid zwitterion;
gluconic acid derivative		bacterial metabolite
5-methoxysalicylic acid[no description available]low00methoxysalicylic acidbacterial metabolite;
human urinary metabolite
4-hydroxyphenylglycine[no description available]low00hydroxy-amino acidbacterial metabolite
orotidine[no description available]low00nucleoside;
pyrimidinemonocarboxylic acid;
uridines		bacterial metabolite;
fungal metabolite;
plant metabolite
1-phenazinecarboxylic acid[no description available]low00aromatic carboxylic acid;
monocarboxylic acid;
phenazines		antifungal agent;
antimicrobial agent;
bacterial metabolite
4-methyl-3-hydroxyanthranilic acid[no description available]low00aminobenzoic acid;
monohydroxybenzoic acid		bacterial metabolite
tetrangulol[no description available]low00p-quinones;
phenols;
tetraphenes		bacterial metabolite
poly-o-acetylserine[no description available]low00acetate ester;
acetyl-L-serine;
amino acid zwitterion		bacterial metabolite;
Saccharomyces cerevisiae metabolite
alpha-aminopimelic acid[no description available]low00amino dicarboxylic acid;
non-proteinogenic alpha-amino acid		bacterial metabolite
lanthionine[no description available]low00alanine derivative;
non-proteinogenic alpha-amino acid;
organic sulfide		bacterial metabolite
beta-n-methylamino-l-alanine[no description available]low00diamino acid;
L-alanine derivative;
non-proteinogenic L-alpha-amino acid;
secondary amino compound		bacterial metabolite;
neurotoxin
tabtoxin[no description available]low00dipeptide;
L-threonine derivative;
monobactam;
secondary alcohol		bacterial metabolite;
toxin
tabtoxinine beta-lactam[no description available]low00beta-lactam antibiotic;
monobactam;
non-proteinogenic L-alpha-amino acid;
tertiary alpha-hydroxy ketone		apoptosis inducer;
bacterial metabolite;
EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor
mannostatin a[no description available]low00amino cyclitol;
methyl sulfide;
triol		bacterial metabolite;
EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor;
EC 3.2.1.24 (alpha-mannosidase) inhibitor
beta-lipotropin, gln(9)-[no description available]low00catechols;
crown compound;
macrocyclic lactone		bacterial metabolite;
metabolite
ay 25545[no description available]low00acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
tilivalline[no description available]low00indole alkaloid;
indoles;
phenols;
pyrrolobenzodiazepine		bacterial metabolite;
microtubule-stabilising agent;
toxin
3,7-dihydroxytropolone[no description available]low00alpha-hydroxy ketone;
cyclic ketone;
enol;
triol		antineoplastic agent;
bacterial metabolite
chrysobactin[no description available]low00catechols;
dipeptide;
monocarboxylic acid;
primary alcohol;
primary amino compound		bacterial metabolite;
siderophore
pyrrolomycin a[no description available]medium00antibiotic antifungal agent;
C-nitro compound;
organochlorine compound;
pyrroles		antibacterial agent;
bacterial metabolite
u-47929[no description available]low00alkaloid;
aziridines;
dipeptide;
pyrrolidines		antibacterial agent;
bacterial metabolite;
DNA synthesis inhibitor
aminoimidazole ribotide[no description available]low001-(phosphoribosyl)imidazole;
aminoimidazole		bacterial metabolite
deferrioxamine e[no description available]low00cyclic desferrioxamine;
cyclic hydroxamic acid;
macrocycle		antineoplastic agent;
bacterial metabolite;
marine metabolite;
siderophore
3-hydroxy-5-cholestenoic acid[no description available]low003beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
cholestanoid;
monocarboxylic acid;
steroid acid		bacterial metabolite
gabaculine[no description available]low005-aminocyclohexa-1,3-diene-1-carboxylic acidbacterial metabolite;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
chloroorienticin b[no description available]low00cyclic ether;
glycopeptide;
heterodetic cyclic peptide;
monosaccharide derivative;
organochlorine compound;
polyphenol		antimicrobial agent;
bacterial metabolite
lanosterol[no description available]low0014alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid		bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
acetylglucosamine[no description available]low00N-acetyl-D-hexosamine;
N-acetylglucosamine		bacterial metabolite
n-acetylneuraminic acid[no description available]low00N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite
D-leucine[no description available]low00D-alpha-amino acid zwitterion;
D-alpha-amino acid;
leucine		bacterial metabolite;
Saccharomyces cerevisiae metabolite
xylobiose[no description available]low00glycosylxylosebacterial metabolite
pentostatin[no description available]low00coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
nanaomycin a[no description available]low00benzoisochromanequinone;
monocarboxylic acid;
organooxygen heterocyclic antibiotic;
p-quinones		bacterial metabolite
yersiniabactin[no description available]low00monocarboxylic acid;
phenols;
secondary alcohol;
thiazolidines		bacterial metabolite;
siderophore
phosphoramidon[no description available]low00deoxyaldohexose phosphate;
dipeptide		bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
mupirocin[no description available]low00alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
stigmatellin[no description available]low00aromatic ether;
chromones;
olefinic compound;
phenols		bacterial metabolite;
quinol oxidation site inhibitor
benzylideneacetone[no description available]low00benzylideneacetonebacterial metabolite;
EC 3.1.1.4 (phospholipase A2) inhibitor;
flavouring agent;
fragrance
flavin mononucleotide[no description available]low00flavin mononucleotide;
vitamin B2		bacterial metabolite;
coenzyme;
cofactor;
human metabolite;
mouse metabolite
lincomycin[no description available]low00carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
6-oxopiperidine-2-carboxylate[no description available]low00delta-lactam;
monocarboxylic acid		bacterial metabolite
orlistat[no description available]low00beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
2-ketogluconate[no description available]low00keto-D-gluconic acidbacterial metabolite
sf 2370[no description available]low00bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound		antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist
chuangxinmycin[no description available]low00indole alkaloid;
monocarboxylic acid;
thiinoindole		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor
cyclic 3',5'-uridine monophosphate[no description available]low003',5'-cyclic pyrimidine nucleotidebacterial metabolite;
mammalian metabolite;
signalling molecule
schizokinen[no description available]medium002-hydroxy carboxylic acid;
hydroxamic acid		bacterial metabolite;
siderophore
5-hydroxybenzimidazole[no description available]low00benzimidazoles;
phenols		bacterial metabolite;
human metabolite;
rat metabolite
t-muurolol[no description available]low00cadinane sesquiterpenoid;
carbobicyclic compound;
octahydronaphthalenes;
tertiary alcohol		bacterial metabolite;
fungicide;
marine metabolite;
plant metabolite;
volatile oil component
n-(3-oxododecanoyl)homoserine lactone[no description available]low00N-(3-oxododecanoyl)homoserine lactone;
N-acyl-L-homoserine lactone		bacterial metabolite
coelichelin[no description available]medium00formamides;
hydroxamic acid;
tetrapeptide		bacterial metabolite;
siderophore
tylosin[no description available]low00aldehyde;
disaccharide derivative;
enone;
leucomycin;
macrolide antibiotic;
monosaccharide derivative		allergen;
bacterial metabolite;
environmental contaminant;
xenobiotic
zeaxanthin[no description available]low00carotenolantioxidant;
bacterial metabolite;
cofactor
clavulanic acid[no description available]low00oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
echinenone[no description available]low00carotenoneanimal metabolite;
bacterial metabolite;
cofactor;
marine metabolite
cembrene a[no description available]low00cycloalkatriene;
diterpene;
macrocycle		animal metabolite;
bacterial metabolite;
coral metabolite
soraphen a[no description available]low00cyclic hemiketal;
ether;
macrolide;
olefinic compound		bacterial metabolite;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
teratogenic agent
neomethymycin[no description available]low00enone;
macrolide antibiotic;
monosaccharide derivative		bacterial metabolite
methymycin[no description available]low00enone;
macrolide antibiotic;
monosaccharide derivative		bacterial metabolite
narbomycin[no description available]low00enone;
macrolide antibiotic;
monosaccharide derivative		bacterial metabolite
picromycin[no description available]low00enone;
macrolide antibiotic;
monosaccharide derivative		bacterial metabolite
l 683590[no description available]low00ether;
lactol;
macrolide;
secondary alcohol		antifungal agent;
bacterial metabolite;
immunosuppressive agent
acetylspiramycin[no description available]low00acetate ester;
aldehyde;
disaccharide derivative;
ether;
macrolide;
tertiary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
turimycin[no description available]low00leucomycin;
macrolide antibiotic		bacterial metabolite
natamycin[no description available]low00antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
reumycin[no description available]low00carbonyl compound;
pyrimidotriazine		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
8-hydroxyadenine[no description available]low006-aminopurines;
heteroaryl hydroxy compound;
nucleobase analogue;
oxopurine		bacterial metabolite;
human metabolite
lasalocid[no description available]low00beta-hydroxy ketone;
monocarboxylic acid;
monohydroxybenzoic acid;
oxanes;
oxolanes;
polyether antibiotic;
secondary alcohol;
tertiary alcohol		bacterial metabolite;
coccidiostat;
ionophore
rhodopin[no description available]low00carotenol;
tertiary alcohol		bacterial metabolite
spheroidenone[no description available]low00carotenonebacterial metabolite
spirilloxanthin[no description available]low00carotenoid etherbacterial metabolite
pederin[no description available]low00cyclic ketal;
diol;
oxanes;
polyketide;
secondary alcohol;
secondary carboxamide		antimitotic;
antineoplastic agent;
bacterial metabolite;
vesicant
bialaphos[no description available]low00phosphinic acids;
tripeptide		antimicrobial agent;
bacterial metabolite
cystothiazole a[no description available]low001,3-thiazoles;
biaryl;
enoate ester;
enol ether;
methyl ester;
organonitrogen heterocyclic antibiotic		antifungal agent;
antineoplastic agent;
bacterial metabolite
pepstatin[no description available]low00pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
rifamycin sv[no description available]low00acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
tetrodotoxin[no description available]low00azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
filipin[no description available]low00macrolide;
olefinic compound;
polyol		bacterial metabolite;
fluorescent probe
bongkrekic acid[no description available]low00ether;
olefinic compound;
tricarboxylic acid		apoptosis inhibitor;
ATP/ADP translocase inhibitor;
bacterial metabolite;
EC 2.5.1.18 (glutathione transferase) inhibitor;
toxin
sibiromycin[no description available]low00aminoglycoside antibiotic;
hemiaminal;
phenols;
pyrrolobenzodiazepine		antineoplastic agent;
bacterial metabolite
piericidin a[no description available]low00aromatic ether;
methylpyridines;
monohydroxypyridine;
secondary allylic alcohol		antimicrobial agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor;
mitochondrial respiratory-chain inhibitor
manumycin[no description available]low00enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol		antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite
microcystin rr[no description available]low00microcystin;
organic molecular entity		bacterial metabolite;
environmental contaminant;
xenobiotic
aurachin b[no description available]low00A-type aurachin;
heteroaryl hydroxy compound;
olefinic compound;
quinoline N-oxide		bacterial metabolite
aurachin c[no description available]low00C-type aurachin;
hydroxylamines;
organic heterobicyclic compound;
quinolone		antibacterial agent;
bacterial metabolite;
EC 1.8.5.4 (sulfide:quinone reductase) inhibitor
demycarosylturimycin h[no description available]low00aldehyde;
disaccharide derivative;
ether;
macrolide;
tertiary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
asukamycin[no description available]low00enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
bacterioruberin[no description available]low00C50 carotenoid;
tertiary alcohol;
tetrol		bacterial metabolite;
biological pigment
elaiophylin[no description available]low00lactol;
macrodiolide;
monosaccharide derivative		antifungal agent;
autophagy inhibitor;
bacterial metabolite
kalimantacin a[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
carbamate ester;
fatty acid derivative;
secondary carboxamide		antibacterial agent;
antimicrobial agent;
bacterial metabolite
rosaramicin[no description available]low00aldehyde;
enone;
epoxide;
macrolide antibiotic;
monosaccharide derivative		bacterial metabolite
aureothin[no description available]low004-pyranones;
C-nitro compound;
ketene acetal;
olefinic compound;
oxolanes		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor
platensimycin[no description available]low00aromatic amide;
cyclic ether;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor
cyclo(leucyl-prolyl)[no description available]low00dipeptide;
homodetic cyclic peptide;
pyrrolopyrazine		bacterial metabolite;
marine metabolite
benzamidoxime[no description available]low00amidoximebacterial metabolite;
genotoxin;
mammalian metabolite
triacsin c[no description available]low00hydrazone;
nitroso compound;
olefinic compound		antimalarial;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
vasodilator agent
tmc-95a[no description available]low00indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol		antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
fungal metabolite;
proteasome inhibitor
elloramycin[no description available]low00alpha-L-rhamnoside;
carboxylic ester;
enol ether;
enone;
methyl ester;
monosaccharide derivative;
phenols;
tertiary alpha-hydroxy ketone;
tetracenomycin		antimicrobial agent;
bacterial metabolite
candicidin[no description available]low00macrolide antibiotic;
polyene antibiotic		antifungal drug;
bacterial metabolite
chlorobactene[no description available]low00benzenes;
carotenoid phi-end group;
carotenoid		bacterial metabolite
levodione[no description available]low00cyclohexanonesbacterial metabolite
holomycin[no description available]low00acetamides;
dithiolopyrrolone antibiotic		antibacterial agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite
phevalin[no description available]low00benzenes;
pyrazinone		bacterial metabolite;
calpain inhibitor
fr 900848[no description available]low00cyclopropanes;
nucleoside analogue;
olefinic compound;
polyketide;
secondary carboxamide		antifungal agent;
bacterial metabolite
ossamycin[no description available]low00cyclic hemiketal;
macrolide antibiotic;
organic heterotetracyclic compound;
secondary alcohol;
spiroketal;
tertiary alcohol		antineoplastic agent;
bacterial metabolite
myxochelin b[no description available]low00benzamides;
catechols		bacterial metabolite;
siderophore
pentalenolactone f[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
organic heterotricyclic compound;
sesquiterpene lactone;
spiro-epoxide		bacterial metabolite
streptogramin b[no description available]low00cyclodepsipeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
3-hydroxyproline[no description available]low003-hydroxyproline;
amino acid zwitterion;
D-proline derivative		bacterial metabolite;
human metabolite
chromopyrrolic acid[no description available]low00indoles;
pyrroledicarboxylic acid		bacterial metabolite
ym 216391[no description available]low001,3-oxazoles;
1,3-thiazoles;
azamacrocycle;
benzenes;
heterodetic cyclic peptide		antineoplastic agent;
bacterial metabolite
validoxylamine a[no description available]low00amino cyclitol;
secondary amino compound		animal metabolite;
antibiotic insecticide;
bacterial metabolite;
EC 3.2.1.28 (alpha,alpha-trehalase) inhibitor
32,33,34,35-bacteriohopanetetrol[no description available]low00hopanoid;
tetrol		antimicrobial agent;
bacterial metabolite;
lipoxygenase inhibitor
zincophorin[no description available]low00pyransbacterial metabolite;
ionophore
anticapsin[no description available]low00alicyclic ketone;
epoxide;
L-alanine derivative;
L-alpha-amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		antimetabolite;
antimicrobial agent;
bacterial metabolite;
EC 2.6.1.16 (glutamine--fructose-6-phosphate transaminase (isomerizing)) inhibitor
2-methyltryptophan[no description available]low00amino acid zwitterion;
L-tryptophan derivative		bacterial metabolite
adonixanthin[no description available]low00carotenone;
cyclic ketone;
secondary alcohol		algal metabolite;
animal metabolite;
antineoplastic agent;
bacterial metabolite;
marine metabolite;
plant metabolite
3'-hydroxyechinenone[no description available]low00carotenone;
enone;
secondary alcohol		bacterial metabolite;
biological pigment;
cofactor
tyrocidine[no description available]low00homodetic cyclic peptide;
macrocycle;
peptide antibiotic		antibacterial agent;
bacterial metabolite
ly-146032[no description available]low00heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
thiazomycin[no description available]low00heterodetic cyclic peptideantibacterial agent;
antimicrobial agent;
bacterial metabolite
ristocetin[no description available]low00glycopeptide;
heterodetic cyclic peptide;
macrocycle;
tetrasaccharide derivative		antibacterial drug;
antimicrobial agent;
bacterial metabolite;
platelet-activating factor receptor agonist
vanchrobactin[no description available]low00catechols;
dipeptide;
guanidines;
monocarboxylic acid;
primary alcohol;
triol		bacterial metabolite;
marine metabolite;
siderophore
platencin[no description available]low00aromatic amide;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor
microcystin-lf[no description available]low00microcystinbacterial metabolite;
environmental contaminant;
xenobiotic
avilamycin a[no description available]low00benzoate ester;
cyclic acetal;
dichlorobenzene;
oligosaccharide derivative;
ortho ester;
oxaspiro compound;
phenols;
tertiary alpha-hydroxy ketone		antimicrobial agent;
bacterial metabolite
decarbamylsaxitoxin[no description available]low00alkaloid;
guanidines;
ketone hydrate;
paralytic shellfish toxin;
primary alcohol;
pyrrolopurine		bacterial metabolite;
marine metabolite;
neurotoxin;
toxin;
xenobiotic
borrelidin[no description available]low00aliphatic nitrile;
diol;
macrolide;
monocarboxylic acid;
secondary alcohol		antifungal agent;
antimalarial;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
arenaemycin e[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
organic heterotricyclic compound;
sesquiterpene lactone;
spiro-epoxide		antimicrobial agent;
bacterial metabolite;
EC 1.2.1.12 [glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)] inhibitor
marinopyrrole a[no description available]low00aromatic ketone;
organochlorine compound;
phenols;
pyrroles		antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite
spiruchostatin b[no description available]low00macrocyclic lactone;
organic disulfide;
organic heterobicyclic compound;
spiruchostatin		antineoplastic agent;
bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor
chondramide c[no description available]low00chondramide;
indoles;
phenols		antineoplastic agent;
bacterial metabolite
albaflavenone[no description available]low00carbocyclic antibiotic;
carbotricyclic compound;
cyclic terpene ketone;
enone;
sesquiterpenoid		bacterial metabolite
bacillaene[no description available]low00enamine;
monocarboxylic acid amide;
polyene antibiotic;
polyketide;
secondary alcohol		antibacterial agent;
antimicrobial agent;
bacterial metabolite
bacillithiol[no description available]low00glycoside;
monosaccharide derivative;
thiol		antioxidant;
bacterial metabolite;
cofactor
zwittermicin a[no description available]low004,8-diamino-N-[1-amino-3-(carbamoylamino)-1-oxopropan-2-yl]-2,3,5,7,9-pentahydroxynonanamide;
peptide antibiotic		antifungal agent;
bacterial metabolite
tropodithietic acid[no description available]low00cyclic ketone;
monocarboxylic acid;
organic disulfide;
organic heterobicyclic compound;
organosulfur heterocyclic compound		antibacterial agent;
bacterial metabolite;
marine metabolite;
signalling molecule;
toxin
jadomycin b[no description available]low00glycoside;
jadomycin;
organic heteropentacyclic compound		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor;
bacterial metabolite
chondramide a[no description available]low00chondramide;
indoles;
phenols		antineoplastic agent;
bacterial metabolite
staphyloferrin b[no description available]low00oxo carboxylic acid;
tertiary alcohol;
tricarboxylic acid amide;
tricarboxylic acid		bacterial metabolite;
siderophore
quinolobactin[no description available]low00aromatic ether;
monohydroxyquinoline;
phenols;
quinolinemonocarboxylic acid		bacterial metabolite;
siderophore
staphyloferrin a[no description available]low00D-ornithine derivative;
pentacarboxylic acid;
tertiary alcohol;
tricarboxylic acid amide		bacterial metabolite;
siderophore
roseoflavin[no description available]low00benzopteridineantimicrobial agent;
bacterial metabolite
marinoquinoline a[no description available]low00pyrroloquinolinebacterial metabolite
coumermycin[no description available]low00aromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles		antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor
streptolydigin[no description available]low00bridged compound;
cyclic ketal;
enol;
monocarboxylic acid amide;
N-glycosyl compound;
organic heterobicyclic compound;
pyrrolidinone;
spiro-epoxide		antimicrobial agent;
bacterial metabolite;
EC 2.7.7.6 (RNA polymerase) inhibitor
opt 80[no description available]low00carboxylic ester;
glycoside;
macrolide antibiotic;
organochlorine compound;
phenols		antibacterial drug;
bacterial metabolite;
EC 2.7.7.6 (RNA polymerase) inhibitor
brasilicardin a[no description available]low00benzoate ester;
carbotricyclic compound;
diterpenoid;
N-acetyl-D-glucosaminide;
non-proteinogenic alpha-amino acid;
phenols		antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
immunosuppressive agent
zorbamycin[no description available]low00glycopeptideantimicrobial agent;
bacterial metabolite
phleomycin d1[no description available]low00bi-1,3-thiazole;
chelate-forming peptide;
disaccharide derivative;
glycopeptide;
guanidines		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
acarbose[no description available]low00chondramide;
indoles;
organochlorine compound;
phenols		antineoplastic agent;
bacterial metabolite
duramycin[no description available]low00heterodetic cyclic peptide;
macrocycle		antimicrobial agent;
apoptosis inducer;
bacterial metabolite
boromycin[no description available]low00macrodiolide;
macrolide antibiotic;
organoboron compound;
oxaspiro compound;
zwitterion		anti-HIV agent;
antibacterial agent;
bacterial metabolite
chondramide d[no description available]low00chondramide;
indoles;
phenols		antineoplastic agent;
bacterial metabolite
1-tuberculosinyladenosine[no description available]low00organic cationbacterial metabolite
aurachin a[no description available]low00A-type aurachin;
furoquinoline;
quinoline N-oxide;
tertiary alcohol		antibacterial agent;
bacterial metabolite
cyclooctatin[no description available]low00carbotricyclic compound;
diterpenoid;
primary alcohol;
secondary alcohol;
tertiary alcohol		bacterial metabolite;
EC 3.1.1.5 (lysophospholipase) inhibitor
indolmycin[no description available]low001,3-oxazoles;
indoles;
secondary amino compound		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor
scytonemin[no description available]low00enone;
organic heterotricyclic compound;
organonitrogen heterocyclic compound;
polyphenol;
ring assembly		bacterial metabolite;
biological pigment;
ultraviolet filter
althiomycin[no description available]low001,3-thiazoles;
aldoxime;
ether;
gamma-lactam;
pentapeptide;
peptide antibiotic;
primary alcohol;
pyrroline;
secondary carboxamide;
tertiary carboxamide		antibacterial agent;
bacterial metabolite;
protein synthesis inhibitor
cerulomycin[no description available]low00aldoxime;
aromatic ether;
bipyridines;
pyridine alkaloid		antineoplastic agent;
bacterial metabolite;
marine metabolite
undecylprodigiosin[no description available]low00alkaloid;
aromatic ether;
tripyrrole		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
biological pigment;
immunosuppressive agent;
radiosensitizing agent
tilimycin[no description available]low00phenols;
pyrrolobenzodiazepine		alkylating agent;
apoptosis inducer;
bacterial metabolite;
toxin
gallic acid[no description available]low00trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
creatine[no description available]low00glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
thioctic acid[no description available]low00dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
oxaloacetic acid[no description available]low00C4-dicarboxylic acid;
oxo dicarboxylic acid		geroprotector;
metabolite
n-(3-(aminomethyl)benzyl)acetamidine[no description available]low00aralkylamine;
carboxamidine;
primary amino compound		angiogenesis inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector
2,4-dinitrophenol[no description available]low00dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
mercaptoethanol[no description available]low00alkanethiol;
primary alcohol		geroprotector
3,4-dichloroisocoumarin[no description available]low00isocoumarins;
organochlorine compound		geroprotector;
serine protease inhibitor
cgp 52411[no description available]low00phthalimidesgeroprotector;
tyrosine kinase inhibitor
acetaminophen[no description available]low00acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ag 1295[no description available]low00quinoxaline derivativegeroprotector
rtki cpd[no description available]low00aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
tyrphostin a1[no description available]low00methoxybenzenesgeroprotector
amoxapine[no description available]low00dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
buformin[no description available]low00biguanidesantineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent
ethosuximide[no description available]low00dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethoxyquin[no description available]low00aromatic ether;
quinolines		antifungal agrochemical;
food antioxidant;
genotoxin;
geroprotector;
herbicide;
Hsp90 inhibitor;
neuroprotective agent;
UDP-glucuronosyltransferase activator
carbonyl cyanide p-trifluoromethoxyphenylhydrazone[no description available]low00aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
foscarnet[no description available]low00carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
ibuprofen[no description available]low00monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
juglone[no description available]low00hydroxy-1,4-naphthoquinonegeroprotector;
herbicide;
reactive oxygen species generator
kinetin[no description available]low006-aminopurines;
furans		cytokinin;
geroprotector
lamotrigine[no description available]low001,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
loratadine[no description available]low00benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
methiothepin[no description available]low00aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
mianserin[no description available]low00dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
nitrendipine[no description available]low00C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
masoprocol[no description available]low00catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
oxatomide[no description available]low00benzimidazoles;
diarylmethane;
N-alkylpiperazine		anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
resveratrol[no description available]low00polyphenol;
resorcinols;
stilbenol		antioxidant;
geroprotector;
glioma-associated oncogene inhibitor;
phytoalexin
trimethadione[no description available]low00oxazolidinoneanticonvulsant;
geroprotector
tyrphostin a9[no description available]low00alkylbenzenegeroprotector
nad[no description available]low00NADgeroprotector
promethazine hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
dimethylnitrosamine[no description available]low00nitrosaminegeroprotector;
mutagen
pantothenic acid[no description available]low00pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
phenformin[no description available]low00biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
lithocholic acid[no description available]low00bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
naphthazarin[no description available]low00hydroxy-1,4-naphthoquinoneacaricide;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
geroprotector;
plant metabolite
4-hydroxyphenylethanol[no description available]low00phenolsanti-arrhythmia drug;
antioxidant;
cardiovascular drug;
fungal metabolite;
geroprotector;
plant metabolite;
protective agent
dibromoacetic acid[no description available]low002-bromocarboxylic acid;
monocarboxylic acid		apoptosis inducer;
geroprotector;
marine metabolite
2-(2'-hydroxyphenyl)benzoxazole[no description available]low001,3-benzoxazoles;
phenols		geroprotector
ethidium bromide[no description available]low00organic bromide saltgeroprotector;
intercalator;
trypanocidal drug
paraquat[no description available]low00organic cationgeroprotector;
herbicide
thioflavin t[no description available]low00organic chloride saltfluorochrome;
geroprotector;
histological dye
2-(2-hydroxyphenyl)benzothiazole[no description available]low00benzothiazoles;
phenols		geroprotector
selegiline[no description available]low00selegiline;
terminal acetylenic compound		geroprotector
danazol[no description available]low0017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
metergoline[no description available]low00carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
butylated hydroxytoluene[no description available]low00phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
bezafibrate[no description available]low00aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
lonidamine[no description available]low00dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
nicardipine hydrochloride[no description available]low00dihydropyridinegeroprotector
acarbose[no description available]low00tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
pergolide mesylate[no description available]low00methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
doxazosin mesylate[no description available]low00methanesulfonate saltgeroprotector
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose[no description available]low00gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
thioridazine hydrochloride[no description available]low00hydrochloridefirst generation antipsychotic;
geroprotector
mianserin hydrochloride[no description available]low00hydrochloridegeroprotector
alfatradiol[no description available]low0017alpha-hydroxy steroid;
3-hydroxy steroid;
estradiol		estrogen;
geroprotector
loxapine succinate[no description available]low00succinate saltgeroprotector
guanfacine hydrochloride[no description available]low00acetamidesgeroprotector
amperozide[no description available]low00diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
amperozide hydrochloride[no description available]low00hydrochlorideanxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
2-(1H-benzimidazol-2-yl)aniline[no description available]low00benzimidazoles;
primary arylamine;
substituted aniline		geroprotector
methionine sulfoximine[no description available]low00L-alpha-amino acid zwitterion;
L-methionine derivative;
methionine sulfoximine;
non-proteinogenic L-alpha-amino acid		EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor;
geroprotector
thiazolidine-4-carboxylic acid, (r)-isomer[no description available]low00thiazolidinemonocarboxylic acid;
thioproline		geroprotector;
metabolite
catechin[no description available]low00hydrategeroprotector
nitroflurbiprofen[no description available]low00biphenyls;
carboxylic ester;
nitrate ester;
organofluorine compound		cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector;
non-steroidal anti-inflammatory drug;
vasodilator agent
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine[no description available]low00(trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline		geroprotector;
serotonergic agonist
fullerene c60[no description available]low00fullerenegeroprotector
oxoline[no description available]low00aromatic ketone;
tetralins		geroprotector
latrepirdine[no description available]low00methylpyridines;
pyridoindole		geroprotector
vincristine sulfate[no description available]low00organic sulfate saltantineoplastic agent;
geroprotector
glucosamine[no description available]low00D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
carnosine[no description available]low00amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
theanine[no description available]low00amino acid zwitterion;
N(5)-alkyl-L-glutamine		geroprotector;
neuroprotective agent;
plant metabolite
nicotinamide-beta-riboside[no description available]low00N-glycosylnicotinamide;
pyridine nucleoside		geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
nortriptyline hydrochloride[no description available]low00organic tricyclic compoundgeroprotector
kanamycin sulfate[no description available]low00aminoglycoside sulfate saltantibacterial drug;
geroprotector
glaucarubinone[no description available]low00carboxylic ester;
organic heteropentacyclic compound;
quassinoid;
secondary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone;
tetrol		antimalarial;
antineoplastic agent;
geroprotector;
plant metabolite
vinpocetine[no description available]low00alkaloidgeroprotector
dihydroergocristine monomesylate[no description available]low00methanesulfonate saltalpha-adrenergic antagonist;
geroprotector;
vasodilator agent
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol[no description available]low00carbotetracyclic compound;
polyphenol		estrogen receptor agonist;
estrogen receptor antagonist;
geroprotector;
neuroprotective agent
isoliquiritigenin[no description available]low00chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene[no description available]low00C-nitro compound;
sulfonamide;
toluenes		bone density conservation agent;
EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor;
geroprotector
brl 15572[no description available]low00monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol		geroprotector;
serotonergic antagonist
ly 367265[no description available]low00dihydropyridine;
fluoroindole;
tertiary amino compound;
thiadiazoloquinoline		antidepressant;
geroprotector;
serotonergic antagonist;
serotonin uptake inhibitor
methylergonovine maleate[no description available]low00ergoline alkaloidgeroprotector
butein[no description available]low00chalcones;
polyphenol		antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor
baicalein[no description available]low00trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chicoric acid[no description available]low00organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
rosmarinic acid[no description available]low00rosmarinic acidgeroprotector;
plant metabolite
ellagic acid[no description available]low00catechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol		antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent
cis-flupenthixol dihydrochloride[no description available]low00hydrochloridegeroprotector
10-hydroxy-2-decenoic acid[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
hydroxy monounsaturated fatty acid;
omega-hydroxy-medium-chain fatty acid;
straight-chain fatty acid		animal metabolite;
geroprotector
enalapril[no description available]low00dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one[no description available]low00coumarinsgeroprotector
guanabenz acetate[no description available]low00dichlorobenzenegeroprotector
everolimus[no description available]low00cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
l 744832[no description available]low00benzenes;
ether;
isopropyl ester;
secondary carboxamide;
sulfone;
thiol		antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
geroprotector
5-(4-phenylbutoxy)psoralen[no description available]low00aromatic ether;
benzenes;
psoralens		geroprotector;
immunosuppressive agent;
potassium channel blocker
3,3-diethyl-2-pyrrolidinone[no description available]low00pyrrolidin-2-onesanticonvulsant;
geroprotector
n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride[no description available]low00hydrochloridegeroprotector;
metabotropic glutamate receptor agonist;
neuroprotective agent
trametinib[no description available]low00acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine[no description available]low00aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines		geroprotector;
P450 inhibitor
lfm a13[no description available]low00aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
chromium tripicolinate[no description available]low00chromium coordination entityanti-obesity agent;
geroprotector;
hypoglycemic agent;
nutraceutical
didanosine[no description available]low00purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
caffeic acid[no description available]low00catechols;
hydroxycinnamic acid		antioxidant;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
CHIC-35[no description available]low00aromatic compound;
organic heterotricyclic compound;
organochlorine compound;
primary carboxamide		EC 3.5.1.98 (histone deacetylase) inhibitor
phosphoglycolohydroxamate[no description available]low00amidoalkyl phosphate;
hydroxamic acid		EC 5.3.1.1 (triose-phosphate isomerase) inhibitor
n-hydroxy-4-acetylaminobiphenyl[no description available]low00hydroxamic acid
oxamethacin[no description available]low00aromatic ether;
hydroxamic acid;
N-acylindole;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
tepoxalin[no description available]low00aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles		antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ibuproxam[no description available]low00hydroxamic acidiron chelator;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
serine hydroxamate[no description available]low00hydroxamic acid;
serine derivative		EC 6.1.1.11 (serine--tRNA ligase) inhibitor
marimastat[no description available]low00hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
argininehydroxamic acid[no description available]low00guanidines;
hydroxamic acid;
L-arginine derivative
phosphonoacetohydroxamate[no description available]low00hydroxamic acid;
organic phosphonate
gamma-glutamyl hydroxamate[no description available]low00amino acid zwitterion;
glutamic acid derivative;
hydroxamic acid
prinomastat[no description available]low00aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines		antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
rhodotorulic acid[no description available]low002,5-diketopiperazines;
hydroxamic acid;
L-ornithine derivative		fungal metabolite;
siderophore
bw b70c[no description available]low00aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
linoleic acid hydroxamate[no description available]low00hydroxamic acid
ik 682[no description available]low00hydroxamic acid;
pyrrolidin-2-ones;
quinolines
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide[no description available]low00D-valine derivative;
hydroxamic acid		antineoplastic agent;
autophagy inducer;
EC 3.4.24.24 (gelatinase A) inhibitor;
melanin synthesis inhibitor
chir 090[no description available]low00acetylenic compound;
benzamides;
hydroxamic acid;
L-threonine derivative;
morpholines		antimicrobial agent;
EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor;
lipopolysaccharide biosynthesis inhibitor
tosedostat[no description available]low00carboxylic ester;
hydroxamic acid;
secondary carboxamide
n(alpha)-acetylfusarinines[no description available]low002,5-diketopiperazines;
acetamides;
carboxylic ester;
homoallylic alcohol;
hydroxamic acid;
primary alcohol		siderophore
oligomycin a[no description available]low00antibiotic antifungal agent;
diketone;
oligomycin;
pentol		antineoplastic agent;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
nematicide
ConditionIndicatedRelationship StrengthStudiesTrials
47,XX,+210low10
47,XY,+210low10
A-V Dissociation0low10
Abnormalities, Autosome0low40
Abnormalities, Chromosomal0low40
Abnormalities, Chromosome0low40
Abnormalities, Drug-Induced0low50
Abnormalities, Multiple0low10
Ache0low10
Acquired-Immune Deficiency Syndrome Dementia Complex0low10
Acrania0low20
ACTH-Producing Pituitary Adenoma0low10
ACTH-Secreting Pituitary Adenoma0low10
Actinic Reticuloid Syndrome0low10
Acute Brain Injuries0low40
Acute Confusional Senile Dementia0low100
Acute Disease0low160
Acute Edematous Pancreatitis0low10
Acute Hepatic Failure0low10
Acute Kidney Failure0low60
Acute Kidney Injury0low60
Acute Kidney Insufficiency0low60
Acute Liver Failure0low10
Acute Liver Injury, Drug-Induced0low30
Acute Lung Injury0low80
Acute Lymphoid Leukemia0low20
Acute Myelogenous Leukemia0low140
Acute Myeloid Leukemia0low140
Acute Myeloid Leukemia with Maturation0low140
Acute Myeloid Leukemia without Maturation0low140
Acute Onset Vascular Dementia0low10
Acute Pancreatitis0low10
Acute Peripheral Vestibulopathy0low10
Acute Promyelocytic Leukemia0low110
Acute Renal Failure0low60
Acute Renal Injury0low60
Acute Renal Insufficiency0low60
Acute Vestibular Neuritis0low10
Acute-On-Chronic Liver Failure0low10
Acute-On-Chronic Liver Failure (ACLF)0low10
Addiction, Opioid0low10
Addison Disease and Cerebral Sclerosis0low10
Adenocarcinoma0low690
Adenocarcinoma Of Kidney0low140
Adenocarcinoma of Lung0low60
Adenocarcinoma, Basal Cell0low690
Adenocarcinoma, Endometrioid0low10
Adenocarcinoma, Follicular0low40
Adenocarcinoma, Granular Cell0low690
Adenocarcinoma, Mucinous0low10
Adenocarcinoma, Oxyphilic0low690
Adenocarcinoma, Papillary0low30
Adenocarcinoma, Renal0low140
Adenocarcinoma, Renal Cell0low140
Adenocarcinoma, Tubular0low690
Adenoma0low100
Adenoma, Basal Cell0low100
Adenoma, Follicular0low100
Adenoma, Malignant0low690
Adenoma, Microcystic0low100
Adenoma, Monomorphic0low100
Adenoma, Papillary0low100
Adenoma, Prostatic0low60
Adenoma, Trabecular0low100
Adenomyosis0low10
Adenoviridae Infections0low10
Adenovirus Infections0low10
Adjuvant Arthritis0low60
ADPKD0low10
Adrenocorticotropic Hormone, Inappropriate Secretion0low20
Adrenoleukodystrophy0low10
Adrenomyeloneuropathy0low10
Adult Polycystic Kidney Disease0low10
Adult Polycystic Kidney Disease Type 10low10
Adult Polycystic Kidney Disease Type 20low10
Adult Premature Aging Syndrome0low10
Adult Progeria0low10
Adult Spinal Muscular Atrophy0low90
Adult-Onset Spinal Muscular Atrophy0low90
Affective Psychosis, Bipolar0low20
African Lymphoma0low90
African Sleeping Sickness0low10
African Trypanosomiasis0low10
Agammaglobulinemia0low10
Age-Related Macular Degeneration0low10
Age-Related Maculopathies0low10
Age-Related Maculopathy0low10
Age-Related Memory Disorders0low50
Aging0low120
Agnogenic Myeloid Metaplasia0low30
Agyria-Pachygyria-Band Spectrum0low10
AIDS Dementia Complex0low10
AIDS Encephalopathy0low10
AIDS-Related Dementia Complex0low10
Airflow Obstruction, Chronic0low40
Airway Remodeling0low10
Airway Remodelling0low10
Airway Wall Remodelling0low10
Akinetic-Rigid Variant of Huntington Disease0low40
Alcohol Abuse0low50
Alcohol Addiction0low50
Alcohol Dependence0low50
Alcohol Drinking0low40
Alcohol Related Neurodevelopmental Disorder0low10
Alcohol Use Disorder0low50
Alcohol-Related Birth Defects0low10
Alcoholic Intoxication, Chronic0low50
Alcoholism0low50
ALD (Adrenoleukodystrophy)0low10
Alexander Disease0low10
Alexander's Disease0low10
ALL, Childhood0low20
Allergic Contact Dermatitis0low20
Allergic Encephalomyelitis0low50
Allergic Encephalomyelitis, Experimental0low50
Allergic Reaction0low40
Allergy0low40
Allergy, Food0low10
Allodynia0low30
Allodynia, Mechanical0low30
Allodynia, Tactile0low30
Allodynia, Thermal0low30
Alloxan Diabetes0low40
ALS - Amyotrophic Lateral Sclerosis0low40
Alveolitis, Fibrosing0low30
Alzheimer Dementia0low100
Alzheimer Disease0low100
Alzheimer Disease, Early Onset0low100
Alzheimer Disease, Late Onset0low100
Alzheimer Sclerosis0low100
Alzheimer Syndrome0low100
Alzheimer Type Senile Dementia0low100
Alzheimer-Type Dementia (ATD)0low100
Alzheimer's Disease0low100
Alzheimer's Disease, Focal Onset0low100
Alzheimer's Diseases0low100
American Trypanosomiasis0low10
AML M30low110
Amyotrophic Lateral Sclerosis0low40
Amyotrophic Lateral Sclerosis With Dementia0low40
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 10low40
Amyotrophic Lateral Sclerosis, Guam Form0low40
Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam0low40
Amyotrophy, Neurogenic Scapuloperoneal, New England Type0low90
Anaplastic Astrocytoma0low20
Anaplastic Large-Cell Lymphoma0low20
Anaplastic Oligodendroglioma0low10
Anemia, Cooley's0low30
Anemia, Erythroblastic0low30
Anemia, Mediterranean0low30
Anemia, Sickle Cell0low20
Aneuploid0low40
Aneuploid Cell0low40
Aneuploidy0low40
Angiitis0low10
Angiogenesis, Pathologic0low100
Angiogenesis, Pathological0low100
Angiomatosis Retinae0low10
Animal Mammary Carcinoma0low40
Ankylosing Spondylarthritis0low10
Ankylosing Spondylitis0low10
Ankylosing Spondyloarthritis0low10
ANLL0low140
Anoxemia0low110
Anoxia0low110
Anoxia-Ischemia, Brain0low20
Anoxia-Ischemia, Cerebral0low20
Anoxia, Fetal0low10
Anoxic-Ischemic Encephalopathy0low20
Anterior Choroidal Artery Infarction0low10
Antibody Deficiency Syndrome0low10
Anticipation, Genetic0low10
Anxiety0low40
Anxiety Disorders0low10
Anxiety Neuroses0low10
Anxiety States, Neurotic0low10
Apoplexy0low30
Arachnoidal Cerebellar Sarcoma, Circumscribed0low50
Argentaffinoma0low10
Arrhythmia0low20
Arrhythmias, Cardiac0low20
Arrythmia0low20
Arteriosclerosis, Coronary0low10
Arteriosclerotic Dementia0low10
Arteriosclerotic Encephalopathy, Subcortical0low10
Arthritis, Adjuvant0low60
Arthritis, Adjuvant-Induced0low60
Arthritis, Collagen-Induced0low60
Arthritis, Degenerative0low60
Arthritis, Experimental0low60
Arthritis, Rheumatoid0low110
Arthroses0low60
Arthrosis0low60
Ascites0low10
Aseptic Necrosis of Bone0low10
Aseptic Necrosis of Femur Head0low10
Asthma0low100
Asthma, Bronchial0low100
Asthmatic Airway Remodeling0low10
Asthmatic Airway Remodelling0low10
Asthmatic Airway Wall Remodeling0low10
Asthmatic Airway Wall Remodelling0low10
Astrocytoma0low20
Astrocytoma, Grade I0low20
Astrocytoma, Grade II0low20
Astrocytoma, Grade III0low20
Astrocytoma, Grade IV0low280
Astrocytoma, Protoplasmic0low20
Astrocytoma, Subependymal Giant Cell0low20
Astrocytosis0low10
Astroglioma0low20
Astrogliosis0low10
Asymmetric Diabetic Proximal Motor Neuropathy0low10
Ataxia Telangiectasia0low40
Ataxia Telangiectasia Syndrome0low40
Ataxia-Telangiectasia0low40
Atherogenesis0low50
Atherosclerosis0low50
Atherosclerosis, Coronary0low10
ATLL0low20
Atrial Fibrillation0low10
Atrioventricular Dissociation0low10
Atrophy, Muscle0low60
Atrophy, Muscular, Peroneal0low10
Atypical Ductal Hyperplasia0low10
Aujeszky Disease0low10
Aujeszky's Disease0low10
Auricular Fibrillation0low10
Auriculo-Ventricular Dissociation0low10
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome0low10
Autism, Dementia, Ataxia, and Loss of Purposeful Hand Use0low10
Autoimmune Diabetes0low50
Autoimmune Disease0low10
Autoimmune Diseases0low10
Autoimmune Encephalomyelitis, Experimental0low50
Autoimmune Experimental Encephalomyelitis0low50
Autosomal Dominant Cerebellar Ataxia, Type II0low10
Autosomal Dominant Juvenile Parkinson Disease0low10
Autosomal Dominant Juvenile Parkinsonism0low10
Autosomal Dominant Parkinsonism0low10
Autosomal Dominant Polycystic Kidney0low10
Autosomal Dominant Striatonigral Degeneration0low10
Autosomal Recessive Juvenile Parkinson Disease0low10
Autosomal Recessive Juvenile Parkinsonism0low10
Autosomal Recessive Parkinsonism0low10
Autosome Abnormalities0low40
Avascular Necrosis of Bone0low10
Avascular Necrosis Of Femoral Head, Primary0low10
Avascular Necrosis of Femur Head0low10
Azorean Ataxia0low10
Azorean Disease0low10
Azorean Disease (Machado-Joseph)0low10
Azorean Disease, Nervous System0low10
Azorean Neurologic Disease0low10
B Virus Infection0low10
B-Cell Chronic Lymphocytic Leukemia0low50
B-Cell Leukemia, Chronic0low50
B-Cell Lymphoma0low60
B-Cell Malignancy, Low-Grade0low50
B-Lymphocytic Leukemia, Chronic0low50
B16 Melanoma0low110
Bacterial Pneumonia0low10
Bare Lymphocyte Syndrome0low20
Barrett Epithelium0low10
Barrett Esophagus0low10
Barrett Metaplasia0low10
Barrett Syndrome0low10
Barrett's Esophagus0low10
Barrett's Syndrome0low10
Bechterew Disease0low10
Bechterew's Disease0low10
Becker Muscular Dystrophy0low10
Becker's Muscular Dystrophy0low10
Benign Cerebellar Neoplasms0low30
Benign Mastocytoma0low10
Benign Neoplasms0low630
Benign Neoplasms, Brain0low320
Benign Prostatic Hyperplasia0low60
Benign Supratentorial Neoplasms0low10
Berger Disease0low10
Berger's Disease0low10
Bertielliasis0low10
beta Thalassemia0low30
beta-Thalassemia0low30
Bile Duct Cancer0low20
Bile Duct Neoplasms0low20
Biliary Tract Cancer0low10
Biliary Tract Neoplasms0low10
Binge Alcohol Consumption0low20
Binge Drinking0low20
Binswanger Disease0low10
Binswanger Encephalopathy0low10
Binswanger's Disease0low10
Bipolar Disorder0low20
Bipolar Mood Disorder0low20
Bladder Cancer0low210
Bladder Disorder, Neurogenic0low10
Bladder Neoplasms0low210
Bladder Neurogenesis0low10
Bladder Tumors0low210
Bladder, Neurogenic0low10
Blast Crisis0low10
Blast Phase0low10
Blastocyst Disintegration0low10
Blood Clot0medium11
Blood Poisoning0low70
Blood Pressure, High0low30
Bloodstream Infection0low70
Bloom Syndrome0low10
Bloom-Torre-Machacek Syndrome0low10
Bloom's Syndrome0low10
Blue-Eared Pig Disease0low10
Body Weight0low90
Bone Cancer0low90
Bone Inflammation0low10
Bone Loss, Osteoclastic0low20
Bone Marrow Fibrosis0low30
Bone Marrow Neoplasms0low10
Bone Necrosis0low10
Bone Neoplasms0low90
Bone Resorption0low20
Bowel Diseases, Inflammatory0low10
Bradyarrhythmia0low10
Bradyarrhythmias0low10
Bradycardia0low10
Brain Anoxia-Ischemia0low20
Brain Cancer0low320
Brain Damage, Chronic0low10
Brain Diseases0low10
Brain Disorders0low10
Brain Hypoxia-Ischemia0low20
Brain Injuries0low40
Brain Injuries, Acute0low40
Brain Injuries, Focal0low40
Brain Ischemia0low40
Brain Ischemia-Anoxia0low20
Brain Ischemia-Hypoxia0low20
Brain Lacerations0low40
Brain Metastases0low320
Brain Neoplasm, Primary0low320
Brain Neoplasms0low320
Brain Neoplasms, Benign0low320
Brain Neoplasms, Malignant0low320
Brain Neoplasms, Malignant, Primary0low320
Brain Neoplasms, Primary Malignant0low320
Brain Tumor, Primary0low320
Brain Tumor, Recurrent0low320
Brain Tumors0low320
Breast Cancer0low1500
Breast Carcinoma0low1500
Breast Neoplasms0low1500
Breast Tumors0low1500
Bright Disease0low10
Brill-Symmers Disease0low10
Broad Thumb-Hallux Syndrome0low10
Broad Thumbs and Great Toes, Characteristic Facies, and Mental Retardation0low10
Bronchial Asthma0low100
Bronchial Hyperreactivity0low10
Bronze Schilder Disease0low10
Bulbospinal Neuronopathy0low90
Burkitt Cell Leukemia0low90
Burkitt Leukemia0low90
Burkitt Lymphoma0low90
Burkitt Tumor0low90
Burkitt's Leukemia0low90
Burkitt's Lymphoma0low90
Burkitt's Tumor0low90
Burns, Chemical0low10
C gattii Infection0low20
C neoformans Infection0low20
C. gattii Infection0low20
C. neoformans Infection0low20
Cachexia0low20
Calcification, Pathologic0low10
Calcinosis0low10
Calcinosis, Tumoral0low10
Cancer0low630
Cancer of Bile Duct0low20
Cancer of Biliary Tract0low10
Cancer of Bladder0low210
Cancer of Bone0low90
Cancer of Brain0low320
Cancer of Breast0low1500
Cancer of Cervix0low170
Cancer of Colon0low650
Cancer of Digestive System0low10
Cancer of Endocrine Gland0low20
Cancer of Endometrium0low150
Cancer of Esophagus0low160
Cancer of Gallbladder0low20
Cancer of Gastrointestinal Tract0low50
Cancer of Head0low120
Cancer of Head and Neck0low120
Cancer of Kidney0low130
Cancer of Larynx0low20
Cancer of Liver0low530
Cancer of Lung0low880
Cancer of Mouth0low70
Cancer of Nasopharynx0low80
Cancer of Neck0low120
Cancer of Ovary0low380
Cancer of Pancreas0low450
Cancer of Parathyroid0low10
Cancer of Pituitary0low40
Cancer of Prostate0low770
Cancer of Rectum0low10
Cancer of Skin0low90
Cancer of Stomach0low570
Cancer of Testis0low10
Cancer of the Bile Duct0low20
Cancer of the Biliary Tract0low10
Cancer of the Bladder0low210
Cancer of the Bone0low90
Cancer of the Brain0low320
Cancer of the Breast0low1500
Cancer of the Cervix0low170
Cancer of the Colon0low650
Cancer of the Digestive System0low10
Cancer of the Endocrine Gland0low20
Cancer of the Endometrium0low150
Cancer of the Esophagus0low160
Cancer of the Gallbladder0low20
Cancer of the Gastrointestinal Tract0low50
Cancer of the Head0low120
Cancer of the Head and Neck0low120
Cancer of the Kidney0low130
Cancer of the Larynx0low20
Cancer of the Liver0low530
Cancer of the Lung0low880
Cancer of the Mouth0low70
Cancer of the Nasopharynx0low80
Cancer of the Neck0low120
Cancer of the Ovary0low380
Cancer of the Pancreas0low450
Cancer of the Parathyroid0low10
Cancer of the Pituitary0low40
Cancer of the Prostate0low770
Cancer of the Rectum0low10
Cancer of the Retina0low20
Cancer of the Skin0low90
Cancer of the Stomach0low570
Cancer of the Testes0low10
Cancer of the Testis0low10
Cancer of the Thyroid0low170
Cancer of the Tongue0low50
Cancer of the Urinary Tract0low10
Cancer of the Uterine Cervix0low170
Cancer of the Uterus0low40
Cancer of Thyroid0low170
Cancer of Tongue0low50
Cancer of Urinary Tract0low10
Cancer of Uterus0low40
Cancer Pain0low20
Cancer-Associated Pain0low20
Cancer-Related Pain0low20
Cancer, Hepatocellular0low530
Cancer, Retinal0low20
Cancer, Supratentorial0low10
Candidiasis, Chronic Mucocutaneous0medium11
Capillary Leak Syndrome0low10
Capsule Opacification0low10
Carcinogenesis0low60
Carcinoid0low10
Carcinoid Tumor0low10
Carcinoid, Goblet Cell0low10
Carcinoma0low260
Carcinoma of Endocrine Gland0low20
Carcinoma of Endometrium0low150
Carcinoma, Anaplastic0low260
Carcinoma, Colloid0low10
Carcinoma, Cribriform0low690
Carcinoma, Ductal, Breast0low10
Carcinoma, Ductal, Pancreatic0low80
Carcinoma, Ehrlich Tumor0low10
Carcinoma, Embryonal0low40
Carcinoma, Endometrioid0low10
Carcinoma, Epidermoid0low360
Carcinoma, Granular Cell0low690
Carcinoma, Hepatocellular0low510
Carcinoma, Hypernephroid0low140
Carcinoma, Infiltrating Duct0low10
Carcinoma, Intraductal0low10
Carcinoma, Intraductal, Noninfiltrating0low10
Carcinoma, Invasive Ductal, Breast0low10
Carcinoma, Large Cell0low30
Carcinoma, Lewis Lung0low10
Carcinoma, Mammary Ductal0low10
Carcinoma, Mucinous0low10
Carcinoma, Non-Small Cell Lung0low380
Carcinoma, Non-Small-Cell Lung0low380
Carcinoma, Oat Cell0low50
Carcinoma, Ovarian Epithelial0low10
Carcinoma, Pancreatic Ductal0low80
Carcinoma, Papillary0low50
Carcinoma, Papillary, Follicular0low10
Carcinoma, Planocellular0low360
Carcinoma, Renal Cell0low140
Carcinoma, Signet Ring Cell0low10
Carcinoma, Small Cell0low50
Carcinoma, Small Cell Lung0low20
Carcinoma, Spindle-Cell0low260
Carcinoma, Squamous0low360
Carcinoma, Squamous Cell0low360
Carcinoma, Squamous Cell of Head and Neck0low40
Carcinoma, Transitional Cell0low30
Carcinoma, Tubular0low690
Carcinoma, Undifferentiated0low260
Carcinomatosis0low260
Cardiac Arrhythmia0low20
Cardiac Arrhythmias0low20
Cardiac Dysrhythmia0low20
Cardiac Failure0low20
Cardiac Hypertrophy0low130
Cardiac Remodeling, Ventricular0low30
Cardiomegaly0low130
Cardiometabolic Syndrome0low10
Cardiomyopathy, Dilated, 3B0low10
Cardiomyopathy, Dilated, X-Linked0low10
Cardiomyopathy, Hypertrophic0low10
Cardiomyopathy, Hypertrophic Obstructive0low10
Cardiovascular Diseases0low10
Cardiovascular Stroke0low100
Carditis0low20
Cat Diseases0low10
Cataract0low20
Cataract, Membranous0low20
CD30-Positive Anaplastic Large-Cell Lymphoma0low20
CD30+ Anaplastic Large-Cell Lymphoma0low20
Cell Transformation, Neoplastic0low240
Cell Transformation, Viral0low80
Central Core Disease0low10
Central Core Disease of Muscle0low10
Central Core Myopathy0low10
Central Nervous System Disorders, Intracranial0low10
Central Nervous System Intracranial Disorders0low10
Central Nervous System Neoplasm0low20
Central Nervous System Neoplasms0low20
Central Nervous System Neoplasms, Primary0low20
Central Nervous System Tumor0low20
Central Nervous System Tumors0low20
Centriacinar Emphysema0low10
Centrilobular Emphysema0low10
Cenuriasis0low10
Cerebellar Cancer0low30
Cerebellar Degeneration with Slow Eye Movements0low10
Cerebellar Neoplasms0low30
Cerebellar Neoplasms, Benign0low30
Cerebellar Neoplasms, Malignant0low30
Cerebellar Neoplasms, Primary0low30
Cerebellar Tumors0low30
Cerebelloparenchymal Disorder I0low10
Cerebelloretinal Angiomatosis, Familial0low10
Cerebral Anoxia-Ischemia0low20
Cerebral Astrocytoma0low20
Cerebral Hypoxia-Ischemia0low20
Cerebral Infarct0low10
Cerebral Infarction0low10
Cerebral Infarction, Left Hemisphere0low10
Cerebral Infarction, Middle Cerebral Artery0low10
Cerebral Infarction, Right Hemisphere0low10
Cerebral Ischemia0low40
Cerebral Ischemia-Anoxia0low20
Cerebral Ischemia-Hypoxia0low20
Cerebral Primitive Neuroectodermal Tumor0low30
Cerebral Stroke0low30
Cerebral, Left Hemisphere, Infarction0low10
Cerebral, Right Hemisphere, Infarction0low10
Cerebroatrophic Hyperammonemia0low10
Cerebrovascular Accident0low30
Cerebrovascular Accident, Acute0low30
Cerebrovascular Apoplexy0low30
Cerebrovascular Stroke0low30
Cervical Cancer0low170
Cervical Neoplasms0low170
Cervix Cancer0low170
Cervix Dysplasia0low10
Cervix Neoplasms0low170
Cestode Infections0low10
Chagas Disease0low10
Chagas' Disease0low10
Charcot Disease0low40
Charcot-Marie Disease0low10
Charcot-Marie-Tooth Disease0low10
Charcot-Marie-Tooth Disease, Autosomal Dominant, With Focally Folded Myelin Sheaths, Type 1A0low10
Charcot-Marie-Tooth Disease, Autosomal Dominant, with Focally Folded Myelin Sheaths, Type 1B0low10
Charcot-Marie-Tooth Disease, Demyelinating, Type 1A0low10
Charcot-Marie-Tooth Disease, Demyelinating, Type 1B0low10
Charcot-Marie-Tooth Disease, Slow Nerve Conduction Type, Linked To Duffy0low10
Charcot-Marie-Tooth Disease, Type 1A0low10
Charcot-Marie-Tooth Disease, Type 1B0low10
Charcot-Marie-Tooth Disease, Type I0low10
Charcot-Marie-Tooth Disease, Type IA0low10
Charcot-Marie-Tooth Disease, Type IB0low10
Charcot-Marie-Tooth Disease, Type II0low10
Charcot-Marie-Tooth Hereditary Neuropathy0low10
Charcot-Marie-Tooth Neuropathy, Type 1A0low10
Charcot-Marie-Tooth Neuropathy, Type 1B0low10
Charcot-Marie-Tooth Syndrome0low10
Chemical and Drug Induced Liver Injury0low30
Chemical Burns0low10
Chemically-Induced Liver Toxicity0low30
Child Development Deviations0low10
Child Development Disorders0low10
Child Development Disorders, Specific0low10
Childhood Cerebral Astrocytoma0low20
Childhood Muscular Dystrophy, Pseudohypertrophic0low10
Childhood Pseudohypertrophic Muscular Dystrophy0low10
Chlamydia pneumoniae Infections0low10
Chlamydophila Infections0low10
Cholangiocarcinoma0low30
Cholangiocellular Carcinoma0low30
Chondrosarcoma0low10
Chorea, Chronic Progressive Hereditary (Huntington)0low40
Choriocarcinoma0low30
Choroid Neovascularization0low10
Choroidal Neovascularization0low10
Chromophil Renal Cell Carcinoma0low140
Chromophobe Renal Cell Carcinoma0low140
Chromosomal Aberrations0low40
Chromosomal Instability0low30
Chromosomal Stability0low30
Chromosomal Translocation0low150
Chromosome 17p13.3 Deletion Syndrome0low10
Chromosome 6-Linked Autosomal Recessive Parkinsonism0low10
Chromosome Aberrations0low40
Chromosome Abnormalities0low40
Chromosome Deletion0low50
Chromosome Instability0low30
Chromosome Inversion0low10
Chromosome Stability0low30
Chronic Actinic Dermatitis0low10
Chronic Airflow Obstruction0low40
Chronic Disease0low30
Chronic Encephalopathy0low10
Chronic Idiopathic Myelofibrosis0low30
Chronic Illness0low30
Chronic Kidney Diseases0low30
Chronic Kidney Failure0low10
Chronic Kidney Insufficiency0low30
Chronic Lymphocytic Leukemia0low50
Chronic Obstructive Airway Disease0low40
Chronic Obstructive Lung Disease0low40
Chronic Obstructive Pulmonary Disease0low40
Chronic Obstructive Pulmonary Diseases0low40
Chronic Pain0low10
Chronic Progressive Hereditary Chorea (Huntington)0low40
Chronic Progressive Subcortical Encephalopathy0low10
Chronic Renal Diseases0low30
Chronic Renal Insufficiency0low30
Chronically Ill0low30
Cicatrix, Hypertrophic0low10
Cirrhosis0low200
Cirrhosis, Liver0low20
Clarkson Disease0low10
Classic Lissencephaly0low10
Classical Lissencephalies and Subcortical Band Heterotopias0low10
Classical Lissencephaly Syndrome0low10
Classical Swine Fever0low10
Clear Cell Renal Carcinoma0low140
Clear Cell Renal Cell Carcinoma0low140
Cleft Spine0low10
Clinical Capillary Leak Syndrome0low10
Clinically Isolated CNS Demyelinating Syndrome0low10
Clinically Isolated Syndrome, CNS Demyelinating0low10
CNS Disorders, Intracranial0low10
CNS Neoplasm0low20
CNS Neoplasms0low20
COAD0low40
Cocaine Abuse0low10
Cocaine Addiction0low10
Cocaine Dependence0low10
Cocaine-Related Disorders0low10
Cocarcinogenesis0low10
Cochlear Hearing Loss0low10
Coenuriasis0low10
Cognition Disorders0low30
Cognitive Decline0low20
Cognitive Dysfunction0low20
Cognitive Impairments0low20
Colitis Gravis0low10
Colitis, Granulomatous0low10
Colitis, Mucous0low10
Colitis, Ulcerative0low10
Collagen Arthritis0low60
Collecting Duct Carcinoma0low140
Collecting Duct Carcinoma (Kidney)0low140
Collecting Duct Carcinoma of the Kidney0low140
Colon Cancer0low650
Colon Neoplasms0low650
Colon, Irritable0low10
Colonic Cancer0low650
Colonic Neoplasms0low650
Colonic Polyps0low10
Colorectal Cancer0low320
Colorectal Carcinoma0low320
Colorectal Neoplasms0low320
Colorectal Tumors0low320
Complication, Postoperative0low40
Condition, Preneoplastic0low20
Conditions, Preneoplastic0low20
Cone-Rod Degenerations0low10
Cone-Rod Dystrophies0low10
Cone-Rod Dystrophy0low10
Cone-Rod Dystrophy 20low10
Cone-Rod Retinal Dystrophy0low10
Congenital Telangiectatic Erythema0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Congestive Heart Failure0low20
Conjunctival Neoplasms0low10
Convulsive Generalized Seizure Disorder0low10
Convulsive Seizure Disorder, Generalized0low10
COPD0low40
Corneal Opacity0low10
Coronary Arteriosclerosis0low10
Coronary Artery Disease0low10
Coronary Atherosclerosis0low10
Corticotroph Adenoma0low10
Coxsackie Virus Infections0low20
Coxsackievirus Infections0low20
Cranial Nerve II Injuries0low20
Craniofacial Abnormalities0low20
Craniofacial Microsomia0low10
Craniorachischisis0low20
Crohn Disease0low10
Crohn's Disease0low10
Crohn's Enteritis0low10
Cronkhite-Canada Syndrome0low10
Cryptococcosis0low20
Cryptococcus gattii Infection0low20
Cryptococcus Infection0low20
Cryptococcus Infections0low20
Cryptococcus neoformans Infection0low20
Cryptogenic Fibrosing Alveolitis0low10
Cushing Disease0low20
Cushing Disease, Pituitary0low20
Cushing's Disease0low20
CVA (Cerebrovascular Accident)0low30
Cystadenocarcinoma, Mucinous0low10
Cystadenocarcinoma, Serous0low20
Cystadenoma, Serous0low10
Cystic Fibrosis0low20
Cystic Fibrosis of Pancreas0low20
Cytogenetic Aberrations0low40
Cytogenetic Abnormalities0low40
Cytomegalic Inclusion Disease0low30
Cytomegalovirus0low160
Cytomegalovirus Infections0low30
DCIS0low10
DDD MPGNII0low10
DDPAC0low10
Deafness Neurosensory0low10
Deficiency Syndrome, Immunologic0low10
Deficiency Syndromes, Antibody0low10
Deficiency Syndromes, Immunologic0low10
Deficiency, Mental0low20
Deficiency, Oxygen0low110
Degenerative Disc Disease0low10
Degenerative Diseases, Central Nervous System0low40
Degenerative Diseases, Nervous System0low40
Degenerative Diseases, Neurologic0low40
Degenerative Diseases, Spinal Cord0low40
Degenerative Intervertebral Discs0low10
Degenerative Intervertebral Disks0low10
Degenerative Neurologic Diseases0low40
Degenerative Neurologic Disorders0low40
Delayed Effects, Prenatal Exposure0low30
Delayed Hypersensitivity0low10
Dementia Complex, Acquired Immune Deficiency Syndrome0low10
Dementia Complex, AIDS-Related0low10
Dementia Praecox0low40
Dementia With Amyotrophic Lateral Sclerosis0low40
Dementia, Alzheimer Type0low100
Dementia, Frontotemporal0low10
Dementia, Frontotemporal, with Parkinsonism0low10
Dementia, Hereditary Dysphasic Disinhibition0low10
Dementia, Presenile0low100
Dementia, Primary Senile Degenerative0low100
Dementia, Senile0low100
Dementia, Vascular0low10
Demyelinating Diseases0low10
Demyelinating Disorders0low10
Demyelination0low10
Demyelinogenic Leukodystrophy0low10
Dense Deposit Disease0low10
Dependence, Opioid0low10
Depression0low10
Depression, Bipolar0low20
Dermatitis, Actinic0low10
Dermatitis, Allergic Contact0low20
Dermatitis, Allergic Eczematous0low20
Dermatitis, Atopic0low10
Dermatitis, Contact, Allergic0low20
Development Disorders, Child0low10
Developmental Defects, Neural Tube0low20
Developmental Delay Disorders0low10
Developmental Disabilities0low10
Developmental Neural Tube Defects0low20
Di Guglielmo Disease0low130
Di Guglielmo's Disease0low130
Diabetes Mellitus, Adult-Onset0low30
Diabetes Mellitus, Brittle0low50
Diabetes Mellitus, Experimental0low40
Diabetes Mellitus, Insulin-Dependent0low50
Diabetes Mellitus, Insulin-Dependent, 10low50
Diabetes Mellitus, Juvenile-Onset0low50
Diabetes Mellitus, Ketosis-Prone0low50
Diabetes Mellitus, Ketosis-Resistant0low30
Diabetes Mellitus, Maturity-Onset0low30
Diabetes Mellitus, Non Insulin Dependent0low30
Diabetes Mellitus, Non-Insulin-Dependent0low30
Diabetes Mellitus, Noninsulin Dependent0low30
Diabetes Mellitus, Noninsulin-Dependent0low30
Diabetes Mellitus, Slow-Onset0low30
Diabetes Mellitus, Stable0low30
Diabetes Mellitus, Sudden-Onset0low50
Diabetes Mellitus, Type 10low50
Diabetes Mellitus, Type 20low30
Diabetes Mellitus, Type I0low50
Diabetes Mellitus, Type II0low30
Diabetes, Autoimmune0low50
Diabetic Amyotrophy0low10
Diabetic Asymmetric Polyneuropathy0low10
Diabetic Autonomic Neuropathy0low10
Diabetic Glomerulosclerosis0low10
Diabetic Kidney Disease0low10
Diabetic Mononeuropathy0low10
Diabetic Mononeuropathy Simplex0low10
Diabetic Nephropathies0low10
Diabetic Nephropathy0low10
Diabetic Neuralgia0low10
Diabetic Neuropathies0low10
Diabetic Neuropathy, Painful0low10
Diabetic Polyneuropathy0low10
Diastematomyelia0low20
Diathesis0low10
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated0low20
Diffuse Mixed Small and Large Cell Lymphoma0low10
Diffuse Mixed-Cell Lymphoma0low10
Diffuse Small Cleaved-Cell Lymphoma0low10
Diffuse Undifferentiated Lymphoma0low10
Diffuse Well-Differentiated Lymphocytic Lymphoma0low50
Digestive System Cancer0low10
Digestive System Neoplasms0low10
Dipylidiasis0low10
Disabilities, Developmental0low10
Disability, Intellectual0low20
Disc Degeneration0low10
Disc Degradation0low10
Disease Exacerbation0low250
Disease Models, Animal0low1050
Disease Progression0low250
Disease Resistance0low10
Disease Susceptibility0low10
Disease, Pulmonary0low10
Diseases, Pulmonary0low10
Disinhibition-Dementia-Parkinsonism-Amyotrophy Complex0low10
Disinhibition-Dementia-Parkinsonism-Amytrophy Complex0low10
Disintegration of Blastocyst0low10
Disintegration of Embryo0low10
Disk Degeneration0low10
Disk Degradation0low10
Disrupted In B-Cell Malignancy0low50
Distal Spinal Muscular Atrophy0low90
Dominantly-Inherited Spinocerebellar Ataxias0low10
Double Cortex Syndrome0low10
Down Syndrome0low10
Down Syndrome, Partial Trisomy 210low10
Down's Syndrome0low10
Drug Withdrawal Symptoms0low30
Drug-Induced Abnormalities0low50
Drug-Induced Acute Liver Injury0low30
Drug-Induced Liver Disease0low30
Drug-Induced Liver Injury0low30
Duchenne and Becker Muscular Dystrophy0low10
Duchenne Muscular Dystrophy0low10
Duchenne-Becker Muscular Dystrophy0low10
Duchenne-Type Progressive Muscular Dystrophy0low10
Duct-Cell Carcinoma of the Pancreas0low80
Duct-Cell Carcinoma, Pancreas0low80
Ductal Carcinoma In Situ0low10
Ductal Carcinoma of the Pancreas0low80
Dysembryoma0low20
Dysmenorrhea0low10
Dysmetabolic Syndrome X0low10
Dysmyelinogenic Leukodystrophy0low10
Dysmyelopoietic Syndromes0low40
E coli Infections0low10
E. coli Infection0low10
Ear Diseases0low10
Early Onset Alzheimer Disease0low100
EBV Infections0low30
Eczema, Atopic0low10
Eczema, Infantile0low10
Edema-Proteinuria-Hypertension Gestosis0low10
Edema, Pulmonary0low10
Edemas, Pulmonary0low10
Ehrlich Ascites Tumor0low10
Electrocardiogram QT Prolonged0low10
Electrolytes0low10
Embolic Infarction, Middle Cerebral Artery0low10
Embolus, Middle Cerebral Artery0low10
Embryo Death0low10
Embryo Disintegration0low10
Embryo Loss0low10
Embryo Resorption0low10
Emphysema, Pulmonary0low10
Emphysemas, Pulmonary0low10
Encephalitis, Polio0low10
Encephalomyelitis, Allergic0low50
Encephalomyelitis, Autoimmune, Experimental0low50
Encephalomyelitis, Experimental Autoimmune0low50
Encephalon Diseases0low10
Encephalopathy0low10
Encephalopathy, AIDS0low10
Encephalopathy, Anoxic-Ischemic0low20
Encephalopathy, Binswanger0low10
Encephalopathy, Binswanger's0low10
Encephalopathy, Chronic0low10
Encephalopathy, Chronic Progressive Subcortical0low10
Encephalopathy, HIV0low10
Encephalopathy, Hypoxic-Ischemic0low20
Encephalopathy, Ischemic0low40
Encephalopathy, Subcortical Arteriosclerotic0low10
Encephalopathy, Subcortical, Chronic Progressive0low10
Encephalopathy, Toxic0low10
End-Stage Kidney Disease0low10
End-Stage Renal Disease0low10
Endocarditis, Loeffler0low20
Endocarditis, Loeffler's0low20
Endocrine Cancer0low20
Endocrine Gland Cancer0low20
Endocrine Gland Carcinoma0low20
Endocrine Gland Neoplasms0low20
Endometrial Cancer0low150
Endometrial Carcinoma0low150
Endometrial Diseases0low10
Endometrial Neoplasms0low150
Endometrioid Adenocarcinoma0low10
Endometrioma0low80
Endometriosis0low80
Endometrium Cancer0low150
Endotoxemia0low30
Endotoxin Shock0low10
Enlarged Heart0low130
Enteritis0low10
Enteritis, Granulomatous0low10
Enteritis, Regional0low10
Enterovirus Infections0low10
Ependymoblastoma0low30
EPH Complex0low10
EPH Gestosis0low10
EPH Toxemias0low10
Epidemic Acute Poliomyelitis0low10
Epidemic Neurolabyrinthitis0low10
Epilepsy, Akinetic0low10
Epilepsy, Atonic0low10
Epilepsy, Generalized0low10
Epilepsy, Tonic0low10
Episodic Recurrent Vertigo0low10
Epithelial Neoplasms0low10
Epithelial Neoplasms, Malignant0low260
Epithelial Ovarian Cancer0low10
Epithelial Ovarian Carcinoma0low10
Epithelial Tumors, Malignant0low260
Epithelioma0low260
Epstein-Barr Virus Infection0low30
Epstein-Barr Virus Infections0low30
ER-Negative PR-Negative HER2-Negative Breast Cancer0low40
ER-Negative PR-Negative HER2-Negative Breast Neoplasms0low40
Erythremic Myelosis0low130
Erythroblastic Anemia0low30
Erythroblastic Leukemia, Acute0low130
Erythroderma, Sezary0low10
Erythroleukemia0low130
Escherichia coli Infections0low10
Esophageal Cancer0low160
Esophageal Neoplasms0low160
Esophageal Squamous Cell Carcinoma0low50
Esophagus Cancer0low160
Esophagus Neoplasm0low160
Esophagus, Barrett0low10
ESRD0low10
Ethanol Abuse0low50
Ewing Sarcoma0low10
Ewing Tumor0low10
Ewing's Sarcoma0low10
Ewing's Tumor0low10
Exencephaly0low20
Experimental Allergic Encephalomyelitis0low50
Experimental Autoimmune Encephalomyelitis0low50
Experimental Diabetes Mellitus0low40
Experimental Hepatoma0low30
Experimental Hepatomas0low30
Experimental Leukemia0low20
Experimental Leukemias0low20
Experimental Liver Neoplasms0low30
Experimental Lung Inflammation0low20
Experimental Mammary Neoplasms0low70
Experimental Melanoma0low110
Experimental Melanomas0low110
Experimental Neoplasms0low90
Experimental Parkinson Disease0low10
Experimental Parkinsonism0low10
Experimental Parkinsonism, MPTP-Induced0low10
Experimental Radiation Injuries0low10
Extracutaneous Mastocytoma0low10
Extrahepatic Cholangiocarcinoma0low30
Extravascular Hemolysis0low10
Eye Cancer, Retinoblastoma0low20
Eye Diseases0low10
Eye Disorders0low10
Facioauriculovertebral Dysplasia0low10
Facioauriculovertebral Sequence0low10
FAE (Fetal Alcohol Effects)0low10
Familial Alzheimer Disease (FAD)0low100
Familial Atrial Fibrillation0low10
Familial Cerebello-Retinal Angiomatosis0low10
Familial Idiopathic Pulmonary Fibrosis0low10
Familial Juvenile Parkinsonism0low10
Familial Nonmedullary Thyroid Cancer0low10
Familial Parkinson Disease, Autosomal Recessive0low10
Familial Pick's Disease0low10
Familial Retinoblastoma0low20
Familial Waldenstrom's Macroglobulinaemia0low20
FASD0low10
Feline Diseases0low10
Femoral Head, Avascular Necrosis Of0low10
Femur Head Necrosis0low10
Fetal Alcohol Spectrum Disorder0low10
Fetal Alcohol Spectrum Disorders0low10
Fetal Alcohol Syndrome0low10
Fetal Anoxia0low10
Fetal Death0medium11
Fetal Demise0medium11
Fetal Hypoxia0low10
Fetal Mummification0medium11
Fever0low10
Fever, Zika0low10
Fibrillary Astrocytoma0low20
Fibrinoid Degeneration of Astrocytes0low10
Fibrocystic Disease of Pancreas0low20
Fibrocystic Pulmonary Dysplasia0low10
Fibroid0low10
Fibroid Tumor0low10
Fibroid Uterus0low10
Fibroids, Uterine0low10
Fibroma0low10
Fibroma, Shope0low10
Fibroma, Uterine0low10
Fibromatosis0low10
Fibromyoma0low10
Fibromyxoma0low10
Fibrosarcoma0low40
Fibroses, Pulmonary0low30
Fibrosing Alveolitis, Cryptogenic0low10
Fibrosis0low200
Fibrosis, Bone Marrow0low30
Fibrosis, Liver0low20
Fibrosis, Pulmonary0low30
First and Second Branchial Arch Syndrome0low10
First and Second Pharyngeal Arch Syndromes0low10
Focal Brain Injuries0low40
Focal Emphysema0low10
Focal Onset Alzheimer's Disease0low100
Focal Segmental Glomerulosclerosis0low20
Follicular Large-Cell Lymphoma0low10
Follicular Lymphoma0low10
Follicular Lymphoma, Giant0low10
Follicular Lymphoma, Grade 10low10
Follicular Lymphoma, Grade 20low10
Follicular Lymphoma, Grade 30low10
Follicular Mixed-Cell Lymphoma0low10
Follicular Thyroid Carcinoma0low40
Food Allergy0low10
Food Hypersensitivity0low10
Fra(X) Syndrome0low60
Fragile X Mental Retardation Syndrome0low60
Fragile X Syndrome0low60
Fragile X-F Mental Retardation Syndrome0low60
FRAXA Syndrome0low60
FRAXE Syndrome0low60
Friedreich Ataxia0low10
Friedreich Disease0low10
Friedreich Familial Ataxia0low10
Friedreich Hereditary Ataxia0low10
Friedreich Hereditary Spinal Ataxia0low10
Friedreich Spinocerebellar Ataxia0low10
Friedreich's Ataxia0low10
Friedreich's Disease0low10
Friedreich's Familial Ataxia0low10
Friedreich's Hereditary Ataxia0low10
Friedreich's Hereditary Spinal Ataxia0low10
Frontotemporal Dementia0low10
Frontotemporal Dementia with Parkinsonism0low10
Frontotemporal Dementia with Parkinsonism-170low10
Frontotemporal Dementia, Ubiquitin-Positive0low10
Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions0low10
Frontotemporal Lobe Dementia0low10
Frontotemporal Lobe Dementia (FLDEM)0low10
FTD-GRN0low10
FTD-PGRN0low10
FTDP-170low10
FTLD with TDP-43 Pathology0low10
FTLD-17 GRN0low10
FTLD-TDP0low10
Fulminant Hepatic Failure0low10
Fulminating Hepatic Failure0low10
Fulminating Liver Failure0low10
Gall Bladder Cancer0low20
Gallbladder Cancer0low20
Gallbladder Neoplasms0low20
Gangliocytoma0low10
Ganglioneuroma0low10
Gastric Cancer0low570
Gastric Cancer, Familial Diffuse0low570
Gastric Neoplasms0low570
Gastrointestinal Cancer0low50
Gastrointestinal Neoplasms0low50
Gehrig's Disease0low40
Gemistocytic Astrocytoma0low20
Generalized Convulsive Epilepsy0low10
Generalized Nonconvulsive Epilepsy0low10
Generalized Nonconvulsive Seizure Disorder0low10
Generalized Onset Seizure Disorder0low10
Generalized Resistance to Thyroid Hormone0low10
Generalized Seizure Disorder, Convulsive0low10
Generalized Seizure Disorder, Nonconvulsive0low10
Generalized Thyroid Hormone Resistance0low10
Genetic Anticipation0low10
Genetic Predisposition0low60
Genetic Predisposition to Disease0low60
Genetic Susceptibility0low60
Genome Instability0low60
Genome Stability0low60
Genomic Instability0low60
Genomic Stability0low60
Germinoblastoma0low50
Gestational Trophoblastic Disease0low10
Gestational Trophoblastic Neoplasia0low10
Gestational Trophoblastic Neoplasms0low10
Gestosis, EPH0low10
Giant Cell Glioblastoma0low280
Giant Follicular Lymphoma0low10
Glandular and Epithelial Neoplasms0low10
Glandular Neoplasms0low10
Glenoid Labral Tears0low10
Glial Cell Tumors0low240
Glial Scar0low10
Glioblastoma0low280
Glioblastoma Multiforme0low280
Glioblastoma, Retinal0low20
Glioma0low240
Glioma, Astrocytic0low20
Glioma, Retinal0low20
Gliosis0low10
Glomerulonephritis0low10
Glomerulonephritis, Focal Sclerosing0low20
Glomerulonephritis, Hypocomplementemic0low10
Glomerulonephritis, IGA0low10
Glomerulonephritis, Membranoproliferative0low10
Glomerulonephritis, Mesangiocapillary0low10
Glomerulosclerosis, Diabetic0low10
Glomerulosclerosis, Focal0low20
Glomerulosclerosis, Focal Segmental0low20
Goldenhar Disease0low10
Goldenhar Syndrome0low10
Goldenhar Syndrome with Ipsilateral Radial Defect0low10
Goldenhar-Gorlin Syndrome0low10
Graft vs Host Disease0low10
Graft-Versus-Host Disease0low10
Graft-vs-Host Disease0low10
Granulocytic Leukemia0low170
Granulocytic Leukemia, Chronic0low50
Granuloma, Hodgkin0low30
Granuloma, Hodgkin's0low30
Granuloma, Hodgkins0low30
Granuloma, Malignant0low30
Grawitz Tumor0low140
Grippe0low10
GRN-Related Frontotemporal Dementia0low10
Growth Retardation, Facial Abnormalities, and Central Nervous System Dysfunction0low10
Guam Disease0low40
Guam Form of Amyotrophic Lateral Sclerosis0low40
Haemolysis0low10
Harding Passey Melanoma0low110
HbS Disease0low20
HDDD10low10
HDDD20low10
Head and Neck Cancer0low120
Head and Neck Neoplasm0low120
Head and Neck Neoplasms0low120
Head and Neck Squamous Cell Carcinoma0low40
Head And Neck Squamous Cell Carcinomas0low40
Head Cancer0low120
Head Neoplasm0low120
Head Neoplasms0low120
Head, Neck Neoplasms0low120
Hearing Loss, Cochlear0low10
Hearing Loss, Sensorineural0low10
Heart Attack0low100
Heart Block0low10
Heart Decompensation0low20
Heart Disease, Ischemic0low10
Heart Enlargement0low130
Heart Failure0low20
Heart Failure, Congestive0low20
Heart Failure, Left-Sided0low20
Heart Failure, Right-Sided0low20
Heart Hypertrophy0low130
Helicobacter Infections0low10
Hematopoetic Myelodysplasia0low40
Hemifacial Microsomia0low10
Hemifacial Microsomia with Radial Defects0low10
Hemoglobin F Disease0low30
Hemoglobin S Disease0low20
Hemolysis0low10
Hemorrhage, Subarachnoid0low10
Hemorrhagic Shock0low10
Hepatic Cancer0low530
Hepatic Cirrhosis0low20
Hepatic Failure, Acute0low10
Hepatic Failure, Fulminant0low10
Hepatic Neoplasms0low530
Hepatitis B0low10
Hepatitis B Virus Infection0low10
Hepatitis, Drug-Induced0low30
Hepatitis, Toxic0low30
Hepatocellular Cancer0low530
Hepatocellular Carcinoma0low510
Hepatoma0low510
Hepatoma, Experimental0low30
Hepatoma, Morris0low30
Hepatoma, Novikoff0low30
Hepatomas, Experimental0low30
Hereditary Areflexic Dystasia0low10
Hereditary Dysphasic Disinhibition Dementia0low10
Hereditary Motor and Sensory Neuropathy 1A0low10
Hereditary Motor and Sensory Neuropathy 1B0low10
Hereditary Motor and Sensory Neuropathy IA0low10
Hereditary Motor And Sensory Neuropathy IB0low10
Hereditary Motor and Sensory-Neuropathy Type II0low10
Hereditary Motor Neuronopathy0low90
Hereditary Motor, and Sensory Neuropathy Type I0low10
Hereditary Retinoblastoma0low20
Hereditary Spinal Ataxia, Friedreich0low10
Hereditary Spinal Ataxia, Friedreich's0low10
Hereditary Spinal Sclerosis0low10
Hereditary Type I Motor and Sensory Neuropathy0low10
Herpes Simplex0low30
Herpes Simplex Virus Infection0low30
Herpesviridae Infections0low10
Herpesvirus 4 Infections, Human0low30
Herpesvirus Infections0low10
Heterotopia, Subcortical Band0low10
Hippel-Lindau Disease0low10
Histiocytic Lymphoma, Nodular0low10
HIV0low20
HIV Coinfection0low90
HIV Dementia0low10
HIV Encephalopathy0low10
HIV Infections0low90
HIV-1 Cognitive and Motor Complex0low10
HIV-1-Associated Cognitive Motor Complex0low10
HIV-Associated Cognitive Motor Complex0low10
HMN Distal Type I0low10
HMSN 1A0low10
HMSN 1B0low10
HMSN I0low10
HMSN IA0low10
HMSN IB0low10
HMSN II0low10
HMSN Type I0low10
HMSN Type II0low10
HMSN1A0low10
HMSN1B0low10
HNSCC0low40
Hodgkin Disease0low30
Hodgkin Lymphoma0low30
Hodgkin Lymphoma, Adult0low30
Hodgkin's Disease0low30
Hodgkin's Lymphoma0low30
Hodgkins Disease0low30
Hog Cholera0low10
Homologous Wasting Disease0low10
Hormone-Dependent Neoplasms0low30
HPV Infection0low30
HTLV I Associated T Cell Leukemia Lymphoma0low20
HTLV-Associated Leukemia-Lymphoma0low20
HTLV-I-Associated T-Cell Leukemia-Lymphoma0low20
HTLV-III Infections0low90
HTLV-III-LAV Infections0low90
Human Flu0low10
Human Herpes Virus 4 Infections0low30
Human Herpesvirus 4 Infections0low30
Human Influenza0low10
Human Mammary Carcinoma0low1500
Human Papillomavirus Infection0low30
Human T Lymphotropic Virus Associated Leukemia Lymphoma0low20
Human T Lymphotropic Virus-Associated Leukemia-Lymphoma0low20
Human T-Cell Leukemia-Lymphoma0low20
Huntington Chorea0low40
Huntington Chronic Progressive Hereditary Chorea0low40
Huntington Disease0low40
Huntington Disease, Akinetic-Rigid Variant0low40
Huntington Disease, Juvenile0low40
Huntington Disease, Juvenile-Onset0low40
Huntington Disease, Late Onset0low40
Huntington's Chorea0low40
Huntington's Disease0low40
Hutchinson Gilford Progeria Syndrome0low10
Hutchinson-Gilford Progeria Syndrome0low10
Hutchinson-Gilford Syndrome0low10
Hyalinosis, Segmental0low20
Hyalinosis, Segmental Glomerular0low20
Hyperalgesia0low30
Hyperalgesia, Mechanical0low30
Hyperalgesia, Primary0low30
Hyperalgesia, Secondary0low30
Hyperalgesia, Tactile0low30
Hyperalgesia, Thermal0low30
Hyperalgesic Sensations0low30
Hyperalgia0low30
Hyperalgia, Mechanical0low30
Hyperalgia, Primary0low30
Hyperalgia, Secondary0low30
Hypereosinophilic Syndrome0low20
Hypereosinophilic Syndrome, Idiopathic0low20
Hyperglycemia0low20
Hyperglycemia, Postprandial0low20
Hypernephroma0low140
Hyperoxia0low20
Hyperplasia0low10
Hypersensitivity0low40
Hypersensitivity, Delayed0low10
Hypersensitivity, Food0low10
Hypersensitivity, Tuberculin-Type0low10
Hypersensitivity, Type IV0low10
Hypertension0low30
Hypertension-Edema-Proteinuria Gestosis0low10
Hypertension, Pulmonary0low20
Hypertrophy0low20
Hypertrophy, Left Ventricular0low10
Hypertrophy, Right Ventricular0low10
Hypesthesia0low10
Hypesthesia, Tactile0low10
Hypesthesia, Thermal0low10
Hypoesthesia0low10
Hypogammaglobulinemia0low10
Hypopharyngeal Squamous Cell Carcinoma0low40
Hypoxemia0low110
Hypoxia0low110
Hypoxia-Ischemia, Brain0low20
Hypoxia-Ischemia, Cerebral0low20
Hypoxic-Ischemic Encephalopathy0low20
IDDM0low50
Idiocy0low20
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low30
Idiopathic Fibrosing Alveolitis, Chronic Form0low10
Idiopathic Hypereosinophilic Syndrome0low20
Idiopathic Myelofibrosis0low30
Idiopathic Parkinson Disease0low10
Idiopathic Parkinson's Disease0low10
Idiopathic Proctocolitis0low10
Idiopathic Pulmonary Fibrosis0low10
Idiopathic Pulmonary Fibrosis, Familial0low10
IGA Glomerulonephritis0low10
IGA Nephropathy0low10
Iga Nephropathy 10low10
Ileitis, Regional0low10
Ileitis, Terminal0low10
Ileocolitis0low10
Immunodeficiency Syndrome, Severe Combined0low20
Immunodeficiency, Severe Combined0low20
Immunoglobulin A Nephropathy0low10
Immunologic Deficiency Syndrome0low10
Immunologic Deficiency Syndromes0low10
Immunologic Deficiency, Severe Combined0low20
Immunological Deficiency Syndromes0low10
Impaired Sensation0low10
Inappropriate ACTH Secretion Syndrome0low20
Inappropriate Adrenocorticotropic Hormone Secretion0low20
Inclusion Disease0low30
Infantile Paralysis0low10
Infantile Respiratory Distress Syndrome0low10
Infarction, Cerebral0low10
Infarction, Cerebral, Left Hemisphere0low10
Infarction, Cerebral, Right Hemisphere0low10
Infarction, Left Hemisphere, Cerebral0low10
Infarction, Middle Cerebral Artery0low10
Infarction, Right Hemisphere, Cerebral0low10
Infections, Adenoviridae0low10
Infections, Adenovirus0low10
Infections, Coxsackie Virus0low20
Infections, Coxsackievirus0low20
Infections, Cytomegalovirus0low30
Infections, E coli0low10
Infections, EBV0low30
Infections, Enterovirus0low10
Infections, Epstein-Barr Virus0low30
Infections, Escherichia coli0low10
Infections, Helicobacter0low10
Infections, Herpesviridae0low10
Infections, Herpesvirus0low10
Infections, Plasmodium0low30
Infections, Respiratory Syncytial Virus0low10
Infections, Retroviridae0low20
Infections, Retrovirus0low20
Infections, Roseolovirus0low10
Infections, Salmonella0low20
Infections, Tumor Virus0low10
Infertility, Female0low10
Inflammation0low500
Inflammatory Bowel Disease 10low10
Inflammatory Bowel Disease, Ulcerative Colitis Type0low10
Inflammatory Bowel Diseases0low10
Inflammatory Breast Cancer0low10
Inflammatory Breast Cancer (IBC)0low10
Inflammatory Breast Carcinoma0low10
Inflammatory Breast Neoplasms0low10
Inflammatory Response Syndrome, Systemic0low10
Influenza0low10
Influenza in Humans0low10
Influenza, Human0low10
Iniencephaly0low20
Injuries0low10
Injuries and Wounds0low10
Injuries, Acute Brain0low40
Injuries, Brain0low40
Injuries, Experimental Radiation0low10
Injuries, Radiation0low30
Injuries, Spinal0low10
Injuries, Spinal Cord0low10
Injuries, Tendon0low10
Injuries, Wounds0low10
Injury, Ischemia-Reperfusion0low90
Injury, Myocardial Reperfusion0low70
Injury, Reperfusion0low90
Innate Inflammatory Response0low500
Insulin Resistance0low10
Insulin Resistance Syndrome X0low10
Insulin Sensitivity0low10
Insulin-Dependent Diabetes Mellitus 10low50
Intellectual Development Disorder0low20
Intellectual Disability0low20
Interstitial Cell Tumor0low10
Interstitial Nephritis0low20
Interstitial Pneumonitis, Usual0low10
Intervertebral Disc Degeneration0low10
Intervertebral Disk Degeneration0low10
Intestinal Diseases0low10
Intestinal Polyposis0low10
Intracapillary Glomerulosclerosis0low10
Intracranial Astrocytoma0low20
Intracranial Central Nervous System Disorders0low10
Intracranial CNS Disorders0low10
Intracranial Neoplasms0low320
Intraductal Carcinoma, Noninfiltrating0low10
Intrahepatic Cholangiocarcinoma0low30
Intravascular Hemolysis0low10
Invasive Ductal Carcinoma, Breast0low10
Invasiveness, Neoplasm0low400
Inversion, Chromosomal0low10
Inversion, Chromosome0low10
Irritable Bowel Syndrome0low10
Ischemia-Anoxia, Brain0low20
Ischemia-Anoxia, Cerebral0low20
Ischemia-Hypoxia, Brain0low20
Ischemia-Hypoxia, Cerebral0low20
Ischemia-Reperfusion Injury0low90
Ischemia, Cerebral0low40
Ischemia, Myocardial0low10
Ischemic Encephalopathy0low40
Ischemic Heart Disease0low10
Ischemic Necrosis Of Femoral Head0low10
Ischemic-Hypoxic Encephalopathy0low20
Isolated Lissencephaly Sequence0low10
Joseph Azorean Disease0low10
Joseph Disease0low10
Juvenile Huntington Disease0low40
Juvenile Parkinson Disease0low10
Juvenile Parkinson Disease, Autosomal Dominant0low10
Juvenile Parkinson Disease, Autosomal Recessive0low10
Juvenile Parkinsonism, Autosomal Dominant0low10
Juvenile Parkinsonism, Autosomal Recessive0low10
Juvenile Pilocytic Astrocytoma0low20
Juvenile-Onset Diabetes0low50
Juvenile-Onset Huntington Disease0low40
Kahler Disease0medium131
Keloid0low40
Ki-1 Lymphoma0low20
Kidney Cancer0low130
Kidney Diseases0low30
Kidney Failure, Acute0low60
Kidney Failure, Chronic0low10
Kidney Insufficiency, Acute0low60
Kidney Insufficiency, Chronic0low30
Kidney Neoplasms0low130
Kidney Scarring0low10
Kidney, Polycystic0low10
Kidney, Polycystic, Autosomal Dominant0low10
Kienbock Disease0low10
Kienbock's Disease0low10
Kienboeck Disease0low10
Kienboeck's Disease0low10
Kimmelstiel-Wilson Disease0low10
Kimmelstiel-Wilson Syndrome0low10
Koch's Disease0low20
Kochs Disease0low20
Large Lymphoid Lymphoma, Nodular0low10
Large-Cell Lymphoma, Follicular0low10
Laryngeal Cancer0low20
Laryngeal Neoplasms0low20
Laryngeal Squamous Cell Carcinoma0low40
Larynx Cancer0low20
Larynx Neoplasms0low20
Late Effects, Prenatal Exposure0low30
Late Onset Alzheimer Disease0low100
Late-Onset Huntington Disease0low40
Lateral Facial Dysplasia0low10
Left Hemisphere, Cerebral Infarction0low10
Left Hemisphere, Infarction, Cerebral0low10
Left Main Coronary Artery Disease0low10
Left Main Coronary Disease0low10
Left Main Disease0low10
Left Middle Cerebral Artery Infarction0low10
Left Ventricle Remodeling0low30
Left Ventricular Dysfunction0low10
Left Ventricular Hypertrophy0low10
Left Ventricular Remodeling0low30
Left-Sided Heart Failure0low20
Leiomyoma0low10
Leiomyoma, Uterine0low10
Leishmania Infection0low10
Leishmaniasis0low10
Lens Opacities0low20
Lesion of Sciatic Nerve0low10
Leucocythaemia0medium291
Leucocythemia0medium291
Leukemia0medium291
Leukemia L 12100low20
Leukemia L12100low20
Leukemia Lymphoma, Adult T Cell0low20
Leukemia Lymphoma, T Cell, Acute, HTLV I Associated0low20
Leukemia Model, Animal0low20
Leukemia-Lymphoma, Adult T-Cell0low20
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated0low20
Leukemia, Acute Lymphoblastic0low20
Leukemia, Acute Monocytic0low10
Leukemia, Acute Myelogenous0low140
Leukemia, Acute Myeloid0low140
Leukemia, Acute Promyelocytic0low110
Leukemia, Adult T-Cell0low20
Leukemia, B Cell, Chronic0low50
Leukemia, B-Cell, Chronic0low50
Leukemia, Chronic Lymphatic0low50
Leukemia, Chronic Lymphocytic0low50
Leukemia, Chronic Lymphocytic, B-Cell0low50
Leukemia, Chronic Myelogenous0low50
Leukemia, Chronic Myeloid0low50
Leukemia, Eosinophilic0low20
Leukemia, Erythroblastic, Acute0low130
Leukemia, Experimental0low20
Leukemia, Granulocytic0low170
Leukemia, Granulocytic, Chronic0low50
Leukemia, Lymphoblastic0low20
Leukemia, Lymphoblastic, Acute0low20
Leukemia, Lymphoblastic, Acute, L10low20
Leukemia, Lymphoblastic, Acute, L20low20
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive0low20
Leukemia, Lymphoblastic, Acute, T Cell0low20
Leukemia, Lymphoblastic, Acute, T-Cell0low20
Leukemia, Lymphoblastic, Burkitt-Type0low90
Leukemia, Lymphoblastic, Chronic0low50
Leukemia, Lymphocytic, Acute0low20
Leukemia, Lymphocytic, Acute T Cell0low20
Leukemia, Lymphocytic, Acute, L10low20
Leukemia, Lymphocytic, Acute, L20low20
Leukemia, Lymphocytic, Acute, T-Cell0low20
Leukemia, Lymphocytic, Chronic0low50
Leukemia, Lymphocytic, Chronic, B Cell0low50
Leukemia, Lymphocytic, Chronic, B-Cell0low50
Leukemia, Lymphocytic, L30low90
Leukemia, Lymphocytic, T Cell0low20
Leukemia, Lymphocytic, T-Cell0low20
Leukemia, Lymphoid, Acute0low20
Leukemia, Monoblastic, Acute0low10
Leukemia, Monocytic, Acute0low10
Leukemia, Monocytic, Chronic0low170
Leukemia, Myeloblastic, Acute0low140
Leukemia, Myelocytic0low170
Leukemia, Myelocytic, Acute0low140
Leukemia, Myelocytic, Chronic0low50
Leukemia, Myelogenous0low170
Leukemia, Myelogenous, Acute0low140
Leukemia, Myelogenous, Chronic0low50
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0low50
Leukemia, Myelogenous, Ph1 Positive0low50
Leukemia, Myelogenous, Ph1-Positive0low50
Leukemia, Myeloid0low170
Leukemia, Myeloid, Acute0low140
Leukemia, Myeloid, Acute, M10low140
Leukemia, Myeloid, Acute, M20low140
Leukemia, Myeloid, Acute, M30low110
Leukemia, Myeloid, Acute, M40low20
Leukemia, Myeloid, Acute, M50low10
Leukemia, Myeloid, Acute, M60low130
Leukemia, Myeloid, Chronic0low50
Leukemia, Myeloid, Naegeli-Type0low20
Leukemia, Myeloid, Ph1 Positive0low50
Leukemia, Myeloid, Ph1-Positive0low50
Leukemia, Myeloid, Philadelphia Positive0low50
Leukemia, Myeloid, Philadelphia-Positive0low50
Leukemia, Myeloid, Schilling Type0low10
Leukemia, Myeloid, Schilling-Type0low10
Leukemia, Myelomonocytic, Acute0low20
Leukemia, Nonlymphoblastic, Acute0low140
Leukemia, Nonlymphocytic, Acute0low140
Leukemia, Pre-B-Cell0low30
Leukemia, Progranulocytic0low110
Leukemia, Promyelocytic, Acute0low110
Leukemia, T-Cell0low20
Leukemia, T-Cell, Acute0low20
Leukemias, Experimental0low20
Leukocyte Disorders0low10
Leukodystrophy with Rosenthal Fibers0low10
Leukoencephalopathy, Subcortical0low10
Leukoma0low10
Lewy Body Parkinson Disease0low10
Lewy Body Parkinson's Disease0low10
Leydig Cell Tumor0low10
Libman-Sacks Disease0low50
Lindau Disease0low10
Lindau's Disease0low10
Linear Skull Fracture0low10
Lipodystrophy0low10
Lissencephalies, Classical0low10
Lissencephaly 10low10
Lissencephaly Sequence, Isolated0low10
Lissencephaly Syndrome, Miller-Dieker0low10
Lissencephaly Type 10low10
Lissencephaly-Subcortical Band Heterotopia0low10
Lissencephaly, Classic0low10
Lissencephaly, Miller-Dieker0low10
Lissencephaly, Type 10low10
Lissencephaly, X-Linked0low10
Lissencephaly, X-Linked, 10low10
Liver Cancer0low530
Liver Cancer, Adult0low510
Liver Cell Carcinoma0low510
Liver Cell Carcinoma, Adult0low510
Liver Cirrhosis0low20
Liver Failure, Acute0low10
Liver Failure, Acute-On-Chronic0low10
Liver Failure, Fulminant0low10
Liver Fibrosis0low20
Liver Injury, Drug-Induced0low30
Liver Injury, Drug-Induced, Acute0low30
Liver Neoplasms0low530
Liver Neoplasms, Experimental0low30
Lobar Pneumonia0low20
Local Neoplasm Recurrence0low10
Local Neoplasm Recurrences0low10
Locoregional Neoplasm Recurrence0low10
Loeffler Endocarditis0low20
Loeffler's Endocarditis0low20
Long QT Syndrome0low10
Lou Gehrig Disease0low40
Lou Gehrig's Disease0low40
Lou-Gehrigs Disease0low40
Louis-Bar Syndrome0low40
Lung Adenocarcinoma0low60
Lung Cancer0low880
Lung Diseases0low10
Lung Inflammation0low20
Lung Injury, Acute0low80
Lung Injury, Ventilator-Induced0low30
Lung Neoplasms0low880
Lupus Erythematosus Disseminatus0low50
Lupus Erythematosus, Systemic0low50
Lymph Node Metastasis0low20
Lymphatic Metastasis0low20
Lymphatic Sarcoma0low10
Lymphoblastic Leukemia0low20
Lymphoblastic Leukemia, Acute0low20
Lymphoblastic Leukemia, Acute, Adult0low20
Lymphoblastic Leukemia, Acute, Childhood0low20
Lymphoblastic Leukemia, Acute, L10low20
Lymphoblastic Leukemia, Acute, L20low20
Lymphoblastic Leukemia, Acute, T Cell0low20
Lymphoblastic Leukemia, Acute, T-Cell0low20
Lymphoblastic Leukemia, Chronic0low50
Lymphoblastic Lymphoma0low20
Lymphocyte Depletion Hodgkin's Lymphoma0low30
Lymphocyte-Rich Classical Hodgkin's Lymphoma0low30
Lymphocytic Leukemia, Acute0low20
Lymphocytic Leukemia, Chronic0low50
Lymphocytic Leukemia, Chronic, B Cell0low50
Lymphocytic Leukemia, Chronic, B-Cell0low50
Lymphocytic Leukemia, L10low20
Lymphocytic Leukemia, L20low20
Lymphocytic Leukemia, L30low90
Lymphocytic Leukemia, T Cell, Acute0low20
Lymphocytic Leukemia, T-Cell0low20
Lymphocytic Leukemia, T-Cell, Acute0low20
Lymphocytic Lymphoma0low50
Lymphocytic Lymphoma, Diffuse, Poorly Differentiated0low20
Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated0low20
Lymphocytic Lymphoma, Diffuse, Well Differentiated0low50
Lymphocytic Lymphoma, Diffuse, Well-Differentiated0low50
Lymphocytic Lymphoma, Nodular, Poorly Differentiated0low10
Lymphocytic Lymphoma, Nodular, Poorly-Differentiated0low10
Lymphocytic Lymphoma, Well Differentiated0low50
Lymphocytic Lymphoma, Well-Differentiated0low50
Lymphogranuloma, Malignant0low30
Lymphoma0low50
Lymphoma, Atypical Diffuse Small Lymphoid0low10
Lymphoma, B-Cell0low60
Lymphoma, Burkitt0low90
Lymphoma, Centrocytic Small-Cell0low20
Lymphoma, Diffuse0low10
Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Follicular0low10
Lymphoma, Follicular Large-Cell0low10
Lymphoma, Follicular, Grade 10low10
Lymphoma, Follicular, Grade 20low10
Lymphoma, Follicular, Grade 30low10
Lymphoma, Follicular, Mixed Cell0low10
Lymphoma, Follicular, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Follicular, Mixed Small and Large Lymphoid0low10
Lymphoma, Follicular, Small and Large Cleaved Cell0low10
Lymphoma, Follicular, Small and Large Cleaved-Cell0low10
Lymphoma, Giant Follicular0low10
Lymphoma, High-Grade0low10
Lymphoma, Histiocytic, Nodular0low10
Lymphoma, Intermediate-Grade0low10
Lymphoma, Large Cell, Follicular0low10
Lymphoma, Large Lymphoid, Nodular0low10
Lymphoma, Large-Cell, Anaplastic0low20
Lymphoma, Large-Cell, Follicular0low10
Lymphoma, Large-Cell, Ki-10low20
Lymphoma, Low-Grade0low10
Lymphoma, Lymphoblastic0low20
Lymphoma, Lymphocytic0low50
Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated0low20
Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated0low20
Lymphoma, Lymphocytic, Diffuse, Well Differentiated0low50
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated0low50
Lymphoma, Lymphocytic, Intermediate0low20
Lymphoma, Lymphocytic, Nodular, Poorly Differentiated0low10
Lymphoma, Lymphocytic, Nodular, Poorly-Differentiated0low10
Lymphoma, Lymphocytic, Plasmacytoid0low20
Lymphoma, Lymphocytic, Well Differentiated0low50
Lymphoma, Lymphocytic, Well-Differentiated0low50
Lymphoma, Lymphoplasmacytoid0low20
Lymphoma, Lymphoplasmacytoid, CLL0low50
Lymphoma, Malignant0low50
Lymphoma, Mantle-Cell0low20
Lymphoma, Mixed0low10
Lymphoma, Mixed Cell, Diffuse0low10
Lymphoma, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Mixed Small and Large Cell, Diffuse0low10
Lymphoma, Mixed-Cell0low10
Lymphoma, Mixed-Cell, Diffuse0low10
Lymphoma, Mixed-Cell, Follicular0low10
Lymphoma, Nodular0low10
Lymphoma, Nodular, Large Follicular Center Cell0low10
Lymphoma, Nodular, Large Follicular Center-Cell0low10
Lymphoma, Nodular, Mixed Lymphocytic Histiocytic0low10
Lymphoma, Nodular, Mixed Lymphocytic-Histiocytic0low10
Lymphoma, Nodular, Mixed Small and Large Cell0low10
Lymphoma, Non-Hodgkin0low10
Lymphoma, Non-Hodgkin, Familial0low10
Lymphoma, Non-Hodgkin's0low10
Lymphoma, Non-Hodgkins0low10
Lymphoma, Nonhodgkin's0low10
Lymphoma, Nonhodgkins0low10
Lymphoma, Pleomorphic0low10
Lymphoma, Small and Large Cleaved-Cell, Diffuse0low10
Lymphoma, Small Cleaved Cell, Diffuse0low10
Lymphoma, Small Cleaved Cell, Follicular0low10
Lymphoma, Small Cleaved-Cell, Diffuse0low10
Lymphoma, Small Cleaved-Cell, Follicular0low10
Lymphoma, Small Follicular Center-Cell0low10
Lymphoma, Small Lymphocytic0low50
Lymphoma, Small Lymphocytic, Plasmacytoid0low50
Lymphoma, Small Lymphoid, Follicular0low10
Lymphoma, Small Non-Cleaved-Cell0low10
Lymphoma, Small Noncleaved-Cell0low10
Lymphoma, Small-Cell0low50
Lymphoma, Small-Cell, Centrocytic0low20
Lymphoma, Undifferentiated0low10
Lymphoma, Undifferentiated, Diffuse0low10
Lymphoplasmacytoid Lymphoma, CLL0low50
Lymphosarcoma0low10
M3 ANLL0low110
Machado-Joseph Azorean Disease0low10
Machado-Joseph Disease0low10
Machado-Joseph Disease Type I0low10
Machado-Joseph Disease Type II0low10
Machado-Joseph Disease Type III0low10
Machado-Joseph Disease Type IV0low10
Macroglobulinemia0low20
Macular Degeneration0low10
Macular Degeneration, Age-Related0low10
Macular Dystrophy0low10
Maculopathies, Age-Related0low10
Maculopathy0low10
Maculopathy, Age-Related0low10
Malaria0low30
Malaria, Falciparum0low30
Malignancy0low630
Malignant Cerebellar Neoplasms0low30
Malignant Epithelial Neoplasms0low260
Malignant Glioma0low240
Malignant Melanoma0low240
Malignant Neoplasm of Breast0low1500
Malignant Neoplasms0low630
Malignant Neoplasms, Brain0low320
Malignant Primary Brain Neoplasms0low320
Malignant Primary Brain Tumors0low320
Malignant Supratentorial Neoplasms0low10
Malignant Tumor of Breast0low1500
Malignant Tumor of Urinary Bladder0low210
Mammary Cancer0low1500
Mammary Carcinoma, Animal0low40
Mammary Carcinoma, Human0low1500
Mammary Ductal Carcinoma0low10
Mammary Neoplasm, Human0low1500
Mammary Neoplasms0low40
Mammary Neoplasms, Animal0low40
Mammary Neoplasms, Experimental0low70
Mammary Neoplasms, Human0low1500
Manganese Poisoning0low10
Manic Depression0low20
Manic Disorder0low20
Manic-Depressive Psychosis0low20
Mantle-Cell Lymphoma0low20
Mantle-Zone Lymphoma0low20
Mar (X) Syndrome0low60
Marie-Struempell Disease0low10
Marker X Syndrome0low60
Marsh Fever0low30
Martin-Bell Syndrome0low60
Mast-Cell Sarcoma0low10
Mastocytoma0low10
Mastocytoma, Benign0low10
Mastocytoma, Extracutaneous0low10
Mastocytoma, Malignant0low10
Maturity-Onset Diabetes0low30
Maturity-Onset Diabetes Mellitus0low30
MCA Infarct0low10
MCA Infarction0low10
Mechanical Allodynia0low30
Mechanical Hyperalgesia0low30
Mediterranean Anemia0low30
Medulloblastoma0low50
Medulloblastoma, Adult0low50
Medulloblastoma, Childhood0low50
Medulloblastoma, Desmoplastic0low50
Medulloepithelioma0low30
Medullomyoblastoma0low50
Melanocytic Medulloblastoma0low50
Melanodermic Leukodystrophy0low10
Melanoma0low240
Melanoma, B160low110
Melanoma, Cloudman S910low110
Melanoma, Experimental0low110
Melanoma, Harding-Passey0low110
Melanomas, Experimental0low110
Membranoproliferative Glomerulonephritis0low10
Membranoproliferative Glomerulonephritis Type II0low10
Membranoproliferative Glomerulonephritis, Type I0low10
Membranoproliferative Glomerulonephritis, Type II0low10
Membranoproliferative Glomerulonephritis, Type III0low10
Memory Deficits0low50
Memory Disorder, Semantic0low50
Memory Disorder, Spatial0low50
Memory Disorders0low50
Memory Disorders, Age-Related0low50
Memory Loss0low50
Menstruation, Painful0low10
Mental Deficiency0low20
Mental Deterioration0low20
Mental Retardation0low20
Mental Retardation, Psychosocial0low20
Mental Retardation, X-Linked, Associated With Fragile Site Fraxe0low60
Mental Retardation, X-Linked, Associated With Marxq280low60
Menzel Type OPCA0low10
Mesangiocapillary Glomerulonephritis0low10
Mesangiocapillary Glomerulonephritis, Type I0low10
Mesangiocapillary Glomerulonephritis, Type II0low10
Mesothelioma0low10
Metabolic Cardiovascular Syndrome0low10
Metabolic Syndrome0low10
Metabolic Syndrome X0low10
Metabolic X Syndrome0low10
Metastase0low230
Metastases, Neoplasm0low230
Metastasis0low230
Metastasis, Neoplasm0low230
Microcalcification0low10
Microcalcinosis0low10
Microcytemia, beta Type0low30
Micrometastases, Neoplasm0low10
Micrometastasis0low10
Micrometastasis, Neoplasm0low10
Microsatellite Instability0low20
Microsomia Hemifacial Radial Defects0low10
Middle Cerebral Artery Circulation Infarction0low10
Middle Cerebral Artery Embolic Infarction0low10
Middle Cerebral Artery Embolus0low10
Middle Cerebral Artery Infarction0low10
Middle Cerebral Artery Occlusion0low10
Middle Cerebral Artery Stroke0low10
Middle Cerebral Artery Syndrome0low10
Middle Cerebral Artery Thrombosis0low10
Middle Cerebral Artery Thrombotic Infarction0low10
Mild Cognitive Impairment0low20
Mild Neurocognitive Disorder0low20
Miller-Dieker Lissencephaly Syndrome0low10
Miller-Dieker Syndrome0low10
Mixed Cellularity Hodgkin's Lymphoma0low30
Mixed Glioma0low240
Mixed Oligodendroglioma-Astrocytoma0low10
Mixed Oligodendroglioma-Ependymoma0low10
Mixed Small and Large Cell Lymphoma, Diffuse0low10
Mixed-Cell Lymphoma0low10
Mixed-Cell Lymphoma, Diffuse0low10
Mixed-Cell Lymphoma, Follicular0low10
MODY0low30
Moeschler Clarren Syndrome0low10
Mongolism0low10
Monoblastic Leukemia, Acute0low10
Monocytic Leukemia, Acute0low10
Monocytic Leukemia, Chronic0low170
Mononeuropathy, Diabetic0low10
Monosomy, Partial0low50
Motor Neuron Disease, Amyotrophic Lateral Sclerosis0low40
Mouth Cancer0low70
Mouth Neoplasms0low70
MPGN0low10
MPGNII0low10
MPTP Neurotoxicity Syndrome0low30
MPTP Poisoning0low30
MPTP-Induced Degeneration of the Striatum0low30
MPTP-Induced Experimental Parkinsonism0low10
MPTP-Induced Parkinsonism0low30
MS (Multiple Sclerosis)0low20
Mucoviscidosis0low20
Multiple Abnormalities0low10
Multiple Endocrine Neoplasia Type 10low10
Multiple Endocrine Neoplasia Type I0low10
Multiple Endocrine Neoplasms Type 10low10
Multiple Myeloma0medium131
Multiple Sclerosis0low20
Multiple Sclerosis, Acute Fulminating0low20
Multiple System Tauopathy with Presenile Dementia0low10
Muscle Contraction0low50
Muscular Atrophy0low60
Muscular Atrophy, Adult Spinal0low90
Muscular Atrophy, Peroneal0low10
Muscular Atrophy, Spinal0low90
Muscular Dystrophies0low30
Muscular Dystrophy0low30
Muscular Dystrophy Pseudohypertrophic Progressive, Becker Type0low10
Muscular Dystrophy, Animal0low10
Muscular Dystrophy, Becker0low10
Muscular Dystrophy, Becker Type0low10
Muscular Dystrophy, Childhood, Pseudohypertrophic0low10
Muscular Dystrophy, Duchenne0low10
Muscular Dystrophy, Duchenne and Becker Types0low10
Muscular Dystrophy, Duchenne Type0low10
Muscular Dystrophy, Pseudohypertrophic0low10
Muscular Dystrophy, Pseudohypertrophic Progressive, Becker Type0low10
Muscular Dystrophy, Pseudohypertrophic Progressive, Duchenne Type0low10
Muscular Dystrophy, Pseudohypertrophic, Childhood0low10
Musculoskeletal Pain0low10
Mycobacterium tuberculosis Infection0low20
Myeloblastic Leukemia, Acute0low140
Myelocytic Leukemia0low170
Myelocytic Leukemia, Acute0low140
Myelocytic Leukemia, Chronic0low50
Myelodysplastic Syndromes0low40
Myelofibrosis0low30
Myelofibrosis With Myeloid Metaplasia0low30
Myelogenous Leukemia0low170
Myelogenous Leukemia, Acute0low140
Myelogenous Leukemia, Chronic0low50
Myelogenous Leukemia, Ph1-Positive0low50
Myeloid Leukemia0low170
Myeloid Leukemia, Acute0low140
Myeloid Leukemia, Acute, M10low140
Myeloid Leukemia, Acute, M20low140
Myeloid Leukemia, Acute, M30low110
Myeloid Leukemia, Acute, M40low20
Myeloid Leukemia, Acute, M50low10
Myeloid Leukemia, Acute, M60low130
Myeloid Leukemia, Chronic0low50
Myeloid Leukemia, Naegeli-Type0low20
Myeloid Leukemia, Ph1-Positive0low50
Myeloid Leukemia, Philadelphia-Positive0low50
Myeloid Leukemia, Schilling-Type0low10
Myeloid Metaplasia0low30
Myeloma-Multiple0medium131
Myeloma, Multiple0medium131
Myeloma, Plasma-Cell0medium131
Myelomatosis0medium131
Myelomonocytic Leukemia, Acute0low20
Myelopathic Muscular Atrophy0low90
Myelopathic Muscular Atrophy, Progressive0low90
Myelopathy, Traumatic0low10
Myeloproliferative Disorders0low20
Myelosclerosis0low30
Myelosis, Nonleukemic0low30
Myocardial Failure0low20
Myocardial Infarct0low100
Myocardial Infarction0low100
Myocardial Ischemia0low10
Myocardial Ischemic Reperfusion Injury0low70
Myocardial Remodeling, Ventricular0low30
Myocardial Reperfusion Injury0low70
Myocarditis0low20
Myodystrophica0low30
Myodystrophy0low30
Myopathy, Central Core0low10
Mystery Swine Disease0low10
Myxofibroma0low10
Nagana0low10
Nasal Polyps0low20
Nasopharyngeal Cancer0low80
Nasopharyngeal Carcinoma0low40
Nasopharyngeal Neoplasms0low80
Nasopharynx Cancer0low80
Nasopharynx Neoplasms0low80
Neck Cancer0low120
Neck Neoplasm0low120
Neck Neoplasms0low120
Necrosis0low70
Necrosis, Aseptic, of Bone0low10
Necrosis, Aseptic, of Femur Head0low10
Necrosis, Avascular, of Bone0low10
Necrosis, Avascular, of Femur Head0low10
Neglected Diseases0low10
Neonatal Respiratory Distress Syndrome0low10
Neoplasia0low630
Neoplasia, Multiple Endocrine Type 10low10
Neoplasm0low630
Neoplasm Invasion0low400
Neoplasm Invasiveness0low400
Neoplasm Metastases0low230
Neoplasm Metastasis0low230
Neoplasm Micrometastases0low10
Neoplasm Micrometastasis0low10
Neoplasm Recurrence, Local0low10
Neoplasm Recurrence, Locoregional0low10
Neoplasm Recurrences, Local0low10
Neoplasm-Associated Pain0low20
Neoplasm-Related Pain0low20
Neoplasms, Benign0low630
Neoplasms, Bile Duct0low20
Neoplasms, Biliary Tract0low10
Neoplasms, Bladder0low210
Neoplasms, Bone0low90
Neoplasms, Bone Marrow0low10
Neoplasms, Brain0low320
Neoplasms, Brain, Benign0low320
Neoplasms, Brain, Malignant0low320
Neoplasms, Brain, Primary0low320
Neoplasms, Breast0low1500
Neoplasms, Central Nervous System0low20
Neoplasms, Cerebellar0low30
Neoplasms, Cerebellar, Benign0low30
Neoplasms, Cerebellar, Malignant0low30
Neoplasms, Cerebellar, Primary0low30
Neoplasms, Cervical0low170
Neoplasms, Cervix0low170
Neoplasms, Colonic0low650
Neoplasms, Colorectal0low320
Neoplasms, Digestive System0low10
Neoplasms, Endocrine Gland0low20
Neoplasms, Endometrial0low150
Neoplasms, Epithelial0low10
Neoplasms, Esophageal0low160
Neoplasms, Experimental0low90
Neoplasms, Experimental Liver0low30
Neoplasms, Experimental Mammary0low70
Neoplasms, Gallbladder0low20
Neoplasms, Gastric0low570
Neoplasms, Gastrointestinal0low50
Neoplasms, Glandular0low10
Neoplasms, Glandular and Epithelial0low10
Neoplasms, Glandular Epithelial0low10
Neoplasms, Head0low120
Neoplasms, Head and Neck0low120
Neoplasms, Hepatic0low530
Neoplasms, Hormone-Dependent0low30
Neoplasms, Intracranial0low320
Neoplasms, Kidney0low130
Neoplasms, Laryngeal0low20
Neoplasms, Liver0low530
Neoplasms, Lung0low880
Neoplasms, Malignant Epithelial0low260
Neoplasms, Mammary0low40
Neoplasms, Mouth0low70
Neoplasms, Multiple Endocrine Type 10low10
Neoplasms, Multiple Endocrine Type I0low10
Neoplasms, Nasopharyngeal0low80
Neoplasms, Neck0low120
Neoplasms, Oral0low70
Neoplasms, Ovarian0low380
Neoplasms, Pancreatic0low450
Neoplasms, Parathyroid0low10
Neoplasms, Primitive Neuroepithelial0low30
Neoplasms, Prostate0low770
Neoplasms, Prostatic0low770
Neoplasms, Pulmonary0low880
Neoplasms, Rectal0low10
Neoplasms, Retinal0low20
Neoplasms, Skin0low90
Neoplasms, Squamous Cell0low10
Neoplasms, Stomach0low570
Neoplasms, Supratentorial0low10
Neoplasms, Testicular0low10
Neoplasms, Testis0low10
Neoplasms, Thyroid0low170
Neoplasms, Tongue0low50
Neoplasms, Upper Aerodigestive Tract0low120
Neoplasms, Urologic0low10
Neoplasms, Uterine0low40
Neoplasms, Uterus0low40
Neoplastic Cell Transformation0low240
Neoplastic Transformation, Cell0low240
Neovascularization, Choroid0low10
Neovascularization, Choroidal0low10
Neovascularization, Pathologic0low100
Neovascularization, Pathological0low100
Nephritis, IGA Type0low10
Nephritis, Interstitial0low20
Nephritis, Tubulointerstitial0low20
Nephroid Carcinoma0low140
Nephropathy, IGA0low10
Nerve Degeneration0low40
Nerve Pain0low30
Nervous System Azorean Disease0low10
Nervous System Degenerative Diseases0low40
Nervous System Diseases0low20
Nervous System Diseases, Manganese-Induced0low10
Nervous System Disorders0low20
Nervous System Poisoning0low10
Nervous System Poisoning, Manganese0low10
Neural Tube Defects0low20
Neural Tube Developmental Defects0low20
Neuralgia0low30
Neuralgia-Neuritis, Sciatic Nerve0low10
Neuralgia, Atypical0low30
Neuralgia, Diabetic0low10
Neuralgia, Iliohypogastric Nerve0low30
Neuralgia, Ilioinguinal0low30
Neuralgia, Perineal0low30
Neuralgia, Stump0low30
Neuralgia, Supraorbital0low30
Neuralgia, Vidian0low30
Neurenteric Cyst0low20
Neuritis, Vestibular0low10
Neuroblastoma0low370
Neuroblastoma, Retinal0low20
Neurodegenerative Diseases0low40
Neurodegenerative Disorders0low40
Neurodermatitis, Atopic0low10
Neurodermatitis, Disseminated0low10
Neurodynia0low30
Neuroectodermal Tumor, Primitive0low30
Neuroectodermal Tumors, Primitive0low30
Neuroendocrine Tumors0low20
Neuroenteric Cyst0low20
Neuroepithelial Neoplasms, Primitive0low30
Neuroepithelial Tumors, Primitive0low30
Neurogenic Bladder0low10
Neurogenic Bladder Disorder0low10
Neurogenic Bladder, Atonic0low10
Neurogenic Bladder, Spastic0low10
Neurogenic Bladder, Uninhibited0low10
Neurogenic Dysfunction of the Urinary Bladder0low10
Neurogenic Muscular Atrophy0low60
Neurogenic Urinary Bladder Disorder0low10
Neurogenic Urinary Bladder, Atonic0low10
Neurogenic Urinary Bladder, Spastic0low10
Neurogenic Urinary Bladder, Uninhibited0low10
Neurologic Degenerative Conditions0low40
Neurologic Degenerative Diseases0low40
Neurologic Diseases, Degenerative0low40
Neurologic Disorders0low20
Neurological Disorders0low20
Neuron Degeneration0low40
Neuronitis, Vestibular0low10
Neuropathic Bladder0low10
Neuropathic Pain0low30
Neuropathy, Type I Hereditary Motor and Sensory0low10
Neuropathy, Type II Hereditary Motor and Sensory0low10
Neuroses, Anxiety0low10
Neurotoxic Disorders0low10
Neurotoxicity Syndrome, Manganese0low10
Neurotoxicity Syndrome, MPTP0low30
Neurotoxicity Syndromes0low10
Neurotoxin Diseases0low10
Neurotoxin Disorders0low10
Neurotrophic Muscular Atrophy0low60
Nevi, Melanocytic0low10
Nevi, Pigmented0low10
Nevus, Melanocytic0low10
Nevus, Pigmented0low10
NIDDM0low30
Nigrospinodentatal Degeneration0low10
Nodular Glomerulosclerosis0low10
Nodular Large Follicular Center-Cell Lymphoma0low10
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma0low30
Nodular Sclerosing Hodgkin's Lymphoma0low30
Non-Depressed Skull Fracture0low10
Non-Hodgkin Lymphoma0low10
Non-Hodgkin's Lymphoma0low10
Non-Small Cell Lung Cancer0low380
Non-Small Cell Lung Carcinoma0low380
Non-Small-Cell Lung Carcinoma0low380
Nonconvulsive Generalized Seizure Disorder0low10
Nonconvulsive Seizure Disorder, Generalized0low10
Noninsulin-Dependent Diabetes Mellitus0low30
Nonlymphoblastic Leukemia, Acute0low140
Nonlymphocytic Leukemia, Acute0low140
Nonmedullary Thyroid Carcinoma0low10
Nonsmall Cell Lung Cancer0low380
Numbness0low10
Oat Cell Carcinoma0low50
Oat Cell Carcinoma of Lung0low20
Oat Cell Lung Cancer0low20
OAVS with Radial Defect0low10
Obesity0low30
Occlusion, Middle Cerebral Artery0low10
Occult Spinal Dysraphism0low20
Occult Spinal Dysraphism Sequence0low20
Oculoauriculovertebral Dysplasia0low10
Oculoauriculovertebral Spectrum0low10
Oculoauriculovertebral Spectrum with Radial Defect0low10
Oculoauriculovertebral Syndrome0low10
Oculopharyngeal Spinal Muscular Atrophy0low90
Oesophageal Squamous Cell Carcinoma0low40
Oligoastrocytoma, Mixed0low20
Oligodendroblastoma0low10
Oligodendroglioma0low10
Oligodendroglioma, Adult0low10
Oligodendroglioma, Childhood0low10
Oligodendroglioma, Well-Differentiated0low10
Olivopontocerebellar Atrophy 20low10
Olivopontocerebellar Atrophy I0low10
Olivopontocerebellar Atrophy II0low10
Olivopontocerebellar Atrophy III0low10
Olivopontocerebellar Atrophy IV0low10
Olivopontocerebellar Atrophy, Holguin Type0low10
Omenn Syndrome0low20
Omenn's Syndrome0low20
Oncogenesis0low60
Oncological Pain0low20
Oncology Pain0low20
OPCA with Macular Degeneration and External Ophthalmoplegia0low10
OPCA with Retinal Degeneration0low10
Open Spine0low10
Opiate Abuse0low10
Opiate Addiction0low10
Opiate Dependence0low10
Opioid Abuse0low10
Opioid Addiction0low10
Opioid Dependence0low10
Opioid Misuse0low10
Opioid Use Disorder0low10
Opioid-Related Disorders0low10
Optic Nerve Avulsion0low20
Optic Nerve Contusion0low20
Optic Nerve Injuries0low20
Optic Nerve Transection0low20
Optic Nerve Trauma0low20
Optic Neuropathy, Traumatic0low20
Oral Cancer0low70
Oral Cavity Squamous Cell Carcinoma0low40
Oral Neoplasms0low70
Oral Squamous Cell Carcinoma0low40
Oral Squamous Cell Carcinomas0low40
Oral Tongue Squamous Cell Carcinoma0low40
Oral-Mandibular-Auricular Syndrome0low10
Oropharyngeal Squamous Cell Carcinoma0low40
Orphan Diseases0low10
Osteitis0low10
Osteoarthritis0low60
Osteoarthritis of Knee0low30
Osteoarthritis of the Knee0low30
Osteoarthritis, Knee0low30
Osteoarthrosis0low60
Osteoarthrosis Deformans0low60
Osteoclastic Bone Loss0low20
Osteogenic Sarcoma0low120
Osteonecrosis0low10
Osteosarcoma0low120
Osteosarcoma Tumor0low120
Otologic Diseases0low10
Otological Diseases0low10
Otomandibular Dysostosis0low10
Ovarian Cancer0low380
Ovarian Cancer, Epithelial0low10
Ovarian Epithelial Cancer0low10
Ovarian Epithelial Carcinoma0low10
Ovarian Neoplasms0low380
Ovary Cancer0low380
Ovary Neoplasms0low380
Overinclusion0low30
Oxygen Deficiency0low110
Pain0low10
Pain, Burning0low10
Pain, Chronic0low10
Pain, Crushing0low10
Pain, Menstrual0low10
Pain, Migratory0low10
Pain, Radiating0low10
Pain, Splitting0low10
Paludism0low30
Panacinar Emphysema0low10
Pancreas Cancer0low450
Pancreas Neoplasms0low450
Pancreatic Cancer0low450
Pancreatic Cystic Fibrosis0low20
Pancreatic Duct Cell Carcinoma0low80
Pancreatic Ductal Carcinoma0low80
Pancreatic Neoplasms0low450
Pancreatic Parenchyma with Edema0low10
Pancreatic Parenchymal Edema0low10
Pancreatitis0low10
Pancreatitis, Acute0low10
Pancreatitis, Acute Edematous0low10
Panlobular Emphysema0low10
Papillary Carcinoma Of Thyroid0low10
Papillary Renal Cell Carcinoma0low140
Papillary Thyroid Carcinoma0low10
Papilloma, Shope0low10
Papillomavirus Infections0low30
Paralysis Agitans0low10
Parathyroid Adenoma0low10
Parathyroid Cancer0low10
Parathyroid Carcinoma0low10
Parathyroid Neoplasms0low10
Parkinson Disease0low10
Parkinson Disease 20low10
Parkinson Disease 2, Autosomal Recessive Juvenile0low10
Parkinson Disease Autosomal Recessive, Early Onset0low10
Parkinson Disease, Autosomal Dominant. Juvenile0low10
Parkinson Disease, Experimental0low10
Parkinson Disease, Familial, Autosomal Recessive0low10
Parkinson Disease, Idiopathic0low10
Parkinson Disease, Juvenile0low10
Parkinson Disease, Juvenile, Autosomal Dominant0low10
Parkinson Disease, Juvenile, Autosomal Recessive0low10
Parkinson's Disease0low10
Parkinson's Disease, Idiopathic0low10
Parkinson's Disease, Lewy Body0low10
Parkinsonian Diseases0low10
Parkinsonian Disorders0low10
Parkinsonian Syndrome0low10
Parkinsonian Syndromes0low10
Parkinsonism0low10
Parkinsonism, Early Onset, with Diurnal Fluctuation0low10
Parkinsonism, Early-Onset, With Diurnal Fluctuation0low10
Parkinsonism, Experimental0low10
Parkinsonism, Juvenile0low10
Parkinsonism, Juvenile, Autosomal Dominant0low10
Parkinsonism, Juvenile, Autosomal Recessive0low10
Paroxysmal Atrial Fibrillation0low10
Paroxysmal Nerve Pain0low30
Partial Fetal Alcohol Syndrome0low10
Partial Monosomy0low50
Partial Trisomy 21 Down Syndrome0low10
Pathologic Angiogenesis0low100
Pathologic Calcification0low10
Pathologic Neovascularization0low100
Perinatal Subarachnoid Hemorrhage0low10
Peripancreatic Fat Necrosis0low10
Peripheral Nerve Diseases0low10
Peripheral Nerve Injuries0low10
Peripheral Nerve Injury0low10
Peripheral Nervous System Disease0low10
Peripheral Nervous System Diseases0low10
Peripheral Nervous System Disorders0low10
Peripheral Neuropathies0low10
Peritoneal Carcinomatosis0low10
Peritoneal Neoplasms0low10
Peritoneal Surface Malignancy0low10
Peroneal Muscular Atrophy0low10
Persistent Atrial Fibrillation0low10
Photodermatitis0low10
Photosensitivity Disorders0low10
Photosensitization0low10
Pigmentary Retinopathy0low10
Pigmented Moles0low10
Pilocytic Astrocytoma0low20
Pituitary ACTH Hypersecretion0low20
Pituitary Adenoma0low40
Pituitary Adenoma, ACTH-Secreting0low10
Pituitary Cancer0low40
Pituitary Carcinoma0low40
Pituitary Corticotropin-Secreting Adenoma0low10
Pituitary Cushing Syndrome0low20
Pituitary Neoplasms0low40
Pituitary Tumors0low40
Pituitary-Dependant Cushing Syndrome0low20
Pituitary-Dependant Hypercortisolism0low20
Pituitary-Dependant Hypercortisolism Disorder0low20
Plasma Cell Myeloma0medium131
Plasma Cell Tumor0low20
Plasmacytoma0low20
Plasmocytoma0low20
Plasmodium falciparum Malaria0low30
Plasmodium Infections0low30
Plica Syndrome0low10
PNET0low30
Pneumonia0low20
Pneumonia, Bacterial0low10
Pneumonia, Lobar0low20
Pneumonia, Pneumococcal0low10
Pneumonitis0low20
PNS (Peripheral Nervous System) Diseases0low10
PNS Diseases0low10
Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine0low30
Poisoning, Blood0low70
Poisoning, Manganese0low10
Poisoning, Nervous System0low10
Polio0low10
Polio Encephalitis0low10
Poliomyelitis0low10
Poliomyelitis Infection0low10
Poliomyelitis, Acute0low10
Poliomyelitis, Nonpoliovirus0low10
Poliomyelitis, Preparalytic0low10
Polycystic Kidney0low10
Polycystic Kidney Disease0low10
Polycystic Kidney Disease 20low10
Polycystic Kidney Disease, Adult0low10
Polycystic Kidney Disease, Adult Type 20low10
Polycystic Kidney Disease, Adult, Type II0low10
Polycystic Kidney Disease, Autosomal Dominant0low10
Polycystic Kidney Disease, Type 20low10
Polycystic Kidney Diseases0low10
Polycystic Kidney, Autosomal Dominant0low10
Polycystic Kidney, Type 1 Autosomal Dominant Disease0low10
Polycystic Kidney, Type 2 Autosomal Dominant Disease0low10
Polycystic Kidneys0low10
Polycystic Renal Disease0low10
Polyploid0low70
Polyploid Cell0low70
Polyploidy0low70
Polyposis, Skin Pigmentation, Alopecia, And Fingernail Changes0low10
Porcine Epidemic Abortion and Respiratory Syndrome0low10
Porcine Reproductive and Respiratory Syndrome0low10
Post-Traumatic Myelopathy0low10
Posterior Choroidal Artery Infarction0low10
Postoperative Complications0low40
Postprandial Hyperglycemia0low20
Poultry Diseases0low10
Pre B-ALL0low30
Pre-B ALL0low30
Pre-B-Cell Leukemia0low30
Pre-Eclampsia0low10
Precancerous Conditions0low20
Precursor B-Cell Lymphoblastic Leukemia0low30
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma0low30
Precursor B-Cell Lymphoblastic Lymphoma0low30
Precursor Cell Lymphoblastic Leukemia-Lymphoma0low20
Precursor T-Cell Lymphoblastic Leukemia0low20
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma0low20
Precursor T-Cell Lymphoblastic Lymphoma0low20
Predisposition, Genetic0low60
Preeclampsia0low10
Preeclampsia Eclampsia 10low10
Pregnancy0medium592
Pregnancy Toxemias0low10
Prenatal Exposure Delayed Effects0low30
Preneoplastic Condition0low20
Preneoplastic Conditions0low20
Prescription Opioid Abuse0low10
Prescription Opioid Misuse0low10
Presenile Alzheimer Dementia0low100
Primary Brain Neoplasms0low320
Primary Central Nervous System Neoplasm0low20
Primary Central Nervous System Neoplasms0low20
Primary Macroglobulinemia0low20
Primary Malignant Brain Neoplasms0low320
Primary Malignant Brain Tumors0low320
Primary Myelofibrosis0low30
Primary Neoplasms, Cerebellum0low30
Primary Parkinsonism0low10
Primary Senile Degenerative Dementia0low100
Primary Supratentorial Neoplasms0low10
Primitive Neuroepithelial Neoplasms0low30
Progeria0low10
Progeria, Adult0low10
Progranulocytic Leukemia0low110
Progressive Chorea, Chronic Hereditary (Huntington)0low40
Progressive Chorea, Hereditary, Chronic (Huntington)0low40
Progressive Muscular Atrophy0low90
Progressive Muscular Dystrophy, Duchenne Type0low10
Progressive Myelopathic Muscular Atrophy0low90
Progressive Proximal Myelopathic Muscular Atrophy0low90
Proliferative Vitreoretinopathy0low20
Promyelocytic Leukemia, Acute0low110
Prostate Cancer0low770
Prostate Neoplasms0low770
Prostatic Adenoma0low60
Prostatic Cancer0low770
Prostatic Hyperplasia0low60
Prostatic Hyperplasia, Benign0low60
Prostatic Hypertrophy0low60
Prostatic Hypertrophy, Benign0low60
Prostatic Neoplasms0low770
Protein Aggregation, Pathological0low20
Proteinuria0low10
Proteinuria-Edema-Hypertension Gestosis0low10
Proximal Myelopathic Muscular Atrophy, Progressive0low90
PRRS0low10
Pseudoaphakia0low20
Pseudohypertrophic Childhood Muscular Dystrophy0low10
Pseudohypertrophic Muscular Dystrophy, Childhood0low10
Pseudorabies0low10
Psychoses, Manic-Depressive0low20
Psychosis, Manic-Depressive0low20
Pulmonary Cancer0low880
Pulmonary Cystic Fibrosis0low20
Pulmonary Disease0low10
Pulmonary Disease, Chronic Obstructive0low40
Pulmonary Diseases0low10
Pulmonary Edema0low10
Pulmonary Edemas0low10
Pulmonary Emphysema0low10
Pulmonary Emphysemas0low10
Pulmonary Fibroses0low30
Pulmonary Fibrosis0low30
Pulmonary Fibrosis, Idiopathic0low10
Pulmonary Hypertension0low20
Pulmonary Inflammation0low20
Pulmonary Neoplasms0low880
Pyaemia0low70
Pyemia0low70
Pyohemia0low70
Pyrexia0low10
Rachischisis0low10
Radiation Injuries0low30
Radiation Injuries, Experimental0low10
Radiation Sickness0low30
Radiation Syndrome0low30
Raillietiniasis0low10
Ramsay Hunt Paralysis Syndrome0low10
Rare Diseases0low10
Reaven Syndrome X0low10
Recrudescence0low30
Rectal Cancer0low10
Rectal Neoplasms0low10
Rectal Tumors0low10
Rectum Cancer0low10
Rectum Neoplasms0low10
Recurrence0low30
Recurrence, Local Neoplasm0low10
Recurrence, Locoregional Neoplasm0low10
Recurrences, Local Neoplasm0low10
Recurrent Vestibular Neuritis0low10
Recurrent Vestibulopathy0low10
Reduced Sensation0low10
Refetoff Syndrome0low10
Refetoff-DeWind-DeGroot Syndrome0low10
Regional Enteritis0low10
Relapse0low30
Remittent Fever0low30
Renal Cancer0low130
Renal Carcinoma0low140
Renal Cell Cancer0low140
Renal Cell Carcinoma0low140
Renal Cell Carcinoma, Papillary0low140
Renal Collecting Duct Carcinoma0low140
Renal Disease, End-Stage0low10
Renal Failure, Acute0low60
Renal Failure, Chronic0low10
Renal Failure, End-Stage0low10
Renal Insufficiency, Acute0low60
Renal Insufficiency, Chronic0low30
Renal Neoplasms0low130
Reperfusion Damage0low90
Reperfusion Injury0low90
Reperfusion Injury, Myocardial0low70
Replication Error Phenotype0low20
Research-Related Injuries0low10
Resistance, Disease0low10
Respiratory Distress Syndrome, Infant0low10
Respiratory Distress Syndrome, Newborn0low10
Respiratory Syncytial Virus Infection0low10
Respiratory Syncytial Virus Infections0low10
Retardation, Mental0low20
Retention Disorders, Cognitive0low50
Reticuloendotheliosis, Familial0low20
Reticulolymphosarcoma0low50
Reticulosarcoma0low10
Reticulum Cell Sarcoma0low10
Reticulum-Cell Sarcoma0low10
Retinal Cancer0low20
Retinal Cone-Rod Dystrophy0low10
Retinal Degeneration0low30
Retinal Diseases0low10
Retinal Neoplasms0low20
Retinal Tumors0low20
Retinitis Pigmentosa0low10
Retinoblastoma0low20
Retroviridae Infections0low20
Retrovirus Infections0low20
Rett Disorder0low10
Rett Syndrome0low10
Rett's Disorder0low10
Rett's Syndrome0low10
Rhabdoid Tumor0low10
Rhabdomyosarcoma0low60
Rhabdomyosarcoma 20low10
Rhabdomyosarcoma, Alveolar0low10
Rhabdomyosarcoma, Embryonal0low10
Rheumatoid Arthritis0low110
Rheumatoid Spondylitis0low10
Right Hemisphere, Cerebral Infarction0low10
Right Hemisphere, Infarction, Cerebral0low10
Right Middle Cerebral Artery Infarction0low10
Right Ventricular Dysfunction0low10
Right Ventricular Hypertrophy0low10
Right-Sided Heart Failure0low20
Rod Cone Dystrophies0low10
Rod-Cone Dystrophy0low10
Roseolovirus Infections0low10
Rotator Cuff Injuries0low10
Rotator Cuff Tears0low10
Rotator Cuff Tendinitis0low10
Rotator Cuff Tendinosis0low10
Roussy Levy Hereditary Areflexic Dystasia0low10
Roussy-Levy Disease0low10
Roussy-Levy Hereditary Areflexic Dystasia0low10
Roussy-Levy Syndrome0low10
Rubinstein Syndrome0low10
Rubinstein-Taybi Syndrome0low10
Runt Disease0low10
SAH (Subarachnoid Hemorrhage)0low10
Salivary Gland Virus Disease0low30
Salmonella Infections0low20
Salmonella Infections, Animal0low10
Salmonellosis0low20
Sarcoma0low10
Sarcoma, Cerebellar, Circumscribed Arachnoidal0low50
Sarcoma, Epithelioid0low10
Sarcoma, Ewing0low10
Sarcoma, Ewing's0low10
Sarcoma, Germinoblastic0low50
Sarcoma, Lymphatic0low10
Sarcoma, Mast-Cell0low10
Sarcoma, Osteogenic0low120
Sarcoma, Reticulum-Cell0low10
Sarcoma, Soft Tissue0low10
Sarcoma, Spindle Cell0low10
Sarcomatoid Renal Cell Carcinoma0low140
Sarcopenia0low10
SCA10low10
Scapuloperoneal Form of Spinal Muscular Atrophy0low90
Scapuloperoneal Spinal Muscular Atrophy0low90
Scars, Hypertrophic0low10
Schilder-Addison Complex0low10
Schistorrhachis0low10
Schizophrenia0low40
Schizophrenic Disorders0low40
Schut-Haymaker Type OPCA0low10
Sciatic Nerve Diseases0low10
Sciatic Nerve Palsy0low10
Sciatic Neuritis0low10
Sciatic Neuropathy0low10
Scleroderma, Systemic0low30
Sclerosis, Disseminated0low20
Sclerosis, Hereditary Spinal0low10
Sclerosis, Systemic0low30
Second Cranial Nerve Injuries0low20
Second Cranial Nerve Trauma0low20
Secondary Cataract0low10
Segmental Glomerular Hyalinosis0low20
Seizure Disorder, Convulsive, Generalized0low10
Seizure Disorder, Generalized0low10
Seizure Disorder, Generalized Nonconvulsive0low10
Seizure Disorder, Generalized Onset0low10
Seizure Disorder, Generalized, Convulsive0low10
Seizure Disorder, Nonconvulsive Generalized0low10
Semantic Dementia0low10
Semantic Memory Disorder0low50
Senile Dementia, Acute Confusional0low100
Senile Dementia, Alzheimer Type0low100
Sensitivity and Specificity0low70
Sensorineural Hearing Loss0low10
Sepsis0low70
Sepsis Syndrome0low10
Septic Shock0low10
Septicemia0low70
Severe Combined Immune Deficiency0low20
Severe Combined Immunodeficiency0low20
Severe Combined Immunodeficiency Syndrome0low20
Severe Combined Immunologic Deficiency0low20
Severe Sepsis0low70
Sezary Syndrome0low10
Sezary's Lymphoma0low10
Shock, Endotoxic0low10
Shock, Hemorrhagic0low10
Shock, Septic0low10
Shock, Toxic0low10
Shy-Magee Syndrome0low10
Sickle Cell Anemia0low20
Sickle Cell Disease0low20
Sickle Cell Disorders0low20
Sickling Disorder Due to Hemoglobin S0low20
Siemerling-Creutzfeldt Disease0low10
Signet Ring Cell Carcinoma0low10
Skin Cancer0low90
Skin Neoplasms0low90
Skull Fracture, Linear0low10
Skull Fracture, Non-Depressed0low10
Skull Fractures0low10
Small Airway Remodeling0low10
Small Airway Remodelling0low10
Small Cell Cancer Of The Lung0low20
Small Cell Carcinoma0low50
Small Cell Lung Cancer0low20
Small Cell Lung Carcinoma0low20
Small Cleaved-Cell Lymphoma, Diffuse0low10
Small Cleaved-Cell Lymphoma, Follicular0low10
Small Follicular Center-Cell Lymphoma0low10
Small Non-Cleaved-Cell Lymphoma0low10
Small Noncleaved-Cell Lymphoma0low10
Small-Cell Lymphoma0low50
Spatial Memory Disorder0low50
Spina Bifida0low10
Spinal Amyotrophy0low90
Spinal Cord Contusion0low10
Spinal Cord Injuries0low10
Spinal Cord Laceration0low10
Spinal Cord Myelodysplasia0low20
Spinal Cord Transection0low10
Spinal Cord Trauma0low10
Spinal Dysraphia0low10
Spinal Dysraphism0low10
Spinal Injuries0low10
Spinal Muscular Atrophy0low90
Spinal Muscular Atrophy, Distal0low90
Spinal Muscular Atrophy, Oculopharyngeal0low90
Spinal Muscular Atrophy, Scapuloperoneal0low90
Spinal Muscular Atrophy, Scapuloperoneal Form0low90
Spinocerebellar Ataxia 10low10
Spinocerebellar Ataxia 20low10
Spinocerebellar Ataxia 30low10
Spinocerebellar Ataxia 40low10
Spinocerebellar Ataxia 50low10
Spinocerebellar Ataxia 60low10
Spinocerebellar Ataxia 70low10
Spinocerebellar Ataxia Type 10low10
Spinocerebellar Ataxia Type 20low10
Spinocerebellar Ataxia Type 30low10
Spinocerebellar Ataxia Type 40low10
Spinocerebellar Ataxia Type 50low10
Spinocerebellar Ataxia Type 60low10
Spinocerebellar Ataxia Type 70low10
Spinocerebellar Ataxia with Slow Eye Movements0low10
Spinocerebellar Ataxia-10low10
Spinocerebellar Ataxia-20low10
Spinocerebellar Ataxia-30low10
Spinocerebellar Ataxia-40low10
Spinocerebellar Ataxia-50low10
Spinocerebellar Ataxia-60low10
Spinocerebellar Ataxia-70low10
Spinocerebellar Ataxia, Autosomal Dominant, with Sensory Axonal Neuropathy0low10
Spinocerebellar Ataxia, Cuban Type0low10
Spinocerebellar Ataxias0low10
Spinocerebellar Ataxias, Dominantly-Inherited0low10
Spinocerebellar Atrophies0low10
Spinocerebellar Atrophy 20low10
Spinocerebellar Atrophy I0low10
Spinocerebellar Atrophy II0low10
Spinocerebellar Atrophy III0low10
Spinocerebellar Atrophy Type 30low10
Spinocerebellar Degeneration with Slow Eye Movements0low10
Spondylarthritis Ankylopoietica0low10
Spondylitis Ankylopoietica0low10
Spondylitis, Ankylosing0low10
Spondyloarthritis Ankylopoietica0low10
Spongioblastoma0low30
Sporadic Retinoblastoma0low20
Squamous Cell Cancer0low10
Squamous Cell Carcinoma0low360
Squamous Cell Carcinoma of Head and Neck0low40
Squamous Cell Carcinoma of Larynx0low40
Squamous Cell Carcinoma of the Head and Neck0low40
Squamous Cell Carcinoma of the Larynx0low40
Squamous Cell Carcinoma of the Mouth0low40
Squamous Cell Carcinoma of the Nasal Cavity0low40
Squamous Cell Carcinoma, Head And Neck0low40
Squamous Cell Neoplasms0low10
Status Dysraphicus0low10
Sterility, Female0low10
Sterility, Postpartum0low10
Stomach Cancer0low570
Stomach Neoplasms0low570
Streptozocin Diabetes0low40
Streptozotocin Diabetes0low40
Striatonigral Degeneration, Autosomal Dominant0low10
Stroke0low30
Stroke, Acute0low30
Stroke, Middle Cerebral Artery0low10
Sub-Fertility, Female0low10
Subacute Vestibular Neuritis0low10
Subarachnoid Hemorrhage0low10
Subarachnoid Hemorrhage, Aneurysmal0low10
Subarachnoid Hemorrhage, Intracranial0low10
Subarachnoid Hemorrhage, Spontaneous0low10
Subcortical Arteriosclerotic Encephalopathy0low10
Subcortical Band Heterotopia0low10
Subcortical Encephalopathy, Chronic Progressive0low10
Subcortical Infarction0low10
Subcortical Laminar Heterotopia0low10
Subcortical Leukoencephalopathy0low10
Subcortical Vascular Dementia0low10
Subendothelial Membranoproliferative Glomerulonephritis0low10
Subependymal Giant Cell Astrocytoma0low20
Subfertility, Female0low10
Substance Withdrawal Syndrome0low30
Suffering, Physical0low10
Supratentorial Neoplasms0low10
Supratentorial Neoplasms, Benign0low10
Supratentorial Neoplasms, Malignant0low10
Supratentorial Neoplasms, Primary0low10
Supratentorial Tumors0low10
Susceptibility, Disease0low10
Susceptibility, Genetic0low60
Swine Diseases0low20
Swine Fever0low10
Swine Fever, Classical0low10
Swine Infertility and Respiratory Syndrome0low10
Symmetric Diabetic Proximal Motor Neuropathy0low10
Symptomatic Generalized Epilepsy0low10
Syndrome X, Insulin Resistance0low10
Syndrome X, Metabolic0low10
Synovial Hypertrophy0low10
Synovial Plica Syndrome0low10
Synovial Thickening0low10
Synovitis0low10
Systemic Anaplastic Large-Cell Lymphoma0low20
Systemic Capillary Leak Syndrome0low10
Systemic Inflammatory Response Syndrome0low10
Systemic Lupus Erythematosus0low50
Systemic Scleroderma0low30
Systemic Sclerosis0low30
T Cell Leukemia Lymphoma, HTLV I Associated0low20
T Cell Leukemia, Adult0low20
T Lymphocytic Leukemia0low20
T-ALL0low20
T-Cell Acute Lymphocytic Leukemia0low20
T-Cell Leukemia0low20
T-Cell Leukemia-Lymphoma, Adult0low20
T-Cell Leukemia-Lymphoma, HTLV-I-Associated0low20
T-Cell Leukemia, Acute0low20
T-Cell Leukemia, Adult0low20
T-Lymphocytic Leukemia0low20
T-Lymphocytic Leukemia, Acute0low20
T-Lymphotropic Virus Type III Infections, Human0low90
Tactile Allodynia0low30
Tapetoretinal Degeneration0low10
Tapeworm Infection0low10
Telangiectasia, Cerebello-Oculocutaneous0low40
Tendon Injuries0low10
Teratocarcinoma0low50
Teratogenesis0low10
Teratoid Tumor0low20
Teratoma0low20
Teratoma, Benign0low20
Teratoma, Cystic0low20
Teratoma, Immature0low20
Teratoma, Malignant0low20
Teratoma, Mature0low20
Testicular Cancer0low10
Testicular Neoplasm0low10
Testicular Neoplasms0low10
Testicular Tumor0low10
Testicular Tumors0low10
Testis Cancer0low10
Testis Neoplasms0low10
Tethered Cord Syndrome0low20
Tethered Spinal Cord Syndrome0low20
Thalassemia Intermedia0low30
Thalassemia Major0low30
Thalassemia Major (beta-Thalassemia Major)0low30
Thalassemia Minor0low30
Thalassemia Minor (beta-Thalassemia Minor)0low30
Thalassemia, beta Type0low30
Thermal Allodynia0low30
Thoracic Neoplasms0low10
Thrombosis0medium11
Thrombosis, Middle Cerebral Artery0low10
Thrombotic Infarction, Middle Cerebral Artery0low10
Thrombus0medium11
Thyroid Adenoma0low170
Thyroid Cancer0low170
Thyroid Cancer, Anaplastic0low30
Thyroid Cancer, Papillary0low10
Thyroid Carcinoma0low170
Thyroid Carcinoma, Anaplastic0low30
Thyroid Carcinoma, Follicular0low40
Thyroid Carcinoma, Papillary0low10
Thyroid Hormone Resistance0low10
Thyroid Hormone Resistance Syndrome0low10
Thyroid Neoplasms0low170
Tongue Cancer0low50
Tongue Neoplasms0low50
Torulosis0low20
Toxemia Of Pregnancy0low10
Toxemias, Pregnancy0low10
Toxic Encephalitis0low10
Toxic Hepatitis0low30
Toxic Shock0low10
Toxic Shock Syndrome0low10
Transformation, Neoplastic Cell0low240
Transformation, Viral Cell0low80
Translocation, Chromosomal0low150
Translocation, Genetic0low150
Trauma0low10
Trauma, Second Cranial Nerve0low20
Trichomonas Vaginitis0low10
Trichomoniasis, Human0low10
Triple Negative Breast Cancer0low40
Triple Negative Breast Neoplasms0low40
Triple-Negative Breast Cancer0low40
Triple-Negative Breast Neoplasm0low40
Trisomy 210low10
Trisomy 21, Meiotic Nondisjunction0low10
Trisomy 21, Mitotic Nondisjunction0low10
Trisomy G0low10
Trophoblastic Neoplasms, Gestational0low10
Trypanosoma cruzi Infection0low10
Trypanosomiasis, African0low10
Trypanosomiasis, South American0low10
Tuberculin-Type Hypersensitivity0low10
Tuberculosis0low20
Tubulointerstitial Nephritis0low20
Tumor of Rete Testis0low10
Tumor Virus Infections0low10
Tumor-Associated Pain0low20
Tumor-Related Pain0low20
Tumorigenesis0low60
Tumorigenic Transformation0low240
Tumors0low630
Tumors, Breast0low1500
Tumors, Central Nervous System0low20
Tumors, Retinal0low20
Type 1 Diabetes0low50
Type 1 Diabetes Mellitus0low50
Type 1 Lissencephaly0low10
Type 1 Spinocerebellar Ataxia0low10
Type 2 Diabetes0low30
Type 2 Diabetes Mellitus0low30
Type 2 Spinocerebellar Ataxia0low10
Type 3 Spinocerebellar Ataxia0low10
Type 4 Spinocerebellar Ataxia0low10
Type 5 Spinocerebellar Ataxia0low10
Type 6 Spinocerebellar Ataxia0low10
Type 7 Spinocerebellar Ataxia0low10
Type I Machado-Joseph Disease0low10
Type II Machado-Joseph Disease0low10
Type II MPGN0low10
Type III Machado-Joseph Disease0low10
Type IV Hypersensitivity0low10
Type IV Machado-Joseph Disease0low10
UADT Neoplasm0low120
UADT Neoplasms0low120
Ulcerative Colitis0low10
Undifferentiated Lymphoma0low10
Upper Aerodigestive Tract Neoplasm0low120
Upper Aerodigestive Tract Neoplasms0low120
Ureteral Obstruction0low30
Urinary Bladder Cancer0low210
Urinary Bladder Disorder, Neurogenic0low10
Urinary Bladder Neoplasms0low210
Urinary Bladder Neurogenesis0low10
Urinary Bladder Neurogenic Dysfunction0low10
Urinary Bladder, Neurogenic0low10
Urinary Tract Cancer0low10
Urinary Tract Neoplasms0low10
Urologic Cancer0low10
Urologic Neoplasms0low10
Urological Cancer0low10
Urological Neoplasms0low10
Usual Interstitial Pneumonia0low10
Uterine Cancer0low40
Uterine Cervical Cancer0low170
Uterine Cervical Dysplasia0low10
Uterine Cervical Neoplasms0low170
Uterine Diseases0low10
Uterine Neoplasms0low40
Uterus Cancer0low40
Uterus Neoplasms0low40
Uveal Neoplasms0low20
Vascular Accident, Brain0low30
Vascular Dementia0low10
Vascular Dementia, Acute Onset0low10
Vasculitis0low10
Ventilator-Induced Lung Injury0low30
Ventricle Remodeling0low30
Ventricular Dysfunction, Left0low10
Ventricular Dysfunction, Right0low10
Ventricular Hypertrophy, Left0low10
Ventricular Hypertrophy, Right0low10
Ventricular Remodeling0low30
Vestibular Nerve Inflammation0low10
Vestibular Nerve Neuritis0low10
Vestibular Neuritis0low10
Vestibular Neuronitis0low10
Vestibular Neuropathy0low10
VHL Syndrome0low10
Viral Cell Transformation0low80
Viral Diseases0low10
Viral Infections0low10
Virus Diseases0low10
Virus Infections0low10
Visceral Pain0low20
Vitreoretinopathy Neovascular Inflammatory0low20
Vitreoretinopathy, Proliferative0low20
von Hippel-Lindau Disease0low10
von Hippel-Lindau Syndrome0low10
Wadia Swami Syndrome0low10
Wadia-Swami Syndrome0low10
Waldenstrom Macroglobulinemia0low20
Waldenstrom's Macroglobulinaemia0low20
Waldenstrom's Macroglobulinemia0low20
Well-Differentiated Oligodendroglioma0low10
Wermer Syndrome0low10
Werner Syndrome0low10
Werner's Syndrome0low10
Werners Syndrome0low10
Wet Lung0low10
Widespread Chronic Pain0low10
Wilhelmsen-Lynch Disease0low10
Withdrawal Symptoms0low30
Wounds0low10
Wounds and Injuries0low10
Wounds and Injury0low10
Wounds, Injury0low10
Wounds, Stab0low10
X-ALD0low10
X-ALD (X-Linked Adrenoleukodystrophy)0low10
X-Linked Adrenoleukodystrophy0low10
X-Linked Lissencephaly0low10
X-Linked Mental Retardation and Macroorchidism0low60
Xenotropic MuLV-related Virus Infection0low20
Xenotropic Murine Leukemia Virus-related Virus Infection0low20
XMRV Infection0low20
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (30)

ArticleYear
Mitigative and anti-inflammatory effects of Trichostatin A against radiation-induced gastrointestinal toxicity and gut microbiota alteration in mice.
International journal of radiation biology, Volume: 99, Issue: 12		2023
A quantitative in vivo assay for craniofacial developmental toxicity of histone deacetylases.
Toxicology letters, May-15, Volume: 342		2021
Combined exposure of lead and cadmium leads to the aggravated neurotoxicity through regulating the expression of histone deacetylase 2.
Chemosphere, Volume: 252		2020
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Journal of molecular medicine (Berlin, Germany), Volume: 96, Issue: 12		2018
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Chemico-biological interactions, Oct-25, Volume: 258		2016
Histone Deacetylase Inhibitors Trichostatin A and MCP30 Relieve Benzene-Induced Hematotoxicity via Restoring Topoisomerase IIα.
PloS one, Volume: 11, Issue: 4		2016
Histone deacetylase–mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity.
Kidney international, Volume: 89, Issue: 2		2016
Trichostatin A reduces cisplatin-induced ototoxicity through the STAT6 signaling pathway.
International journal of molecular medicine, Volume: 36, Issue: 2		2015
Histone deacetylase inhibitor attenuates neurotoxicity of clioquinol in PC12 cells.
Toxicology, May-04, Volume: 331		2015
PTEN methylation involved in benzene-induced hematotoxicity.
Experimental and molecular pathology, Volume: 96, Issue: 3		2014
Histone acetylation and arachidonic acid cytotoxicity in HepG2 cells overexpressing CYP2E1.
Naunyn-Schmiedeberg's archives of pharmacology, Volume: 387, Issue: 3		2014
Trichostatin A epigenetically increases calpastatin expression and inhibits calpain activity and calcium-induced SH-SY5Y neuronal cell toxicity.
The FEBS journal, Volume: 280, Issue: 24		2013
Trichostatin A protects against cisplatin-induced ototoxicity by regulating expression of genes related to apoptosis and synaptic function.
Neurotoxicology, Volume: 37		2013
Prevention of cytotoxicity of nickel by quercetin: the role of reactive oxygen species and histone acetylation.
Toxicology and industrial health, Volume: 29, Issue: 4		2013
Epigenetic modifiers exert renal toxicity through induction of p66shc.
Anticancer research, Volume: 31, Issue: 10		2011
[Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism].
Ai zheng = Aizheng = Chinese journal of cancer, Volume: 28, Issue: 12		2009
Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors.
Investigational new drugs, Volume: 27, Issue: 4		2009
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Neuro-oncology, Volume: 10, Issue: 3		2008
Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells.
American journal of physiology. Renal physiology, Volume: 294, Issue: 3		2008
Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
Leukemia, Volume: 21, Issue: 10		2007
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
Molecular cancer therapeutics, Volume: 5, Issue: 12		2006
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Apoptosis : an international journal on programmed cell death, Volume: 12, Issue: 1		2007
Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.
Molecular cancer, Oct-03, Volume: 5		2006
The histone deacetylase inhibitor trichostatin a has genotoxic effects in human lymphoblasts in vitro.
Toxicological sciences : an official journal of the Society of Toxicology, Volume: 93, Issue: 2		2006
Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
The Journal of neuroscience : the official journal of the Society for Neuroscience, Jul-12, Volume: 26, Issue: 28		2006
Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
The Journal of neuroscience : the official journal of the Society for Neuroscience, Mar-08, Volume: 26, Issue: 10		2006
Antioxidants and trichostatin A synergistically protect against in vitro cytotoxicity of Ni2+ in human hepatoma cells.
Toxicology in vitro : an international journal published in association with BIBRA, Volume: 19, Issue: 2		2005
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
The Journal of pharmacology and experimental therapeutics, Volume: 312, Issue: 1		2005
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Cancer research, Nov-01, Volume: 63, Issue: 21		2003
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
Molecular cancer therapeutics, Volume: 1, Issue: 11		2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (1)

ArticleYear
HOPX Plays a Critical Role in Antiretroviral Drugs Induced Epigenetic Modification and Cardiac Hypertrophy.
Cells, 12-08, Volume: 10, Issue: 12		2021
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (6)

ArticleYear
Trichostatin A ameliorates Alzheimer's disease-related pathology and cognitive deficits by increasing albumin expression and Aβ clearance in APP/PS1 mice.
Alzheimer's research & therapy, 01-04, Volume: 13, Issue: 1		2021
Increased Post-Translational Lysine Acetylation of Myelin Basic Protein Is Associated with Peak Neurological Disability in a Mouse Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
Journal of proteome research, 01-05, Volume: 17, Issue: 1		2018
p62/SQSTM1 in autophagic clearance of a non-ubiquitylated substrate.
Journal of cell science, Aug-15, Volume: 124, Issue: Pt 16		2011
Dysfunction of volume-sensitive chloride channels contributes to cisplatin resistance in human lung adenocarcinoma cells.
Experimental biology and medicine (Maywood, N.J.), Apr-01, Volume: 236, Issue: 4		2011
Impaired activity of volume-sensitive Cl- channel is involved in cisplatin resistance of cancer cells.
Journal of cellular physiology, Volume: 211, Issue: 2		2007
Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.
Drug metabolism and disposition: the biological fate of chemicals, Volume: 32, Issue: 10		2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (11)

ArticleYear
Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy.
Scientific reports, 06-26, Volume: 13, Issue: 1		2023
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue: 1		2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.
European journal of medicinal chemistry, Aug-18, Volume: 83		2014
Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue: 5		2012
New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue: 11		2010
The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.
Blood, Mar-25, Volume: 115, Issue: 12		2010
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
BMC gastroenterology, Aug-01, Volume: 8		2008
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
Antimicrobial agents and chemotherapy, Volume: 52, Issue: 10		2008
Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors.
Journal of enzyme inhibition and medicinal chemistry, Volume: 23, Issue: 4		2008
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
Journal of medicinal chemistry, Jun-03, Volume: 47, Issue: 12		2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (27)

ArticleYear
Trichostatin A, a histone deacetylase inhibitor, alleviates the emotional abnormality induced by maladaptation to stress in mice.
Neuroscience letters, 01-01, Volume: 766		2022
High-throughput cell mechanical phenotyping for label-free titration assays of cytoskeletal modifications.
Cytoskeleton (Hoboken, N.J.), Volume: 74, Issue: 8		2017
The effect of histone deacetylase inhibition on the expression of P-glycoprotein in human placental trophoblast cell lines.
Placenta, Volume: 49		2017
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.
Proceedings of the National Academy of Sciences of the United States of America, 09-06, Volume: 113, Issue: 36		2016
Protection against reperfusion lung injury via aborgating multiple signaling cascades by trichostatin A.
International immunopharmacology, Volume: 25, Issue: 2		2015
Assessment of the effect of trichostatin A on HeLa cells through FT-IR spectroscopy.
Analytical chemistry, Feb-17, Volume: 87, Issue: 4		2015
The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24).
DNA and cell biology, Volume: 33, Issue: 7		2014
HDAC inhibition decreases XIST expression on female IVP bovine blastocysts.
Reproduction (Cambridge, England), Volume: 145, Issue: 1		2013
Superinduction of leptin mRNA in mouse hypothalamic neurons.
Neuroreport, Oct-24, Volume: 23, Issue: 15		2012
Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B.
Chinese medical journal, Volume: 125, Issue: 18		2012
Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 35, Issue: 4		2010
HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Molecular endocrinology (Baltimore, Md.), Volume: 23, Issue: 12		2009
Modulation of transcription parameters in glucocorticoid receptor-mediated repression.
Molecular and cellular endocrinology, Nov-25, Volume: 295, Issue: 1-2		2008
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Molecular therapy : the journal of the American Society of Gene Therapy, Volume: 16, Issue: 6		2008
Haploinsufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation.
The Journal of biological chemistry, Aug-31, Volume: 282, Issue: 35		2007
Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.
Proteomics, Volume: 7, Issue: 10		2007
Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.
Experimental hematology, Volume: 35, Issue: 2		2007
Effects of acetylation, polymerase phosphorylation, and DNA unwinding in glucocorticoid receptor transactivation.
The Journal of steroid biochemistry and molecular biology, Volume: 100, Issue: 1-3		2006
Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Volume: 20, Issue: 1		2006
Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure.
Journal of cellular biochemistry, Nov-01, Volume: 96, Issue: 4		2005
Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
Gynecologic oncology, Volume: 99, Issue: 1		2005
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Volume: 19, Issue: 9		2005
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Journal of medicinal chemistry, Oct-09, Volume: 46, Issue: 21		2003
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
Oncogene, Jan-17, Volume: 21, Issue: 3		2002
Transcriptional repression by XPc1, a new Polycomb homolog in Xenopus laevis embryos, is independent of histone deacetylase.
Molecular and cellular biology, Volume: 19, Issue: 6		1999
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Biochemical and biophysical research communications, Dec-08, Volume: 241, Issue: 1		1997
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation.
The EMBO journal, Mar-01, Volume: 15, Issue: 5		1996
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (7)

ArticleYear
The Antitumor Efficiency of Zinc Finger Nuclease Combined with Cisplatin and Trichostatin A in Cervical Cancer Cells.
Anti-cancer agents in medicinal chemistry, Volume: 20, Issue: 17		2020
Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression,
Asian Pacific journal of cancer prevention : APJCP, Jul-01, Volume: 21, Issue: 7		2020
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Scientific reports, 01-26, Volume: 8, Issue: 1		2018
[Effect of trichostatin alone and combination with imatinb on the proliferation and apoptosis of the K562R cells].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, Volume: 36, Issue: 8		2011
[Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism].
Ai zheng = Aizheng = Chinese journal of cancer, Volume: 28, Issue: 12		2009
Valproic acid, trichostatin and their combination with hemin preferentially enhance gamma-globin gene expression in human erythroid liquid cultures.
Haematologica, Volume: 86, Issue: 7		2001
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
British journal of haematology, Volume: 108, Issue: 4		2000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Natural Sources (1)

ArticleYear
Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas.
Cancer science, Volume: 104, Issue: 10		2013
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]